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Mitochondria have emerged as intriguing therapeutic targets as their 
physiological functions are often altered in pathological conditions such as cancer. 
Numerous studies have illustrated immense potential of nanocarriers in delivering 
mitochondria-acting compounds to their target site. Among the assemblage of 
nanomaterials, carbon nanotubes (CNTs) are becoming more prominent for drug 
delivery due to favourable attributes including their unique shape, which promotes 
cellular-uptake, and large aspect-ratio that facilitates conjugation of bioactive 
molecules on their surface. In the first part of the project, multi-walled CNTs 
(MWCNTs) were functionalized with either mitochondria-targeting fluorescent 
Rhodamine 110 (MWCNT-Rho) or non-targeting Fluorescein (MWCNT-Fluo). 
Despite structural similarities, MWCNTs-Rho associated well with mitochondria in 
contrast to MWCNT-Fluo, which was poorly localized. Preliminary in vitro toxicity 
evaluation revealed that empty MWCNT-Rho neither decreased cell viability 
significantly nor interfered with mitochondrial membrane potential, while seemingly 
being expelled partially from cells. To elucidate the impact of nature of functional 
groups on the eventual drug delivery efficiency, MWCNT-Rho and MWCNT-Fluo 
were entrapped with platinum(IV) prodrug of cisplatin (PtBz) via nano-extraction. 
We found that PtBz entrapped MWCNT-Rho displayed ca. 8-fold augmentation in 
cytotoxicity than construct based on MWCNT-Fluo. Due to its targeting capability 
and biocompatibility, MWCNT-Rho was further co-encapsulated with a 
chemopotentiator 3-bromopyruvate (BP), and the resulting construct MWCNT-
Rho(BP+PtBz) demonstrated superior efficacy over PtBz free drug in all tested cancer 
cell lines. However, in order to devise the nanocarrier for in vivo testing, it is essential 
to ensure that MWCNTs possess satisfactory aqueous suspendability and 
biocompatibility. In this regard, we performed higher degree functionalization on 
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MWCNT-Rho’s surface with water soluble macromolecules, bovine serum albumin 
(BSA) and polyethylene glycol (PEG5000), which are established to be biocompatible 
in vivo. While both functional groups imparted improved compatibility to cells, 
PEG5000 conferred better aqueous suspendability without impeding MWCNTs cellular 
uptake compared to BSA. Additionally, PEG5000 functionalization did not confound 
the mitochondrial targeting capability of MWCNT-Rho, signifying that it is a suitable 
biocompatible molecule for modification of targeted MWCNT-based nanocarrier. In 
order to further expand the potential and explore the versatility of MWCNTs as drug 
delivery platform, short-length MWCNTs (more suspendable and biocompatible), 
were employed for delivering an anticancer peptide targeting hexokinase II at 
mitochondria. Hexokinase II, which is overexpressed and associated more tightly to 
mitochondria in cancer cells, surfaces as viable therapeutic target due to its 
involvement in Warburg effect and apoptosis prevention. In this study, a non-cell-
permeable peptide that disrupts hexokinase II binding to mitochondria (HKII) was 
conjugated on short-length MWCNTs with or without linker. HKII delivered by 
MWCNTs exhibited an increase in cellular internalization compared to peptide 
without carrier. Moreover, the HKII conjugated MWCNTs (with or without linker) 
seemed to have evaded from endosome and be in the vicinity of mitochondria. In 
addition, MWCNT-peptide conjugates were significantly more cytotoxic to cancer 
cells compared to commercially available cell-permeable HKII fusion peptide. Most 
importantly, treatment with MWCNT-peptide conjugates induced hexokinase II 
release from mitochondria and ultimately triggered apoptosis. In short, we 
demonstrated that MWCNTs could be designed into a versatile nanocarrier targeting 
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Chapter 1  Introduction 
 
Section 1.4.1 in this chapter was collated in the following article: 
 
• Wong Bin Sheng, Yoong Sia Lee, et al. Carbon nanotubes for delivery of small 
molecule drugs. Advanced Drug Delivery Reviews, 2013. 65(15): 1964-2015 
 
1.1 Mitochondria and cancer 
 
Mitochondria are double membrane bound organelles of paramount 
importance in cellular processes that are both vital and lethal to mammalian cells. On 
one hand, mitochondria are indispensable for cell survival exemplified by their 
involvement in ATP generation, calcium homeostasis, biosynthesis of amino acids, 
lipids, nucleotides and haem etc. On the other hand, it is long-established that 
mitochondria govern the activation of apoptotic pathways by regulating the 
translocation of pro-apoptotic proteins from the mitochondrial inter-membrane space 
(IMS) to the cytosol, which initiates programmed cell death [1]. In addition, 
mitochondria are also essential in multiple forms of non-apoptotic cell death such as 
autophagy and necroptosis (regulated necrosis) [2, 3].  
Mitochondria harbour own genomic materials (mitochondrial DNA (mtDNA)) 
that encode 13 proteins in the oxidative phosphorylation machinery; 2 ribosomal 
RNAs and 22 transfer RNAs, which are essential for translation within mitochondria 
[4]. Most other (~1,500) proteins constituting the mitochondrial proteome are 
encoded in nuclear DNA, which are subsequently translated in cytosol and sorted to 
mitochondria [5]. Interestingly, mitochondria form a reticular branching network that, 
through interaction with the cytoskeleton, is dynamic and undergoes regular fusion 
and fission [6]. The mitochondrial structural equilibrium, influenced by various 
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metabolic and cellular signals, has been found to affect mitochondrial physiology 
substantially and ultimately impact cellular health [7].  
Given their essential roles, mitochondrial dysfunctions are associated with 
diseases such as diabetes, Alzheimer’s diseases, Parkinson’s diseases [8], and 
particularly tumour survival and progression [9]. Compared to normal cell, cancer 
cell’s mitochondria exhibit stark difference in terms of structure and function [10].  
Cancer cells have adapted to a series of metabolic changes in order to achieve better 
survival regardless of existing conditions such as availability of nutrients. These are 
detailed in the well-regarded Warburg effect, named after Warburg who firstly 
reported such phenomenon in 1927 [11, 12]. The Warburg effect describes malignant 
metabolic alterations encompassing elevated glycolysis [13] as well as defects in 
mitochondrial oxidative respiration (Figure 1.1). These extensive metabolic 
reprogramming also influence the capacity of cancer cells to engage in catabolic 
processes, including apoptosis, necrosis and autophagy [14].  
 
 
Figure 1.1. Normal cells synthesize ATP mainly through oxidative phosphorylation 
whereas malignant cells display elevated glycolysis. In cancer cells, the electron flow 
through the respiratory chain is lesser than normal cells. Hexokinase isoform II 
associates with the voltage-dependent anion channel (VDAC) at the mitochondrial 
outer membrane (OMM) in cancer cells. VDAC interacts with adenine nucleotide 
translocase (ANT) and cyclophilin D (CYPD). The increased binding between 
hexokinase II and VDAC couples ATP produced from mitochondria to the rate-limiting 
step of glycolysis and exaggerates the glycolysis. In cancer cells, pyruvate is 
preferentially converted to lactate by lactate dehydrogenase (LDH) while in normal 
cells the pyruvate generated from glycolysis is imported into mitochondria and enters 
the tricarboxylic acid cycle. (Adapted with permission from Fulda et al., 2010 [9]). 
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Generally, non-cancerous cells depend on oxidative phosphorylation for ATP 
production, whereas cancer cells display augmented glycolysis despite high oxygen 
tension [9]. This is evidenced by the observation that the electron flow through the 
respiratory chain complexes in mitochondria is significantly lower in malignant cells 
compared to normal cells. This preferential ATP generation by aerobic glycolysis 
provides several advantages to cancer cells. Firstly, this allows cancer cells to survive 
under conditions of varying oxygen tension that could be affected by rapidly growing 
malignant accrual [13]. Secondly, elevated production of glucose-6-phosphate by 
aerobic glycolysis could be shuttered into the pentose phosphate pathway to generate 
more biosynthetic precursors for DNA and RNA synthesis to meet the demand of 
highly proliferative cells [15].  
In glycolysis, hexokinase catalyzes the rate-limiting step, which is the 
phosphorylation of glucose into glucose-6-phosphate, in an ATP-dependent manner. 
Particularly, hexokinase isoform II, which is normally found in embryonic tissues and 
certain adult tissues such as adipose, skeletal muscles, and cardiac muscles, is over- 
expressed (>100-fold) in malignant tumors exhibiting high glycolytic phenotype [16, 
17]. Interestingly, hexokinase II associates more tightly to the voltage-dependent 
anion channel (VDAC) at the mitochondrial outer membrane (OMM) of cancer cells 
than normal cells [9]. This spatial advantage couples residual ATP produced from 
mitochondria directly to the rate-limiting step of glycolysis, giving an edge for cancer 
cells to exaggerate its glycolysis.  
In short, the overall increase in anabolism as a result of aerobic glycolysis is, 
at least in part, caused by the extensive metabolic reprogramming during the 
development of malignancies [9]. In accord, up-regulated oncogenic kinase signaling 
promotes the phosphorylation of hexokinase II by survival protein kinase B (Akt) and 
this in turn facilitates the binding of hexokinase II to VDAC [18]. Interestingly, 
hexokinase II association with VDAC has been shown to offer additional advantage 
to the survival of cancer cells, which is the prevention of pro-apoptotic factors from 
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binding to mitochondria and disrupting OMM integrity [19]. Possible therapeutic 
strategies to target the aberrant mitochondrial metabolism of cancer cells thus include 
dissociation of hexokinase II from its interaction with VDAC on mitochondria. 
Apart from metabolic reprogramming occurred at mitochondrial level, 
frequent mutations of the mtDNA (responsible for the synthesis of respiratory chain 
proteins) is characterized in various types of cancer [20]. Numerous polymorphisms 
and mutations of the mtDNA correlate with an increased risk of developing several 
malignancies including breast cancer, prostate cancer and thyroid cancer [21, 22]. 
However, the expression of mutated respiratory chain complex leads to increased 
electron leakage and reactive oxygen species (ROS) overproduction. To counter this 
potentially detrimental consequence, cancer cells have long been observed to contain 
more antioxidants in order to deal with increased ROS challenges that are associated 
with mitochondrial respiratory defects [23]. Importantly, modifications in the levels 
of ROS have recently been linked to multiple hallmarks in cancer cells including 
elevated cell proliferation, DNA damage and genetic instability, resistance to 
chemotherapy, promotion of carcinogenesis and metastasis [24, 25]. Besides 
impairment in mtDNA expression, the lethal functions of mitochondria are also 
deregulated along the way of neoplastic transformation. Pro-apoptotic factors in 
cancer cells are often reduced in number or activity which, combined with the 
overexpression of anti-apoptotic proteins, cause mitochondria to be more resistant to 
apoptotic induction [26, 27].  
 
1.2 Targeting mitochondria for drug delivery 
 
Despite the numerous therapeutic advantages that could be realized by 
targeting mitochondria, there are very few examples of mito-active drugs [28]. This is 
reflected by the challenges of delivering compounds to this organelle, which 
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possesses a convoluted and complex membrane structure that prohibits access to its 
inner space. The mitochondrion is comprised of four distinct compartments: outer 
mitochondrial membrane (OMM), IMS, inner mitochondrial membrane (IMM), and 
the mitochondrial matrix (Figure 1.2). Unaided entry into the IMS is only possible for 
molecules that are able to freely diffuse through the 2 nm aqueous pores known as 
porin or VDAC on the OMM [29]. Gaining access to the matrix is however arduous 
as the IMM is highly convoluted and densely packed with proteins that stands as a 
rigid barrier against passive diffusion of foreign molecules [28]. Furthermore, anionic 
moiety faces additional challenge in approaching mitochondrial matrix due to the 
strong negative membrane potential (-180 mV) maintained by the IMM for generating 
ATP via the electron transport chain (ETC) [28].  
 
 
Figure 1.2. Diagram of a mitochondrion structure and components. The 
mitochondrion is composed of four compartments: OMM, IMS, IMM, and the matrix. 
The matrix houses mtDNA which is plasmid of approximately 17 kb in size. The ETC, 
located on IMM, is constituted by several protein complexes that maintain an 
electrochemical gradient needed for ATP synthesis, giving rise to the -180 mV 
membrane potential. The ETC is a major source of ROS, which is detrimental if left 
unattended. The protein import machinery is composed of the translocase on the 
outer membrane (TOM) and translocase on the inner membrane (TIM). They 
recognize the mitochondrial targeting sequence (MTS) of proteins synthesized in 
cytoplasm and facilitate the import the unfolded protein to its designated compartment 
in mitochondria (Figure adapted with permission from Yousif et al., 2009 [28]). 
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A well-established approach to direct compounds to mitochondria utilises the 
negative charge of the mitochondrial matrix relative to the cytoplasm (Figure 1.2). 
This electrochemical gradient facilitates accumulation of positively charged 
molecules (cations) in the mitochondrial matrix [30]. However, small charged 
molecules are typically hydrophilic in nature and their translocation from the aqueous 
extracellular or cytosolic space through the hydrophobic cell- or mitochondrial-
membranes is energetically unfavourable. Only if such cation is combined with a 
hydrophobic group does the overall molecule become sufficiently hydrophobic so as 
to allow entry across the hydrophobic biological membranes [30-32]. This category of 
lipophilic and membrane-permeable cations is then able to cross through the 
hydrophobic interior of the phospholipid bilayer of biological membranes while 
retaining their overall positive charge. As a result, these lipophilic cations, for 
example the commonly used mitochondrial fluorescence dyes such as JC-1 or 
MitoTracker® dyes (Figure 1.3), are capable of accumulating at mitochondria [33].  
 
 
Figure 1.3. Chemical structure of examples of mitochondrial localizing fluorescence 
dyes. a) JC-1; b) MitoTracker® Red CMXRos. 
 
1.2.1 Delocalized lipophilic cations (DLCs) for targeting to mitochondria 
 
Although a wide range of delocalized lipophilic cations (DLCs) could in 
principle be utilised for drug targeting to mitochondria, only few such compounds 
have been extensively researched for this purpose. The most prominent example is 




surrounded by three hydrophobic phenyl groups that impart an extended hydrophobic 
surface (Figure 1.4a). The TPP moiety has been employed as a probe to explore 
mitochondrial membrane potential for over 40 years and consequently its behaviour 
and interaction with mitochondria are well defined [30-32]. The relative TPP 
concentration inside negatively charged membrane compartments increases by one 
order of magnitude for every 60 mV of negative membrane potential [32]. Due to 
active transport of salt ions by membrane bound pumps, the interior part of plasma 
membrane is negatively charged relative to the exterior side. As a result, the plasma 
membrane potential ranges generally between -30 to -60 mV, which is sufficient to 
promote up to 10 fold accumulation of TPP inside the cell [32]. Meanwhile, typical 
mitochondrial membrane potential is up to -180 mV, which facilitates a 1000 fold 






Figure 1.4. Chemical structure of triphenylphosphonium (TPP) cation and a 
therapeutic complex containing TPP moiety. a) Structure of triphenylphosphonium 
(TPP) cation. b) MitoQ consisting antioxidant Coenzyme Q10 conjugated with 
mitochondrial targeting DLCs triphenylphosphonium (TPP) via a 10-carbon aliphatic 
chain.  
 
The most extensively investigated example showing enhanced therapeutic 
efficacy conferred by conjugation with TPP for mitochondrial targeting is MitoQ, 
which is patented by Antipodean Pharmaceuticals Inc. [34]. It comprises an 
antioxidant Coenzyme Q10 (ubiquinone) conjugated with mitochondrial targeting 
moiety TPP via a 10-carbon aliphatic chain (Figure 1.4b) [35]. MitoQ is the first drug 
actively designed to target mitochondria for attenuation of oxidative damage and it 




disease [36-38]. In vitro experiments showed that MitoQ selectively associated with 
isolated mitochondria and with mitochondria in cells [39]. Such preferential 
distribution to mitochondria prevented hydrogen peroxide-induced cell death more 
effectively than untargeted antioxidants, suggesting that the accumulation of bioactive 
molecules within their target site mitochondria indeed augments their efficacy [40]. 
Another illustrious example, namely gamitrinib (Figure 1.5), is the mitochondrial 
targeted Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) via 
TPP or 1–4 tandem repeats of cyclic guanidinium [41]. The construct exhibited 
profound improvement in efficacy compared to 17-AAG with excellent selectivity for 
cancer cells/tissues in vitro and in vivo. Accordingly, gamitrinib is currently being 
evaluated in clinical settings [42].   
 
 
Figure 1.5. Structure of Gamitrinibs based on combinatorial modular design. The 
individual modules of Gamitrinibs (mitochondrial targeting, linker, and 17-AAG) are 




Another group of DLCs that have been examined for their application in 
directing compounds to mitochondria is rhodamine group of fluorescent compounds. 
Rhodamine compounds have been used as histological stains and some of the 
members have been utilized in investigating energy state of isolated mitochondria 
[43]. Rhodamine 6G, which is positively charged at pH 7, is demonstrated to inhibit 
oxidative phosphorylation and block adenine nucleotide translocation in isolated rat 
liver mitochondria. Meanwhile, its structural analogue rhodamine B, which is 
uncharged at physiological pH, does not affect energy related mitochondrial functions 
[44]. However, rhodamine 123, which is positively charged at physiological pH, does 
not appear to have the disrupting effects of rhodamine 6G [43]. By screening a 
number of rhodamine compounds, it was observed that only those that are positively 
charged at physiological pH (namely 123, 6G, and 3B) would adopt a substantial 
localization at mitochondria whereas the uncharged members (such as B, 19, 110, and 
116) and the negatively charged structural analogue fluorescein would not. This 
suggests that the affinity of cationic rhodamine molecules towards the negative 
potential across the mitochondrial membrane is the basis for the selective 
mitochondrial localization in living cells [33].  
The application of rhodamine compound for directing molecules to 
mitochondria is reported in a recent study wherein two axially ligated 
rhodamine−Si(IV)−phthalocyanine (Rh-SiPc) conjugates, bearing one and two 
rhodamine B, were synthesized (Figure 1.6a) [45]. The conjugate possessed strong 
photocytotoxic but low dark cytotoxic properties towards human nasopharyngeal 
carcinoma (HK-1) cells. Importantly, specific mitochondrial localization in both HK-
1 and HeLa cells is observed.  
Another recent study also reported the use of rhodamine B for mitochondrial 
directing of radiotracer 64Cu [46]. Results from cellular staining assays showed that 
all positively charged rhodamine64Cu derivatives were able to localize at 
mitochondria of U87MG cells. In addition, the complexes were tumour selective due 
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to higher negative mitochondrial membrane potential in U87MG glioma cells than in 
normal human fibroblasts.  
The third example depicting the application of rhodamine B is a 
mitochondrial targeted prodrug for tumour treatment (4FDT-rhoB) (Figure 1.6b). It 
consists of a fluorinated docetaxel derivative (4FDT) conjugated with rhodamine B 
via a biodegradable ester bond [47]. Although the efficacy of such targeted compound 
was inferior to its parent counterpart, the specific delivery of the prodrug to 












Figure 1.6. Chemical structure of the examples consisting rhodamine B moiety for 
mitochondrial targeting. a) rhodamine−Si(IV)−phthalocyanine (Rh-SiPc) conjugates; b) 
fluorinated docetaxel derivative (4FDT) conjugated with rho B (4FDT-rhoB). In both 
illustrations, rhodamine B is highlighted by black bracket. 
 
1.2.2 Peptide-based sequence for targeting to mitochondria 
 
Peptide based sequences form another prominent branch of mitochondrial 
targeting moiety apart from DLCs. Peptide-based mitochondrial molecular 








and relatively straightforward synthesis with amide coupling. These sequences are 
normally derived from cytosolic synthesized proteins destined for trafficking to 
mitochondria. Besides the 13 proteins encoded by mtDNA, the remaining 
mitochondrial proteins are ciphered in the nuclear genome and synthesized in the 
cytosol. Sorting to mitochondria is facilitated through the N-terminal Mitochondrial 
Targeting Sequence (MTS), in which Arg, Ala, or Ser are abundant while negatively 
charged amino acids like Asp or Glu are rare [48]. Despite the weak consensus 
between different MTSs, they are regarded to consist of alternating hydrophobic 
amino acids and positively charged amino acids that form amphiphilic α-helix, which 
is crucial for the import of nascent proteins into mitochondria [48]. Nevertheless, 
these naturally occurring MTSs are lengthy and their application in targeted delivery 
is limited by challenges in generating conjugates that are soluble and cell permeable 
[9].  
In view of this, several synthetic peptides have been designed and reported to 
have mitochondrial targeting activity. Interestingly, some of them have also intrinsic 
pharmacological properties as well. For example, the SS (Szeto-Schiller) peptide 
antioxidants is a class of short peptide antioxidants that also possess the ability to 
penetrate into IMM (Table 1.1) [49]. The structural motif of these SS peptides 
concurs with the general requirement of mitochondrial targeting, which centres on 
alternating aromatic residues (hydrophobic) and basic amino acids (positively 
charged).  
Their antioxidant properties stem from the tyrosine, or dimethyltyrosine residue. 
Tyrosine can scavenge oxy-radicals to form reactive tyrosyl radical, which undergoes 
radical-radical coupling to give dityrosine or react with superoxide to form tyrosine 
hydroperoxide [49]. Dimethyltyrosine is more efficient than tyrosine in scavenging 
ROS [49]. These SS peptides have been demonstrated to scavenge hydrogen peroxide 
and peroxynitrite and prevent lipid peroxidation effectively [50]. As these peptides 
concentrate >1000-fold in the IMM compared to elsewhere in cytoplasm, they 
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prevent oxidative cell death potently with nM ranged half maximal effective 
concentration [49]. By neutralizing ROS generated in mitochondria, these peptides 
inhibit opening of PTPC and cytochrome c release and thus revert apoptosis. Notably, 
their short length eases the production and aqueous solubility. Furthermore, 
preclinical studies recommend their potential application in ischemia-reperfusion 
injury and neurodegenerative disorders [51, 52]. 
 





Compared to SS peptides, another mitochondrial localizing synthetic peptide 
possesses a totally opposite property: instead of preserving mitochondrial function, it 
directly disrupts OMM integrity. This class of peptide is regarded as antibiotic-like 
pro-apoptotic peptides [53]. These peptides adopt a general tendency to be cationic, 
linear and α-helix-forming. In addition, some of them are found to be amphipathic 
with hydrophobic residues distributed on one side of the helical axis and cationic 
residues on the other [53]. As the cationic residues in the sequences are attracted to 
the head groups of anionic phospholipids, these peptides preferentially associate with 
negatively charged membranes. Upon electrostatically associate with the membrane, 
their amphipathic helices disrupt lipid membrane integrity. Both prokaryotic 
cytoplasmic membranes and eukaryotic mitochondrial membranes, composed mainly 
by anionic phospholipid, maintain large negative transmembrane potentials. This is an 
implicit evidence of the shared evolutionary ancestry of bacteria and mitochondria 
[53]. In contrast, eukaryotic plasma membranes have lower membrane potentials and 
are generally constituted by zwitterionic phospholipids [54]. As a result, these 
antibiotic-like pro-apoptotic peptides selectively disrupt prokaryotic membranes and 
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eukaryotic mitochondrial membranes while leaving eukaryotic plasma membranes 
intact. The most researched example for treatment against neoplastic cells by 
targeting mitochondria is a 14-mer peptide with sequence KLAKLAKKLAKLAK 
(KLA peptide) [53, 55-57]. This peptide was originally designed as a synthetic 
antibacterial peptide that selectively disrupts bacterial cell membrane without 
affecting eukaryotic plasma membranes [53, 57]. It was later discovered that KLA 
peptide potently impairs mitochondrial membrane integrity and triggers apoptosis 
once it is internalized into eukaryotic cells. In accord, conjugating KLA peptides with 
tumour homing domain produced combinatorial compounds that specifically 
accumulate at target tumour cells mitochondria, causing destructions and cell death 
[53, 55, 56]. 
The abovementioned examples of short synthetic mitochondrial localizing 
peptides are however of little practical use for delivering bioactive compounds to 
mitochondria as their intrinsic therapeutic properties will confound the efficacy of the 
ultimate conjugated complex. In light of this, Horton et al. (2008) reported 
engineering of synthetic cell-permeable peptides that function as mitochondria 
transporters [58]. In the generated peptide library, amino acid residues were 
modulated to generate wide variations in terms of lipophilicity as it is envisaged that 
the lipophilicity would be a determining factor for intracellular distribution. A variety 
of hydrophobic amino acids were employed, including unnatural residues displaying 
diphenyl, naphthyl, or hexyl functionalities (Figure 1.7). Fluorinated phenylalanine 
(FF), methylated tyrosine (YMe), and tyrosine (Y) residues were also utilized to 













Figure 1.7. Synthetic peptide-conjugate scaffolds tested for mitochondrial specific 
localization. The scaffolds consist of four or eight amino acids linked to the 
fluorophore thiazole orange (red sphere). The lysine and arginine residues (gray 
spheres) were held constant and the residues in blue were altered to modulate 
lipophilicity. The tetrameric peptides possess a charge of +3, while the octameric 
peptides possess a charge of +5. (Adapted with permission from Horton et al., 2008 
[58]) 
 
Investigation of the correlation between mitochondrial localization and the 
lipophilicity of the +3 charged peptides reveals a trend. These cationic peptides have 
to possess sufficient lipophilicity, which is reflected in a log P value, in order to co-
localize with mitochondria. By examining mitochondrial colocalization coefficient 
obtained in HeLa cells, it is deduced that peptides possessing log P values higher than 
-1.7 were driven to mitochondria, while those with log P values lower than -2.0 were 
excluded from mitochondria. When tetrameric peptides possessing a +5 charge were 
evaluated, the same positive association between lipophilicity and mitochondrial 
localization was observed with slight variation. The lipophilicity threshold for 
mitochondrial localization decreases to -2.6 compared to the +3 peptides (-2.0), with 
more hydrophilic scaffolds maintaining mitochondrial specificity. The significance of 
this report lies with the systematic understanding and characterization of 
physiochemical properties of different synthetic peptides that contribute to 
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mitochondrial specificity. Thus it provides a conceptual framework for designing 
synthetic peptides to achieve mitochondrial targeting. Nevertheless, application of 
these synthetic peptides for mitochondrial targeting is unavoidably restricted by 
issues such as ease of synthesis, stability, possible endosomal entrapment, and lack of 
understanding of cellular uptake mechanism [59, 60].  
 
1.3 Nanocarriers and mitochondrial delivery 
 
A therapeutic compound could be selectively delivered to mitochondria via 
covalent conjugation with the abovementioned mitochondrial targeting moiety. 
Nevertheless, this strategy is inevitably accompanied by limitations. For example, 
DLCs are ineffective in directing large polar cargo and intrinsically toxic to 
mitochondria at high concentration. In addition, covalent conjugation of bioactive 
compound with DLCs entails modification of structure that might lead to alteration of 
chemical properties and hence the resulting activity. As a result, an alternative DS 
that can overcome these limitations, i.e. developing a mitochondrial targeting carrier 
to incorporate the drug without modification, is highly demanded.  
In light of this, great attention has been recently devoted to the development 
of a DS that is able to a) cross several biological barriers; b) protect bioactive agents 
from premature deactivation while improving their pharmacokinetic profile; and c) 
increase intracellular bioavailability of the drugs at their target site. One of the 
emerging DS is represented by nanocarriers, i.e. nano-sized materials (possessing at 
least one dimension in the range of 1 – 100 nm) that can incorporate/encapsulate 
therapeutic compounds and be functionalized to carry multiple moieties such as 
imaging agents or targeting ligands at their surface. Nanocarriers, encompassing 
natural and synthetic polymer conjugates, polymeric nanoparticles, lipid-based 
carriers (such as liposomes and micelles), dendrimers, carbon nanotubes, gold, 
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platinum and titanium oxide nanoparticles (including nano-shells and nano-cages), 
have been subjected to intensive research for potential therapeutic applications [61].  
One favourable attribute of nanocarrier as effective DS for cancer therapy is 
the ability to passively accumulate at tumour tissue due to Enhanced Permeability and 
Retention (EPR) effect. Accordingly, the newly formed tumour vessels for supplying 
nutrients to rapidly growing tumour mass are usually abnormal in architecture with 
poor alignment and wide fenestrations. In addition, it is well recognized that tumour 
tissues lack of effective lymphatic drainage [62]. This allows nanocarriers to 
preferentially accumulate at the tumour sites [62] and such property has been 
harnessed for drug delivery to neoplastic tissues, i.e. passive targeting. Besides, due to 
nanocarrier’s high surface area-to-volume ratio, it is possible to achieve high ligand 
density of targeting moiety on the surface for selective targeting [63]. Hence, 
nanocarriers can potentially increase local drug concentration at tumour site by 
carrying drug molecules to tumour and releasing them only in response to altered 
physical conditions specific to tumour microenvironment. Thus, in the context of 
targeting mitochondria for cancer therapy, the development of nanocarriers to carry 
mito-active agents for improved targeting and bioavailability at mitochondria is of 
great interest.  
 
1.3.1 Polymer based nanocarriers directed to mitochondria 
 
In this regard, Maracche and Dhar reported the engineering of mitochondrial 
targeting polymeric nanoparticle and demonstrated flexible application of this 
nanocarrier for therapeutics against diseases such as cancer, diabetes, and 
Alzheimer’s disease [64]. Notably, FDA approved poly(lactic-coglycolic acid) 
(PLGA) and polyethylene glycol (PEG) based materials were used to synthesize the 
nanoparticle, providing a distinctive edge in terms of biocompatibility. This 
accentuates the potential of advancing the nanoparticle to clinical settings in the near 
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future. Mitochondrial targeted PLGA-b-PEG-TPP copolymer was synthesized by 
conjugating TPP at terminal end of PEG. The polymeric nanoparticle was assembled 
by a polymer-blending technology via nanoprecipitation method [65] that is capable 
of fine-tuning the resulting size and surface charges for optimal mitochondrial 
localization. Accordingly, series of different nanoparticles were formed by blending 
PLGA-b-PEG-TPP with either PLGA-b-PEG-OH or PLGA-COOH at different 
percentages to determine the relationship between nanoparticle size and charge, and 
the affinity to mitochondria (Figure 1.8). Maximal mitochondrial uptake was 
observed for nanoparticle possessing a diameter ranging from 80-100 nm with surface 
charge of ~34 mV. Impressively, effectiveness of the targeted polymeric nanoparticle 
as mitochondrial nanocarrier was rigorously demonstrated in vitro. Mitochondrial 
targeted nanoparticle loaded with curcumin, lonidamine, α-tocopheryl succinate, or 
2,4-dinitrophenol consistently exhibited tremendous enhancement in  in vitro 
therapeutic efficacy against model disease cell lines for Alzheimer’s disease, cancer, 
and obesity. Such rationalized study of the relationship between nanoparticle physical 
properties and mitochondrial uptake provides a generalized approach to the design of 
biodegradable nanocarriers for application in mitochondrial medicine.  
 
Figure 1.8. Synthesis of targeted (left) and non-targeted nanoparticles (right) by 
blending PLGA-b-PEG-TPP with either PLGA-b-PEG-OH or PLGA-COOH and the 




In a follow-up study by the same research group, efficacy of the 
mitochondria-targeted polymeric nanoparticle in enhancing immunotherapeutic 
potential of zinc phthalocyanine (ZnPc) photosensitizer (T-ZnPc-NP) was examined 
(Figure 1.9a) [66]. It was revealed that treatment of MCF-7 cells with targeted T-
ZnPc-NP strongly induced apoptosis while treatment with non-targeted ZnPc-NP 
instigated necrosis upon light stimulation. When isolated bone marrow dendritic cells 
(BMDCs) were co-incubated with MCF-7 cells pre-treated with 20 nM T-ZnPc-NP, a 
two-fold increase in TNF-α and IFN-ɣ secretion were observed compared to MCF-7 
cells pre-treated with non-targeted ZnPc-NP (Figure 1.9b). Co-incubation with MCF-
7 cells pre-treated with free ZnPc turned out to be the poorest regimen in stimulating 
cytokines production in BMDCs. Apart from that, T-ZnPc-NP produced potent cancer 





Figure 1.9. Mitochondria-targeted polymeric nanoparticle enhanced 
immunotherapeutic potential of ZnPc photosensitizer. a) Synthesis of T-ZnPc-NP via 
nanoprecipitation; b) Upon light activation, T-ZnPc-NP stimulates ROS production in 
mitochondria, causing apoptosis. Cancer cell antigens generated from such treatment 





1.3.2 Liposome-like nanocarriers for mitochondrial targeting 
   
 One of the most extensively reviewed mitochondrial targeted nanocarriers is 
dequalinium-based liposome-like vesicles (DQAsomes) [67-70]. Dequalinium is a 
molecule with two symmetrical cationic charge centres separated by a hydrophobic 
carbon chain. DQAsome is made from self-assembly of dequalinium chloride into 
vesicle-like aggregates during sonication in an aqueous suspension.  
  This cationic colloidal DS formed complexes with DNA and the resulting 
DQAsome/DNA complexes (DQAplexes) were shown to enter cells via endocytosis 
[67, 71]. The advantage of the DQAsome is the ability to evade endosomal 
compartments while keeping their grasp on the cargo as cationic lipids are known to 
exert a destabilizing effect on endosomal membranes. In addition, Weissig and co-
workers found that DQAplexes were attracted to mitochondria by electrostatic 
interactions and capable of releasing DNA in close proximity to mitochondria [69]. In 
line with the need to combine efficacy and proper delivery, the authors demonstrated 
that DQAsomes were able to deliver plasmid-sized DNA into mitochondria 
selectively [72] with the aid of surface functionalized MTS.  
  DQAsomes have also been investigated for delivering drugs that may exert 
their effect at mitochondria. In this regard, DQAsome incorporating a labelled 
derivative of paclitaxel was shown to partially co-localize with mitochondria [73]. 
Although treatment with DQAsome-paclitaxel in colon cancer cells resulted in 
roughly two-fold increase in number of apoptotic nuclei compared to physical 
mixture of DQAsome and paclitaxel, more in vitro studies are necessary to ascertain 
if the enhancement in efficacy is significant. Unfortunately, most of the vesicles made 
from dequalinium analogs are cytotoxic [74] and this approach to deliver drugs or 
DNA into mitochondria is still in early stage of development lacking in vivo data for 
translation into clinical use. 
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 The other noteworthy attempt to generate mitochondrial directed liposomal 
based nanocarrier was made by Harashima’s group. They developed MITO-Porter, a 
unique nanocarrier capable of introducing different agents into mitochondria via 
membrane fusion [75, 76]. MITO-Porter is an extension of an exclusive “programmed 
packaging” concept called multifunctional envelope-type nano-device (MEND). 
MEND, which is similar to envelope-type viruses, comprises a condensed core of 
cargo (such as plasmid DNA or proteins) and a lipid envelope equipped with various 
functional groups [77]. MEND liposome functionalized with octa-arginine moieties 
(R8) was successful in delivering green fluorescent protein as model macromolecule 
to cytosol, nucleus, and mitochondria, respectively. The independent fusion with 
different organellar membrane was facilitated by specifically optimized lipid 
composition [75, 78, 79].  
 MITO-Porter (Figure 1.10a), due to the high density of its surface-linked R8, 
is internalized by macropinocytosis [80] and attracted towards mitochondria due to 
the strong positive charge of R8.  As for lipid composition, mixture of dioleoyl 
phosphatidylethanolamine (DOPE) with either phosphatidic acid (PA) or 
sphingomyelin (SM)  exhibited highest mitochondrial fusogenic activities [75]. In a 
subsequent study, incorporation of propidium iodide (PI) within MITO-Porter and the 
selective delivery into mitochondrial matrix for detection of mtDNA was attempted in 
isolated rat liver mitochondria [76]. Nevertheless, colocalization of PI-DNA 
fluorescence with mitochondria observed under confocal microscopy was not 






Figure 1.10. Illustration of Mito-Porter. a) Schematic representation of MITO-Porter, 
which is a liposome with surface modified by high density of octaarginine (R8); b) DF-
MITO-Porter: cargos are incorporated within mitochondria-fusogenic lipid envelope 
(inner) and endosome-fusogenic lipid envelope (outer). R8 functions as a cell-uptake 
device in the outer envelope and as a mitochondrial targeting device in the inner 
envelope. 
 
 It is rationalized that failure to deliver PI into mitochondria of live cells stem 
from inefficient endosomal escape. To address this issue, dual function MITO-Porters 
(DF-MITO-Porter) was constructed with double envelope to combine endosomal 
escape and mitochondrial fusion. The outer envelope harbouring endosome-fusogenic 
property consists of DOPE/PA/STR-R8 (7:2:1, molar ratio) while the inner  envelope 
possessing mitochondria-fusogenic features comprises either 
DOPE/SM/CHEMS/STR-R8 (9:2:1:1, molar ratio) or DOPE/PA/STRR8 (9:2:1, 
molar ratio) (Figure 1.10b) [81].  Mitochondrial targeting property of DF-MITO-
Porter was demonstrated in HeLa cells by confocal microscopy and yet the images 
were still inconclusive. Nonetheless, DNAse I incorporated in DF-MITO-Porter (SM) 
or DF-MITO-Porter (PA) displayed higher digestion activity compared to the control 
incorporated in low fusogenic liposomes.  
 To improve targeting of DF-MITO-Porter to mitochondria, MTS was 
experimented besides R8 [82-84]. MTS derived from rat succinyl CoA synthetase 
was appended on liposomes and its intracellular distribution was compared with R8 




binding of the nanocarrier to isolated mitochondria. In addition, MTS significantly 
conferred higher mitochondrial targeting capability to the liposome compared to R8 
in cell homogenate. However, MTS modified DF-MITO-Porter was found to be 
similar with R8-DF-MITO-Porter in terms of mitochondrial targeting capacity, where 
both constructs demonstrated modest association with mitochondria (~20%) in HeLa 
cells [83]. As a result, the same research group hypothesized that the limited 
trafficking to mitochondria was due to possible aggregation in cells stem from 
lengthy sequence of MTS [84]. Synthetic mitochondrial targeting peptides (R8, SS, 
GS, MPP and CP), possessing shorter length than MTS, were tested for their targeting 
capability after being linked on liposomes [84]. Unfortunately, all peptides were 
incapable to enhance mitochondrial targeting of the whole liposomal conjugate. Once 
again, this highlights towering obstacles, including cellular uptake, endosomal escape, 
intracellular barriers (such as cytoskeleton and mitochondrial membrane), persist 
along the way in developing effective mitochondrial targeting liposomal based 
nanocarriers. 
 
1.4 Carbon nanotubes 
 
Rigorous research had been conducted on liposomal/polymeric nanocarriers 
and comprehensive information had been extracted pertaining to their interactions 
with bio-systems. Several milestones were celebrated for nano-therapeutics such as 
the FDA approval and commercialization of DOXIL® (doxorubicin HCl liposome 
injection). Nevertheless, imperfections linger with the conceptual design of these 
nanocarriers, for example instability and leakiness  of liposomes [85]. Hence, there is 
a continual demand to explore novel nanomaterials for delivering therapeutics to 
circumvent the limitations of conventional nanocarriers; carbon nanotubes (CNTs) 
arise as one. 
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Following their discovery in the insoluble soot of arc-burned graphite rods in 
1991 by Japanese physicist Sumio Iijima, CNTs have since gained enormous 
attention as a versatile nanomaterial for diverse applications [86]. CNTs are well-
ordered allotropes of carbon with a cylindrical nanostructure that possess an 
extremely large length-to-diameter ratio. There are many variables in the structure of 
CNTs, including diameter, length, chirality, and layers. Typically, CNTs are 
classified as single-walled carbon nanotubes (SWCNTs), double-walled carbon 
nanotubes (DWCNTs), and multi-walled carbon nanotubes (MWCNTs) with respect 
to the layers formed (Figure 1.11). SWCNTs have diameters close to 1 nm, and they 
can be illustrated as wrapping a one-atom-thick layer of graphene sheet into a 
seamless cylinder. On the contrary, MWCNTs, which can be conceptualized by 
folding multiple layers of graphene sheets, possess outer diameters ranging from 5 nm 








Figure 1.11. Schematic illustration of single-walled carbon nanotubes, double-walled 
carbon nanotubes, and multi-walled carbon nanotubes.  
 
The three main techniques for production of CNTs are electric arc discharge, 
laser ablation, and chemical vapour deposition. These methods involve synthesis at 
high temperature and pressure with the use of reaction catalysts, resulting in fine 
structures of CNTs with concomitant impurities such as graphitic debris and catalytic 
particles. Various methods, for example oxidation, acid treatment, chromatography, 
filtration and functionalization, are commonly employed for purification. With their 
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exceptionally high tensile strength and elastic modulus, CNTs represent one of the 
strongest and stiffest discovered materials [88, 89]. CNTs are also excellent thermal 
[90, 91] and electrical conductors [92], with additional physical attributes such as 
absorption at near-infrared range (NIR) [93], photoluminescence [94], and generation 
of strong Raman signals [95]. These unique properties allow facile and non-
destructive characterization and detection. Because of these tunable distinctive 
features, CNTs have been investigated and applied in the creation of novel and 
functional microelectronics, energy storage devices, filled composites, nanoprobes, 
sensors and templates etc. [96].  
CNTs are hydrophobic in nature and thus insoluble in water, which limits 
their application in the realm of biomedicine. Therefore, various functionalization 
methods have been employed using diverse biocompatible molecules or polymers to 
improve solubility of CNTs for mitigating issues of aggregation. Besides, these 
functionalization approaches also facilitate attachment of bioactive molecules or drug 
compounds to CNTs.  These processes include: 1) non-covalent functionalization on 
the outer wall of CNTs; 2) defect functionalization at the opened tips and sidewall of 
CNTs; 3) covalent functionalization without introducing defects (on sidewall of 
CNTs) [97]. The most common method for non-covalent modification is the physical 
adsorption of functional moieties containing either aromatic or hydrophobic groups 
on the external wall of CNTs through pi-pi or hydrophobic interactions [63]. CNTs can 
also be modified at the defect sides, which could be generated via oxidation, to 
introduce reactive carboxylic acid groups for further functionalization. Accordingly, 
various hydrophilic or hydrophobic molecules can be conjugated with the carboxylic 
acid groups via amide, ester or other linkages. On the other hand, covalent 
modifications on CNTs’ sidewall can be performed through 1,3-dipolar cycloaddition 
of azomethine ylides. Bioactive molecules/drugs/fluorescent probes can then be 
coupled to the free amino groups on the functionalized CNTs. 
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In terms of biomedical applications, CNTs have also demonstrated 
remarkable potentials, particularly in the areas of tissue engineering, thermal ablation 
for cancer therapy and drug delivery [96]. As novel scaffold materials, CNTs are able 
to support the growth of bone cells [98, 99], neurons [100] and cardiomyocytes, and 
even direct or promote the differentiation of stem cells into specific lineages [101]. 
The ability for CNTs, especially SWCNTs, to absorb and convert electromagnetic 
radiation, specifically NIR, into heat or sound energy has been exploited for 
successful photothermal or photoacoustic therapy against cancer cells [102, 103].  
 
1.4.1 Carbon nanotubes as nanocarrier for cancer drugs 
 
Various therapeutic agents, ranging from small molecule drugs such as 
chemotherapeutics, antimicrobials and anti-inflammatory agents, to more complex 
biologics such as peptide-based vaccines, antibodies, and small interference 
ribonucleic acids (siRNA), have been demonstrated to be successfully delivered by 
CNTs using a multitude of strategies [96, 97], resulting in superior efficacy and 
reduced undesirable toxicity.  
CNTs possess unique features that prompt the speculation of their prospects 
of being effective nanocarriers. Firstly, with their nano-sized dimension, CNTs 
preferentially transport chemotherapeutics to tumour tissue due to the EPR effect [62]. 
Secondly, their needle-like shape facilitates transmembrane penetration via the 
“nanoneedle” mechanism that is independent of CNTs’ functionalization and cell 
types [104]. Besides, CNTs have also been shown to enter cells via energy-dependent 
endocytic pathways [105]. Hence, increasing local drug concentration in cytoplasm 
with the use of CNTs would be possible due to their remarkable ability in 
translocating plasma membrane. Thirdly, owing to their high aspect ratios and surface 
areas, CNTs display extraordinary capacity for drug loading via covalent or non-
covalent approach [106]. Besides the external surface, the interior space of CNTs 
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represents an alternative promising site for drug repository to minimize premature 
deactivation. Encapsulating drugs within the interior cavity of CNTs obviates the 
need of forming chemical bonds between drug molecules and CNTs, thus preserving 
the chemical structure and activity of the therapeutic compounds. Moreover, this 
approach does not obstruct CNTs’ external surface for further functionalization.  
To further augment the efficacy of CNT-based nanocarriers for cancer 
therapy, targeting molecules such as folic acid (FA) [107], antibodies [108], 
epidermal growth factor (EGF) [109] etc., can be further functionalized on the drug-
loaded CNTs (either covalently or non-covalently) to confer active targeting via 
receptor-mediated endocytosis. Besides, imaging molecules, for example radioactive 
nuclides [110] or fluorescence probes [108], can also be conjugated on CNTs’ 
sidewall for straightforward detection and examination of their intracellular 
trafficking or bio-distribution in vitro or in vivo. Coupled with the NIR absorption 
property, multimodal nanocarriers can be created by combining NIR-induced 
photothermal therapy, tumour detection, and selective drug release [111].  
While chemotherapy has long been employed to prevent the progression of 
cancers, either alone or in combination with other treatment modalities like surgery 
and radiation, it is often inevitably accompanied by undesirable systemic toxicity due 
to non-specificity, narrow therapeutic window and the persistent complication of drug 
resistance. Therefore, novel means of selectively delivering anticancer drugs to 
tumours with improved therapeutic efficacy and reduced adverse effects are highly 
desired. In this regard, numerous studies have demonstrated versatility of CNTs as 
nanocarriers for different anti-cancer drugs such as camptothecin, irinotecan, 
etoposide, epirubicin, daunorubicin, methotrexate, gemcitabine, docetaxel (DTX), etc 
[96]. In this dissertation, we limit the elaboration of anticancer drugs delivered using 
CNTs to three most common examples: doxorubicin (DOX), paclitaxel (PTX), and 
platinum (Pt) based anticancer drugs. The discussed studies are summarized in Table 
1.2.   
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Table 1.2. Summary of the discussed examples of using CNTs for delivery of doxorubicin (DOX), paclitaxel (PTX), and platinum (Pt) based anticancer drugs. 
 
CNT System Drug Loading Targeting Mechanism Biological studies Reference 
Doxorubicin 
SWCNTs functionalized with PEG with cyclic 
RGD 
 
Physical adsorption Cyclic RGD against 
integrin αvβ3 
Uptake & cytotoxicity in U87MG & MCF-
7 
[112] 
MWCNTs dispersed with Pluronic F127 
 
Physical adsorption - Cytotoxicity in MCF-7 [113] 
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SWCNTs functionalized with polysaccharide 
coating (CHI &/or sodium alginate) & FA 
 
Physical adsorption FA against FR Uptake & cytotoxicity in HeLa [107] 
SWCNTs functionalized with branched PEG 
2500-NH2 & FA 
 
Physical adsorption FA against FR Uptake & cytotoxicity in HeLa [114] 
EDBE-conjugated MWCNTs covalently 
functionalized with HA 
 
Physical adsorption HA against HR Uptake & cytotoxicity in A549 
 
Biodistribution in EAT bearing mice 
 
Efficacy in chemically-induced breast 
cancer bearing SD rats 
 




MWCNTs covalently functionalized with 
amine-terminated PAMAM dendrimers 
modified with FITC & FA 
 
Physical adsorption FA against FR Uptake & cytotoxicity in high & low FR 
expressing KB 
[116] 
Iron NP-filled PSS modified CNTs conjugated 
with poly(allylamine)-functionalized SiO2-
coated CdTe QDs linked to transferrin 
 
Physical adsorption Transferrin against  
iron nanoparticle for 
magnetic targeting 
Uptake in HeLa & HEK 293 
 
Cytotoxicity in HeLa 
[117] 
CHI-coated SWCNTs covalently 
functionalized with FITC 
 
Physical adsorption - Uptake in EPC [118] 
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Physical adsorption Angiopep 2 peptide 
against LRP receptors 
Uptake & cytotoxicity in C6 & BCED 
 
Biodistribution, efficacy & toxicity in 
glioma bearing BALB/c mice injected with 
C6 into right striatum 
[119] 
MWCNTs linked with EDBE conjugated with 




Physical adsorption FA against FR 
HA against HR 
ES against ER 





Amine-MWCNTs conjugated covalently with 
DEX mesylate 
 
Physical adsorption DEX mesylate for nuclear 
targeting 
Uptake & cytotoxicity in A549 [121] 
SWCNTs non-covalently functionalized with 
FA-terminated methoxy-PEG
 
Physical adsorption FA against FR Uptake & cytotoxicity in HeLa & 3T3 [122] 
SWCNTs covalently linked to P-gp antibody 
labeled with FITC 
Physical adsorption Antibody against P-gp Uptake & cytotoxicity in K562 sensitive & 





PEGylated SWCNTs & MWCNTs 
 
Physical adsorption - Cytotoxicity in MCF-7 & HeLa [124] 
SWCNTs covalently functionalized with biotin 
& fluorescein 
 
Chemical conjugation via 
cleavable disulfide bond 
Biotin against surface 
biotin receptors 





SWCNTs adsorbed with branched PL-PEG 
 
Chemical conjugation via 
ester bond 
- Cytotoxicity in 4T1 
 
PK, biodistribution, efficacy & toxicity in 
BALB/c mice subcutaneously injected 
with 4T1 
[126] 
CNTs (no mention on the specific type) non-
covalently functionalized with PL-PEG-NH2 
 
Physical encapsulation - Synergism study between PTX & C6-
ceramide in L3.6, PANC-1 & MIA PaCa-2 
 
Uptake & cytotoxicity in L3.6. 
[127] 
Platinum (Pt) based drugs 
SWCNTs non-covalently functionalized with 
PL-PEG-NH2 
 





SWCNTs non-covalently functionalized with 
PL-PEG-NH2. FA was attached to the 
remaining axial ligand on Pt(IV) prodrug 
 
Chemical conjugation FA against FR Uptake & cytotoxicity in JAR, KB & 
NTera-2 
[129] 
Oxidized SWCNTs functionalized with EGF 
 
Chemical conjugation via 
ester bond 
EGF against EGFR Uptake in HN13 with EGFR & EGFR-
knockdown. 
 
Cytotoxicity in HN13 with & without 
EGFR, NIH-3T3 & SAA 
 










Doxorubicin (DOX) is undoubtedly the most extensively reported drug model 
in studies of developing CNTs as nanocarriers for cancer therapy. Doxorubicin, a 
topoisomerase II inhibitor, is a widely-used chemotherapeutics for the treatment of 
several human cancers such as bladder, breast, lung, stomach, ovarian cancer etc. In 
spite of their excellent clinical effectiveness, the use of DOX is unfortunately plagued 
with dose limiting myelo-suppression, alopecia, acute nausea and vomiting, vesicant 
effects and, most notably, cardio-toxicity. More effective and safer means of 
delivering DOX specifically to tumour are therefore of paramount interest. In light of 
this, liposomal formulation of DOX, for instance Doxil® and Myocet®, have been 
designed, developed, and applied clinically with lower incidence of cardiotoxicity 
[130, 131]. 
However, the effort of exploring more robust nanocarrier for DOX delivery 
never ceases. By exploiting the feature of DOX’s flat aromatic tetracyclic structure, it 
is revealed that considerable pi-pi and hydrophobic interactions could be established 
with the similar aromatic surfaces of CNTs. In this regard, Liu et al. has engineered 
PEG functionalized SWCNTs supra-molecularly attached with DOX at an ultrahigh 
loading capacity of around 400% [112]. Another study using similar strategy to load 
DOX on MWCNTs dispersed with 1% Pluronic F127, was reported by Ali-Boucetta 
et al. shortly after, validating the results of Liu et al. and suggesting that the non-
covalent attachment of DOX are applicable to both SWCNTs and MWCNTs [113]. 
Remarkably, the MWCNT-DOX complex exhibited significant enhancement in 
cytotoxicity in MCF-7 cells. Meanwhile, the DOX-free carrier (MWCNTs dispersed 
with Pluronic) did not impact cell viability, inferring that the cytotoxicity effect was 
entirely stemmed from improved DOX efficacy. 
The physicochemical properties of DOX are susceptible to changes in 
environmental pH due to presence of an amine group in its structure. Typically, DOX 
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remains unionized and hydrophobic under neutral and basic pH. However, under 
acidic condition, the amine on DOX would be protonated and this leads to an increase 
in overall hydrophilicity. This characteristic is exploited in the loading and release of 
DOX from CNTs. Several studies have consistently verified higher degree of DOX 
loading in basic conditions, as DOX associates stronger with CNTs via pi-pi and 
hydrophobic interactions in its unionized state [114-117]. On the contrary, it was 
demonstrated that DOX dissociated from CNTs’ surface more readily in acidic 
environment than basic conditions due to the protonation of amine [107, 112, 117-
119]. This differential rate of drug release in different pH can be useful in targeted 
delivery of DOX to cancer cells, as tumour microenvironments tend to be more acidic. 
On top of that, as the internal pH environment of lysosomes is acidic (pH 5.5), release 
of DOX from CNTs can be triggered automatically after receptor-mediated 
endocytosis and internalization of the CNT-DOX complex into lysosomal 
compartments, enabling free DOX to enter nucleus and exert its cytotoxic effect.  
To validate this postulation, fluorescein isothiocyanate (FITC) was 
functionalized on SWCNTs that was supra-molecularly loaded with DOX in order to 
study its intracellular trafficking in endothelial progenital cells. DOX appeared 
initially as red fluorescence of lower intensity (due to quenching as a result of energy 
transfer mediated by the pi-pi interaction) and overlapped with the FITC-labelled green 
coloured CNTs in lysosomes. Subsequently in a time dependent manner, DOX was 
observed to be detached from the SWCNTs inside the acidic lysosomes. The released 
free DOX with brighter red fluorescence moved into nucleus, leaving the CNTs 
carrier in the peri-nuclear region without significant exocytosis after 3 h [118]. This 
release and distribution pattern of DOX ensuing CNT–DOX complex uptake in is 
consistent with other studies in other cell types that also used FITC as fluorescent 
label for CNTs [114, 116, 117]. 
To further enhance the therapeutic efficacy and safety profile of DOX, a 
plethora of strategies has been adopted to target CNT-DOX complex selectively to 
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cancer cells. Different small molecule targeting groups such as hyaluronic acid, 
estradiol, and dexamethasone mesylate have been successfully conjugated on CNTs 
[115, 120, 121]. However, as folic acid (FA) is the most commonly used model for 
targeting CNTs to demonstrate enhanced tumour selectivity, only related studies will 
be discussed. It is shown in several studies that supra-molecularly loaded CNT–DOX 
complexes with additional FA functionalization were internalized more efficiently by 
cancer cells overexpressing folate receptor (FR) via FR-mediated endocytosis. 
Moreover, FR targeted CNT-DOX was more cytotoxic than its non-targeted 
counterpart [107, 114, 122]. In one study, DOX loaded oxidized MWCNTs 
containing carboxylic groups were covalently attached with amine-terminated 5 
poly(amidoamine) (PAMAM) dendrimers modified with FITC and FA. The 
constructs were selectively internalized by human epithelial carcinoma KB cells 
expressing high level of FRs and consequently resulted in high toxicity [116]. The 
same construct without FA functionalization, on the other hand, demonstrated 
indiscriminately low uptake and cytotoxicity in both KB cell types. Unfortunately, the 
potency of DOX delivered by the multifunctional MWCNTs complex was at most 
equivalent to free DOX and the free DOX actually displayed considerably higher 
level of cellular uptake. Similar result of FA-conjugated CNT–DOX system being 
more effective than non-FA-conjugated construct (but less potent than free DOX) was 
reproduced in another study, and it was presumably due to slow release of DOX [114]. 
Other than small molecule cancer targeting compounds, biological molecules 
such as peptides, antibodies and even DNA, have also been engaged in order to 
endow DOX-loaded CNT-based nanocarrier with tumour selectivity. In one example, 
cyclic Arg-Gly-Asp (RGD) peptide recognizing integrin αvβ3 that is up-regulated in 
many tumours was conjugated on the terminal group of PEG-functionalized SWCNTs 
loaded with DOX. Higher degree of uptake and cytotoxicity compared to non-
targeted construct without cyclic RGD were observed in integrin αvβ3 positive 
U87MG human glioblastoma cancer cells [112]. While the half maximal inhibitory 
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concentration (IC50) values obtained for cyclic RGD–PEG-SWCNT–DOX were still 
higher than that of free DOX, the targeted construct was found to be more selective 
for tumours that overexpress integrin αvβ3, as it was relatively less toxic to integrin 
αvβ3 negative MCF-7 cells.  
P-glycoprotein (P-gp), found in cancer cells manifesting multidrug resistance, 
is a transmembrane efflux pump that facilitates extrusion of anticancer drugs. 
Targeting DOX to cancer cells using SWCNTs functionalized with antibody against 
P-gp was proved to be effective. A 23-fold enhancement in cellular uptake and 
cytotoxicity in P-gp overexpressing K562 human leukemia cells was observed 
compared to free DOX and non-targeted construct without P-gp antibody [123]. 
Hence, intracellular delivery of DOX was boosted, which is also due to the difficulty 
for P-gp to pump out the entire CNT–DOX complex.  
With the goal to deliver DOX to brain tumours across blood brain barriers, 
angiopep-2 (a peptide that binds to lipoprotein receptor-related protein receptors 
(LRP), which are overexpressed on both blood brain barriers and glioma [132]) was 
covalently attached to phospholipid (PL)-PEG functionalized MWCNTs supra-
molecularly loaded with DOX [119]. Higher uptake of the angiopep-2 tethered 
construct was observed in lysosomes of both brain capillary endothelial cells (BCEC) 
and C6 glioma cells compared to non-targeted construct without angiopep-2. In terms 
of efficacy, the construct also exert heightened toxicity in glioma cells compared to 
free DOX and the non-targeted construct. Intriguingly, the non-targeted CNT 
construct was found to be almost a fold less active than free DOX. Nevertheless, to 
further substantiate the claim on LRP selectivity offered by angiopep-2 
functionalization, it is necessary to include other brain cancer or non-cancerous cell 







Taxanes target and stabilize microtubules, leading to elevated tubulin 
polymerization. Taxane family of compounds includes paclitaxel (PTX) and 
docetaxel (DTX). Both PTX and DTX are widely used in chemotherapy against solid 
tumours, particularly those that are resistant to front line cytotoxic drugs [133, 134]. 
However, taxanes are poorly soluble in water and specific formulations are tailored to 
improve the solubility and bioavailability while alleviate the side effects [124]. For 
example, Taxol® is administered intravenously (i.v.) with Cremophor EL 
(polyethoxylated castor oil) and ethanol as co-solvents [135]. Nevertheless, this 
formulation entails undesirable complications such as hypersensitivity, anaphylaxis 
etc. Additionally, i.v. administered PTX is rapidly cleared from the bloodstream [136] 
while oral administration is hampered by poor bioavailability as a result of low 
solubility and P-gp efflux in digestive tracts [135]. Therefore, application of 
nanocarrier for PTX delivery has been intensively researched. A notable development 
to improve therapeutic profile of PTX is the introduction of Abraxane® (PTX bound 
human albumin nanoparticle), which has been approved for clinical use [137].  
CNTs have been explored as alternative DS for taxanes. Unlike DOX where a 
planar aromatic tetracycline plane exists, the aromatic rings in PTX are however not 
aligned in a common plane. Hence supra-molecular interaction via non-covalent pi–pi 
stacking with CNTs could not be accomplished [124]. As a result, alternative 
approaches for incorporating PTX are adopted. In one example described by Chen et 
al., SWCNTs was covalently functionalized with a second generation taxoid (SB-T-
1214) via linker that can be easily cleaved by intracellular thiols [125]. After cellular 
internalization, the taxoid was postulated to be cleaved and released in the presence of 
thiols to exert its bioactivity. Biotin molecule was additionally functionalized on the 
SWCNTs for targeting tumour cells overexpressing surface biotin receptors. In vitro 
efficacy was studied using leukemia cell line L1210FR (overexpressing surface biotin 
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receptor), W138 human lung fibroblasts, and murine leukemia L1210 cells (with 
basal expression of surface biotin receptor). Biotinylated-CNT-taxoid nano-conjugate 
displayed superior efficacy with a significantly lower IC50 value in L1210FR cell line 
compared to L1210 and W138. In addition, the nano-conjugate entered cells via 
receptor-mediated endocytosis and the drug was released thereafter, which enabled 
the formation of stable microtubule-taxoid complexes. Consequently, mitosis was 
halted and apoptosis was elicited.  
In another attempt, a water soluble SWCNT-PTX conjugate was designed 
and synthesized by Liu et al. by attaching PTX via ester bond to branched PL-PEG 
chains adsorbed on SWCNTs [126]. A drug loading efficiency of around 150 PTX 
molecules on every 100 nm of CNT was reached. The SWCNT-PEG-PTX conjugate 
exhibited excellent stability without agglomeration in various biological media 
including serum. However, in vitro cytotoxicity of the SWCNT-PEG-PTX conjugate 
was found to be comparable to conventional Taxol® against 4T1 murine breast 
cancer cells.  
In contrast to abovementioned covalent approaches involving chemical 
modification of PTX that could compromise the bioactivity, Lay et al. reported 
physical adsorption of PTX on sidewall of PEGylated SWCNTs and MWCNTs [124]. 
PTX was loaded by immersing PEGylated CNTs in saturated PTX solution. The final 
constructs PTX loaded PEG-CNTs were dispersed in aqueous solution well without 
aggregation. The loading capacity was considerably high at 26-36% w/w and this was 
attributed to strong hydrophobic interactions between PTX and CNTs in methanol 
solution during loading procedure. PTX was released from PTX-PEG-CNTs several 
times faster than free hydrophobic PTX in phosphate-buffered saline (PBS) at pH 7.4. 
Notably, at pH 7.4, the release rate of PTX from PEG-SWCNTs was higher than 
PEG-MWCNTs. The release profile is however different at pH 5 wherein PTX was 
released from SWCNTs at a slower rate compared to constructs based on MWCNTs. 
In vitro efficacy conducted in MCF-7 and HeLa cells demonstrated that PTX-PEG-
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CNT displayed higher degree of cytotoxicity with lower IC50 than free PTX. 
Meanwhile, bare PEG-CNTs control exerted negligible toxicity to both cell lines.  
Wu et al. reported an intriguing approach in controlling the release of PTX 
and another water insoluble drug C6-ceramide from the CNTs core by inductive 
heating with an external alternating current or magnetic field pulses [127]. The drugs 
were loaded by depositing the drug solutions at the upper part of vertical CNTs 
anchored on a membrane with a vacuum suction at the bottom. After encapsulation, 
the drug concentration loaded inside CNTs was 100 times lower (PTX: 0.03 µg/mL 
and C6-ceramide: 0.1 µg/mL) than the one used in exogenously applied treatment 
(PTX: 3 µg/mL and C6-ceramide: 10 µg/mL). Even at such higher doses, PTX alone 
or C6-ceramide alone had limited effects in curbing the growth of three multidrug 
resistant pancreatic cancer cell lines. On the contrary, CNTs loaded with PTX and 
C6-ceramide potently induced cell death, indicating the existence of a synergistic 
relationship between the 2 agents. In addition, alternating current or magnetic field 
resulted in controlled release of PTX and C6-ceramide from the CNTs, and the 
therapeutic approach resulted in over 70% cell death, whereas almost 100% of cells 
remained viable in the absence of alternating current or magnetic field. This DS 
enables the delivery of PTX and C6-ceramide at a much lower concentration with 
“on-command” release control and yet comparable cytotoxicity. 
 
1.4.1.3 Platinum (Pt) based drugs 
 
 Platinum (Pt) based anti-cancer agents chelate DNA, forming intra-strand 
adducts that impair transcription and replication, which ultimately triggers apoptosis 
[138]. While being highly effective in limiting tumour progression, the use of Pt-
based drugs is unfortunately restricted by severe dose limiting nephrotoxicity, 
neurotoxicity, and myelosuppression, arising from pre-mature aquation and non-
specific target interactions [139]. Furthermore, premature loss of activity in active 
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Pt(II) complexes is related to poor circulation, limited tumour delivery, and the 
presence of inactivation mechanisms in living biological systems [138]. Hence, in 
order to circumvent premature inactivation of Pt(II) drugs, designing of more inert 
Pt(IV) prodrugs or combining Pt(II) drugs with drug carriers has gained intensive 
research focus [140, 141]. 
An earlier exploration of Pt drug delivery using CNTs was reported jointly by 
Lippard and Dai's research groups, whereby a Pt(IV) prodrug tethered SWCNT 
conjugate was constructed and demonstrated to effectively deliver a lethal dose of 
cisplatin (CDDP) upon intracellular reduction [128]. cis,cis, trans-
[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)], a Pt(IV) complex, was synthesized and 
covalently linked to the surface of SWCNTs, which have been non-covalently 
functionalized with amine-ended PL-PEG chain (SWCNT-PL-PEG-NH2), through 
one of its axial carboxylic (COOH) ligands. This SWCNT-based construct was 
estimated to carry an average of 65 Pt(IV) centres per CNTs. Evidenced by a positive 
shift in the reduction potential of the Pt(IV) complex under pH 6.0, it is speculated 
that after cellular uptake, the low pH in endosomes would facilitate Pt release by 
reductively cleaving the axial ligands linking the Pt(IV) complex to the SWCNTs. 
Remarkably, in testicular carcinoma cells NTera-2, the nano-conjugate showed more 
than 25-fold enhancement in cytotoxicity compared to the Pt(IV) prodrug, while a 
2.5-fold improvement in efficacy was observed compared to CDDP. Pt concentration 
of the cytoplasmic and nuclear fractions of cells treated with the SWCNT-Pt(IV) 
conjugate were 6-8 and 2 times higher than the cells exposed to free Pt(IV) prodrug 
and CDDP alone, respectively. 
A further development to the nano-conjugate was the derivatization of Pt(IV) 
with targeting molecule FA through the remaining axial ligand, forming Pt(IV)-FA. 
The synthesized complexes were then tethered in the same way as reported in the 
abovementioned study [129]. The selectivity of SWCNT-Pt(IV)-FA is demonstrated 
by performing efficacy studies in a three cell lines, FR overexpressing human 
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choriocarcinoma cells JAR and nasopharyngeal carcinoma cells KB, and non-
overexpressing control NTera-2. Both SWCNT-Pt(IV)-FA and Pt(IV)-FA exhibited 
superior cytotoxicity to CDDP in FR overexpressing cells. This implies that FA 
indeed enhanced the uptake and hence cytotoxicity of Pt(IV) complex in FR positive 
cells. Additional proof of FR selectivity is provided with the finding that the IC50 of 
SWCNT-Pt(IV)-FA and CDDP were similar (0.048 µM versus 0.044 µM) in FR 
negative NTera-2 cells. Notably, the enhancement offered by FA was found to be 
further magnified by the use of SWCNTs nanocarriers with 8-fold improvement in 
cytotoxicity compared to the compound alone. When KB cells were incubated with 
SWCNT-Pt(IV)-FA, their nuclear fraction contained considerable amount of Pt while 
such finding could not be observed in Pt(IV)-FA treated cells, indicating that 
SWCNTs facilitated the delivery of Pt to nucleus effectively.  
Another study on targeted delivery of CDDP using SWCNTs was reported by 
Bhirde et al., in which oxidized SWCNTs were functionalized with EGF and either 
CDDP or quantum dot (QD) via direct covalent amide linkage, yielding SWCNT-
CDDP-EGF or SWCNT-QD-EGF [109]. Confocal microscopy and transmission 
electron microscopy (TEM) consistently showed a higher uptake of SWCNT-QD-
EGF in EGFR-expressing head and neck squamous carcinoma cells HN13 compared 
to EGFR-depleted HN13 counterpart. While 10 µM CDDP treatments appeared non-
detrimental, HN13 cells treated with 1.3 µM SWCNT-CDDP-EGF exhibited 
considerable impairment in cell growth. On the other hand, HN13 EGFR-depleted 
cells were minimally affected. To further validate the selectivity offered by targeting 
EGFR, NIH-3T3 fibroblasts, which express less EGFR than HN13, and its EGFR 
overexpressing counterparts SAA cells, were also included in the cell proliferation 
study. It was shown that 70% and 90% of growth inhibition occurred exclusively in 
1.3 µM SWCNT-CDDP-EGF treated HN13 and SAA cells but not in NIH-3T3 cells. 
However, growth inhibition was absent with 10 µM CDDP treatment across all cell 
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lines. These findings indicate that SWCNT-CDDP-EGF with 1.3 µM equivalent of 
CDDP were more cytotoxic and EGFR-selective than 10 µM free CDDP. 
 
1.4.2 Carbon nanotubes as nanocarrier for peptide delivery 
 
Besides small molecule drugs, CNTs have also been demonstrated in 
numerous studies as useful nanocarriers for different bioactive peptides. In one 
example, chemical modification of the sidewall of SWCNTs through 1,3-dipolar 
cycloaddition of azomethine ylides was performed to obtain amine-functionalized 
SWCNTs. After that, a model of penta-peptide and an antigenic epitope from the 
foot-and-mouth disease virus (FMDV) were covalently linked to the functionalized 
SWCNTs (Figure 1.12) [142]. The antigenic peptide corresponds to the sequence of 
residues 141-159 (GSGVRGDFGSLAPRVARQL) of the VPI protein of the virus, 
and it was modified at the N-terminal with an acetylated cysteine. The FMDV 
peptide-SWCNT conjugate was shown to retain the peptide’s structural integrity by 
2D nuclear magnetic resonance spectroscopy. Interestingly, through surface plasmon 
resonance analysis and enzyme-linked immunosorbent assay, it is suggested that the 
peptide bound to the SWCNTs adopts the correct secondary conformation necessary 













Thereafter, two different peptide-SWCNT conjugates were synthesized by 
covalently attaching FMDV peptide to mono- or bis-maleimido derivatized SWCNTs 
using selective chemical ligation (Figure 1.13) [143]. Again, surface plasmon 
resonance analysis revealed that the epitope was appropriately presented for 
recognition by antibodies after conjugated on SWCNTs. Notably, when these peptide-
SWCNT conjugates were injected in mice intraperitoneally, strong anti-peptide 
antibody response was elicited, while cross-reactivity to SWCNTs was negligible. 
Nevertheless, while the mono-derivatized peptide-SWCNT conjugate induced high 
levels of virus-neutralizing antibodies, the bis-derivatized conjugate failed to do so. 
One of the possibilities accounting for such observation is that the two copies of the 
FMDV peptide displayed by the bis-conjugate might interact in vivo and adopt a 
different conformation than the native one displayed on the virus. Another study 
performed by the same research group reported that functionalized SWCNTs were 
able to deliver a fluorescein isothiocyanate (FITC)-labeled peptide responsible for G 
protein function across the cellular membrane. In addition, the construct was found to 











Figure 1.13. Chemical structures of a) mono-derivatized FMDV-SWCNT conjugate 

























In another study, SWCNTs were employed as antigen carriers for poorly 
immunogenic Wilm’s tumor protein (WT1) peptide 427 against tumour, particularly 
hematopoietic malignancies [145]. Spectrally quantifiable chemical approaches were 
adopted to covalently append WT1 peptide ligands onto solubilized SWCNTs and a 
loading of 0.4 mmol/g was achieved. WT1 peptide-SWCNT constructs were rapidly 
internalized in vitro into professional antigen presenting cells (mainly dendritic cells 
and macrophages) within minutes in a dose-dependent manner. Delivery of WT1 
peptide antigen using SWCNTs maintained, but did not enhance, the specific CD4 T 
cell response in vitro compared to exposure with peptide alone. It is justified that 
increasing the number of peptide/major histocompatibility complex formed through 
SWCNTs delivery could not further stimulate the T cell receptor signalling beyond its 
maximum level of activation. Serendipitously, immunization of BALB/c mice with 
the same peptide-SWCNT constructs mixed with immunological adjuvant (TiterMax) 
induced specific immunoglobulin G responses against the peptide, while the peptide 
alone or the peptide mixed with the adjuvant failed to induce comparable response. 
Antibody responses to empty SWCNTs carriers were not detectable in vivo. 
 
1.4.3 Carbon nanotube and mitochondria 
  
Given the versatility and effectiveness of CNTs in delivering various drugs, it 
would be intriguing to explore opportunity for CNTs in mitochondrial medicine. As a 
matter of fact, the application of CNTs in organellar targeting, be it mitochondrial or 
lysosomal delivery, is still at infancy stage. In an exploratory study, FITC labelled 
PL-PEG (PL-PEG-FITC) functionalized SWCNTs (SWCNT-PL-PEG-FITC) (Figure 
1.14) were serendipitously found to be localized at mitochondria in both tumour and 
normal cells (HeLa, MCF-7, ASTC-a-1, COS 7, and EVC304) in a mitochondrial 
transmembrane potential dependent manner [146]. On the contrary, in RAW264.7 
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murine macrophage, SWCNT-PL-PEG-FITC was observed to be mainly distributed 
in lysosomes instead of mitochondria, possibly due to lysosomal trafficking following 
phagocytosis. Notably, when SWCNTs were functionalized with molecules that are 
normally internalized by receptor-mediated endocytosis [FA and bovine serum 
albumin (BSA)], the whole constructs were found to distribute to lysosomes. On the 
contrary, the SWCNTs would travel to mitochondria ensuing direct membrane 
penetration when the functionalized moiety is small molecule chemical compound 
(FITC and PI). Since SWCNTs have been shown to be a potent NIR absorbing 
nanomaterial for thermal destruction of tumour cells [102], this specific mitochondrial 
localization property was capitalized. It was observed that SWCNT-PL-PEG induced 
apoptosis in HeLa cells via mitochondrial damages after irradiation with NIR laser. 
Nevertheless, it should be noted that SWCNTs in this study were not actively 
designed for mitochondrial targeting. Moreover, the exact attributes of SWCNT-PL-
PEG-FITC (for example overall charge of the conjugate) that are responsible for 








Figure 1.14. Structural depiction of SWCNT-PL-PEG-FITC. 
 
Thereafter, two follow-up studies were reported on harnessing the 
mitochondrial localizing property of SWCNT-PL-PEG-FITC in therapeutic regimen 
for cancer [103, 147]. The first study exploited mitochondrial targeting SWCNT-PEG 
in photo-thermal therapy for selective cancer cells destruction via impairing 
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mitochondria. Irradiation using a 980 nm laser at 1 W/cm2 for 120 s of SWCNT-PEG 
in the solution caused elevation of bulk temperature to 76°C whereas irradiation of 
bare aqueous solution led to a temperature increase to only 45°C.  Notably, SWCNT-
PEG selectively destructed target cells mitochondria after irradiation with NIR laser. 
This was demonstrated by mitochondrial depolarization, cytochrome c release, and 
caspase 3 activation in mouse mammary tumour EMT6 cells after the combinatorial 
treatment. Importantly, in female Balb/c mice with EMT6 xenograph, injection of 
SWCNT-PEG plus laser irradiation resulted in an excellent tumour growth 
suppression with a survival rate of 75% and six out of 16 mice displayed complete 
tumour regression. 
Besides photo-thermal therapy, mitochondrial localizing SWCNT-PEG was 
shown to be effective as photo-acoustic treatment modality against cancer [147]. This 
strategy takes advantage of the characteristic that SWCNTs were internalized by 
cancer cells at higher degree than normal cells due to a heightened mitochondrial 
transmembrane potential. With irradiation using a 1064 nm pulse laser, 79.4% of 
EMT6 cells containing SWCNT-PEG intracellularly died within 20 s. This 
combinatorial treatment eliminates cancer cells mainly by triggering apoptosis as a 
result of mitochondrial damage manifested by the membrane depolarization and 
cytochrome c leakage. Notably, this strategy was shown to selectively destroy tumour 
tissue without causing epidermis injury in vivo. Taken together, these discoveries 
pave the establishment of a potential approach using mitochondria-localized 
SWCNTs as photothermal/photoacoustic transducers for cancer treatment. 
On the other hand, the design and synthesis of CNTs for active mitochondria-
targeting has been reported recently [148]. In that study, MWCNTs were 
functionalized covalently with an established MTS derived from N-terminal region of 
subunit VIII of human cytochrome c oxidase (Figure 1.15). The unique mitochondrial 
localizing property of the MTS-MWCNTs, which was fluorescently labelled with a 
sulforhodamine B probe, was validated in RAW264.7 and HeLa cells using wide-
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field epifluorescence microscopy, confocal microscopy, and TEM. The colocalization 
of the conjugates with mitochondria was further confirmed by the presence of 
MWCNTs in isolated mitochondria observed under TEM. Different from the work of 
Zhou et al. [146], whereby active design of CNTs for mitochondrial targeting was 
unnecessary, it was reported herein that targeting peptide was essential to direct CNTs 
to mitochondria. This is evidenced by the finding that control non-targeted 
sulforhodamine B-MWCNTs were not detected in mitochondria after cellular 
internalization. The contradictions might be attributed to the intrinsic dissimilarity in 






Figure 1.15. Structural depiction of mitochondrial targeting MTS (with additional 
fluorescent sulforhodamine B moiety) functionalized MWCNTs. 
 
1.4.4 Concerns regarding CNT-based drug DS 
 
As CNTs interaction with biological species has not been comprehensively 
elucidated, imbalances between wide-spread commercial applications and proper 
regulation might pose serious threats to environment and human health. Combining 
the immense interest of developing CNTs for biomedical applications, it is therefore 
imperative to investigate and scrutinize their impact especially on human. Over the 
past decades, numerous reports have been published on the interactions between 
CNTs with cells in vitro in terms of uptake [104, 149-151], intracellular distribution 
[152-154], potential expulsion [155, 156] and even destruction/metabolism [157, 158]. 
However, with current technologies, it is impossible to accurately control and 
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standardize parameters (e.g. length, diameter, surface defects, etc.) during CNTs 
production. The huge dissimilarities existing between CNT batches employed in 
different research groups impose challenges in comparison and drawing conclusions 
on the findings.  
Despite the on-going debate with concerns on CNTs' long-term 
biocompatibility, reports of in vitro and in vivo CNTs' toxicity should be taken into 
consideration carefully when devising CNTs as drug carriers. Firstly, the metal 
catalyst content in CNTs sample should be considered when investigating the toxicity 
[159]. Besides the reported inhibition of HEK 293 cell proliferation by pristine 
SWCNTs [160], Ding et al. also observed that pristine MWCNTs induce cell cycle 
arrest and apoptosis/necrosis in human skin fibroblasts [161]. As for oxidized CNTs, 
induction of apoptosis of T lymphocytes is reported [162]. Hence, for the purpose of 
drug delivery, it is advisable to employ functionalized CNTs rather than pristine or 
oxidized CNTs. Echoing this, Sayes et al. reported that the cytotoxicity of CNTs was 
dependent on the density of functionalization, with minimal toxicity for the highly 
functionalized CNTs with phenyl-SO3X groups [163].  
The nature of the functional molecules on CNTs surface also plays a 
determining role in the resulting cytotoxicity of CNTs construct. For example, 
presence of excessive surfactants on CNTs is reported to be highly toxic to cells [164]. 
On the other hand, cells exposed to serum stable SWCNTs functionalized with 
biocompatible molecules such as PEG neither enhanced apoptosis/neurosis, nor 
reduced proliferation of various cell lines [112, 165, 166]. In addition, carbon 
nanotubes covalently functionalized with triethylene glycol by 1,3-dipolar 
cycloaddition appeared to be non-toxic to the tested cell lines, including primary 
immune cells [167, 168]. Carbon nanotubes engineered with a biomimetic coating by 
using cell surface mucin mimics were also nontoxic to cells [169, 170]. Several other 
independent groups also reported that CNTs coated by biological molecules, such as 
DNA, amphiphilic helical peptides, and serum proteins, were nontoxic to cells [171, 
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172]. It appears that raw CNTs and CNTs without biologically relevant 
functionalization were cytotoxic while functionalized CNTs that are serum-stable 
exhibits high tolerance in cells. Interestingly, Jin et al. discovered that SWCNTs 
internalized by cells via endocytosis could exit cells through exocytosis without 
affecting the viability [173].  
Nevertheless, widespread concerns persist on the issue that CNTs are 
particularly strong in structure. Systematic understanding on possible degradation by 
cells, especially macrophages, hepatocytes, and kidney cells, are lacking. Hence, the 
risk is that, after CNTs are injected into human body, long-lasting scavenging and 
inflammatory activities towards this non-degradable or less bio-degradable 
nanomaterial might result in continuous oxidative stress. This would lead to a greater 
hazard on tissue destruction or carcinogenesis. Fortunately, despite discrepancies in 
findings on the clearance mechanism, majority of the studies have suggested that 
functionalized CNTs, when i.v. injected into animals such as mice or rats, are prone 
to accumulate in the reticuloendothelial system (RES), for example liver and spleen, 
and then gradually get excreted, possibly via both fecal and renal routes [174-179]. In 
addition, it is generally recognized that large and pristine CNTs, which are poorly 
suspendable in aqueous solution, will form bundles and aggregates that induce 
inflammation and granuloma formation [180, 181]. On the other hand, such toxicities 
are not commonly observed with smaller and individualized CNTs [177, 178, 182]. 
Moreover, functionalization of CNTs with well-established biocompatible moieties 
(such as PEG) have conferred reduced in vivo toxicity after being i.v. injected into 
animals compared to the pristine counterparts [174, 180, 183]. Nevertheless, issues of 
CNTs' effects on reproductive functions and immune responses have only been 
partially addressed [184-187]. Hence, it is essential to systematically investigate the 
impact of CNTs to living systems in all aspects before advancing CNTs into clinical 
stage as drug carrier.  
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Chapter 2  Thesis rationales, hypotheses, and 
objectives 
 
2.1 Rationales and hypotheses 
 
Evasion of apoptosis is a hallmark of malignancy and a major contributor of 
tumorous growth and progression. Furthermore, most downfalls of conventional 
front-line therapeutic regimens are due, majorly if not partly, to the oncogenic 
blockade of apoptosis. This imparts advantages to the cancer cell survival and 
challenges in delivering effective anticancer treatment to patients. Hence, drugs 
designed to bypass different upstream cellular stress signalling and trigger apoptosis 
directly at mitochondrial level may be a potential alternative option for effective 
management of multifactorial diseases such as cancer, regardless of heterogeneity in 
genetic makeup.  
However, it is challenging in securing the presence of potent therapeutic 
compounds at mitochondria to disrupt OMM integrity and unleash pro-apoptotic 
proteins into cytoplasm. The intrinsic characteristics of this organelle, for example 
large negative membrane potential and protective double-membrane barrier, hinder 
the access of foreign molecules. In order to direct a compound to mitochondria, a 
molecule is required to display optimal lipophilicity for membrane permeation and 
sufficient positive charge to be attracted to mitochondria. A therapeutic moiety could 
be modified for targeting to mitochondria by covalent conjugation with mitochondrial 
localizing molecules such as DLCs or MTS. Nevertheless, this strategy is hampered 
by limited cargo size for efficient targeting, solubility and plasma membrane 
permeability of the resulting construct, endosomal entrapment, etc. In light of this, 
nanocarriers could be devised to target mitochondria and circumvent those limitations.  
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Carbon nanotubes (CNTs), the emerging nanomaterial for drug delivery, have 
gained tremendous research interest, due to their unique properties including: 1) 
needle-like structure that facilitate the “piercing” through plasma membrane without 
disrupting membrane integrity; 2) ultrahigh surface area allowing loading of multiple 
moieties at high density; 3) huge interior volume as protective environment for drug 
repository; 4) intrinsic stability ensuring a stable delivery independent of external 
environment; 5) facile surface functionalization allowing attachment of various 
functional groups, such as therapeutic agents, targeting moieties, molecules for 
detection and imaging, etc. These features substantiate the rationalization of CNTs as 
novel nanocarriers to facilitate transport of drugs into cells and revealing the 
possibility of designing novel theranostic nano-devices capable of targeted treatment 
and diagnosis of certain conditions. In this project, MWCNTs were chosen over 
SWCNTs because of their more favourable compatibility with cells (based on 
preliminary findings performed by our group) and larger interior space for efficient 
encapsulation of compounds.  
In this regard, the studies presented in this dissertation were based on the 
following hypotheses: 
1. MWCNTs could be designed to localize at mitochondria by surface 
functionalization with DLCs via stable covalent conjugation. Attachment of 
DLCs at high density on MWCNTs’ surface would confer driving force for 
the resulting nano-conjugate to evade from endosome and travel towards the 
negatively charged mitochondria.  
2. We rationalized that this surface functionalization could improve MWCNTs’ 
compatibility profile in cells compared to the pristine unfunctionalized 
MWCNTs, rendering MWCNTs suitable nanocarriers. As a proof of concept, 
Pt(IV) prodrug of cisplatin (PtBz) was suggested to be stably entrapped 
within the spacious core of the mitochondrial targeting MWCNTs based on 
the principle of nano-extraction. We hypothesized that PtBz could be directed 
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to the mitochondria as alternative target besides the nucleus for enhanced 
efficacy, since mitochondria also possess DNA (mtDNA) [28]. Unlike in the 
nucleus, where multiple DNA repair systems are present to reverse the 
detrimental effects of Pt complexes, such repair mechanisms are regarded to 
be less efficient in the mitochondria [4]. Hence, mitochondria targeting might 
be able to augment the therapeutic efficacy of Pt complexes by inducing 
extensive mtDNA damage, resulting in disruption of the physiological 
functions of mitochondria in regulating cellular energetics. In addition to that, 
co-encapsulation of a compound acting at mitochondria that is also 
synergistic with Pt complexes in mitochondrial targeted MWCNTs might 
further enhance the overall therapeutic efficacy. Such co-delivery of two 
compounds in a single nanocarrier would elicit cell death via different 
mechanisms and this could overwhelm the capacity of cancer cells in 
developing resistance towards a particular agent. 
3. To further solidify our claim that mitochondrial targeted MWCNTs could be 
an effective nanocarrier for future in vivo applications, higher degree 
functionalization on the CNTs’ surface with water soluble and biocompatible 
macromolecules was suggested. We proposed that further modification of 
CNTs’ surface might impart improved aqueous solubility and safety profile in 
cells, paving the development of MWCNTs as more biocompatible 
nanomaterial.  
4. Besides small molecules, MWCNTs are suggested to be also effective for 
delivering bioactive peptides acting on OMM that is otherwise impermeable 
to plasma membrane. A cytotoxic peptide capable of disrupting hexokinase II 
association with mitochondria and elicit apoptosis directly in malignant cells 
was selected as the model peptide to demonstrate our hypothesis. We 
hypothesized that the peptide could be covalently attached on MWCNTs’ 
surface at high density and such conjugation would not affect peptide 
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structural display and bioactivity. Efficient delivery of the peptide across 
plasma membrane and evasion from endosomal entrapment facilitated by 
MWCNTs could improve the efficacy of the peptide in stimulating apoptosis 




To validate the abovementioned rationales and hypotheses, the following 
research objectives were specified:  
1. Rhodamine 110 (Rho 110), one of the mitochondrial targeting DLCs, was 
conjugated via amide bond to amine functionalized MWCNTs to generate 
mitochondrial targeted MWCNT-Rho. The conjugates were characterized by 
various physicochemical analyses to validate the successful functionalization. 
In addition, cellular uptake and intracellular distribution of MWCNT-Rho 
were examined in vitro by microscopy techniques.  
2. The toxicity to cells and impact on mitochondrial function of MWCNT-Rho 
were investigated to ensure the suitability of CNTs to be developed as 
mitochondrial targeting nanocarrier. PtBz was encapsulated into the interior 
space of MWCNT-Rho via nano-extraction to generate mitochondrial 
targeting CNTs loaded with chemotherapeutics. The loading of PtBz in 
MWCNT-Rho was estimated and the constructs were tested in vitro. In 
addition, comparison of cytotoxicity with PtBz alone was performed to 
demonstrate that mitochondrial targeting of PtBz indeed enhanced its efficacy.  
3. Co-encapsulation of a chemosensitizer 3-bromopyruvate (BP), together with 
PtBz in the interior core of MWCNT-Rho, was performed via nano-extraction 
to demonstrate that MWCNTs could be engineered into a versatile 
mitochondrial targeting nanocarrier. The loading of PtBz and BP in 
MWCNT-Rho was estimated and the constructs were tested in vitro. In 
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addition, comparison of cytotoxicity and effect on mitochondrial potential 
with drugs alone were performed to demonstrate that mitochondrial targeting 
of PtBz and BP indeed enhanced their efficacy.  
4. Bovine serum albumin (BSA) and polyethylene glycol (PEG) were selected 
to be the test biocompatible macromolecules for higher degree 
functionalization on MWCNTs. To perform further modification on already 
functionalized MWCNTs, MWCNT-TEG-NH2 and MWCNT-Rho were 
experimented for their ability to accommodate the macromolecules, either by 
covalent conjugation or physical adsorption. The modifications were 
validated and characterized. To demonstrate that these modifications actually 
imparted favourable properties to MWCNTs, suspendability test, in vitro 
cytotoxicity assay, and apoptosis/necrosis staining were carried out.  
5. The cytotoxic peptide, which is capable of disrupting hexokinase II 
association with mitochondria and elicits apoptosis directly in malignant cells, 
was covalently appended to the surface of MWCNTs via different linkers. 
Cellular uptake and intracellular distribution of MWCNT-peptide conjugates 
were investigated and compared with the peptide alone in vitro. The efficacy 
of these nano-conjugates was evaluated and compared with commercially 
available cell-permeable fusion peptide to demonstrate that MWCNTs could 





Chapter 3  Functionalization of MWCNTs for 
targeting to mitochondria 
 
The information contained in this chapter was collated in the following article: 
 
• Yoong Sia Lee, et al. Enhanced cytotoxicity to cancer cells by mitochondria-
targeting MWCNTs containing platinum(IV) prodrug of cisplatin. Biomaterials, 




3.1.1 Rhodamine 110 (Rho 110)  
 
Mitochondria maintain a high negative transmembrane potential at their inner 
membrane for generation of ATP through electron transport chain (ETC). This unique 
physical property is exploited for mitochondrial targeting through the use of 
positively charged DLCs. Among different DLCs, rhodamine family of fluorescent 
compounds selectively localize at mitochondria in living cells in a membrane 
potential dependent manner. Rhodamine compounds have been employed as 
histological stains, and a number of their members (for example rhodamine 6G) were 
utilized in studying the energy state of isolated mitochondria [43]. In one pioneering 
study, Walsh et al. demonstrated the staining of mitochondria-like structures and 
lysosomes in cultured cells by serum proteins conjugated with rhodamine B 
isothiocyanate [43]. Subsequently, it was revealed that mitochondria were selectively 
stained when an isomer of rhodamine B, namely rhodamine 3B, was used [43].  
Thereafter, various rhodamine compounds were screened for specific 
mitochondrial staining and rhodamine 123 emerged as a specific fluorescent probe for 
mitochondria in living cells. After entering into cells, rhodamine 123 escapes endo-
lysosomes efficiently and stains mitochondria selectively without apparent cytotoxic 
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effects. Rhodamine 123 (pKa > 10) possesses a delocalized positive charge on the 
xanthene ring (Figure 3.1a) [43]. However, there is lack of obvious active group on 
the structure for straightforward chemical conjugation to MWCNTs.  
 
 
Figure 3.1. Structural illustrations of a) positively charged rhodamine 123; b) 
uncharged rhodamine 110 (Rho 110).  
 
Rhodamine 110 (Rho 110) is structurally analogous to rhodamine 123 but de-
esterified at 5-position on the benzene ring to yield a carboxylic group (Figure 3.1b). 
This carboxylic group is negatively charged under physiological pH, causing the 
whole molecule to be zwitterionic rather than positive in charge. Hence, it is reported 
that Rho 110 stain mitochondria less efficiently than rhodamine 123 in living cells 
[188]. Nevertheless, the carboxylic group is reactive for conversion into esters, amide, 
carboxylate salts, acid chlorides, alcohols, etc. In this regard, it is therefore 
understandable that for the examples discussed in Section 1.2.1, uncharged rhodamine 
B instead of its charged counterpart rhodamine 6G was used for targeting 
Si(IV)−phthalocyanine and fluorinated docetaxel prodrug to mitochondria. 
 
3.1.2 Covalent functionalization of CNTs’ surface 
 
Pristine CNTs can be shortened and functionalized simultaneously by simple 
treatment with strong oxidizing agents such as HNO3, KMnO4/H2SO4, O2, 
K2Cr2O7/H2SO4 or OsO4 [63]. This “cutting” treatment will result in “defects” on 
CNTs sidewall and opened extremities with abundant carboxylic groups, which 
significantly improve the solubility in polar organic solvents, acids or water. This 




portions are commonly located at the tips of CNTs or site of defects. Excessive 
oxidation, however, will undesirably result in extensive defects that could possibly 
damage CNTs’ structural integrity [63]. In this regard, MWCNTs are superior to 
SWCNTs in maintaining the macroscopic features of CNTs during defect 
functionalization because of the presence of multiple graphene layers in the 
constitution. The carboxylated fractions generated during the oxidizing treatment 
could be exploited for further functionalization via amidation, esterification or salt 
COO-NH3+ formation. In this regard, activation of the carboxylic acids by thionyl 
chloride, N-hydroxysuccinimide (NHS), carbodiimide 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) or O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluoro-phosphate (HATU) is required.  
Subsequently, various hydrophilic moieties could be appended to CNTs via 
amide or ester linkages. Such functionalization offers the advantage of improving the 
suspendability of CNTs in aqueous solutions and reducing toxicity in cells [189]. 
Polymers, for example poly-propionyl-ethylenimineco-ethylenimine, poly-n-
vinylcarbazole, or PEG has been affixed to the surface of CNTs using this method 
[87]. In addition, this approach has been employed to link biological molecules to 
CNTs via stable covalent bonds. For example, Huang et al. functionalized BSA on 
oxidized SWCNTs and MWCNTs via diimide-activated amidation [190]. Similarly, 
streptavidin was complexed to SWCNTs that were pre-functionalized with biotin 
through EDC activated amidation [191]. In short, defection functionalization on 
CNTs’ surface introduces carboxylic groups and carboxylated fractions that enable 
further manipulation, albeit mainly at the ends of the tubular structure. 
The other typical method used to functionalize CNTs’ surface is 1,3-dipolar 
cycloaddition. This non-destructive process is extremely versatile. It requires only an 
α-amino acid (or correspondent ester) to react with an aldehyde or ketone for in situ 
generation of azomethine ylides. These reactive nitrogen-based 1,3-dipoles will attack 
double bonds on CNTs’ surface, forming pyrrolidine rings on the sidewall of CNTs. 
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The amount of pyrrolidine groups can be estimated via electronic absorption 
spectroscopy or calorimetric analysis [63].  
Covalent functionalization offers the possibility of introducing multiple 
functionalities. One illustrative example is reported by Wei Wu et al., in which a 
double and orthogonal functionalization of fluorescein and amphotericin B was 
performed on MWCNTs’ surface [167]. In that study, pristine MWCNTs were 
oxidized in a mixture of concentrated H2SO4:HNO3 (3:1, v/v). The carboxylic groups 
activated to acyl chlorides were coupled to a triethylene glycol diamine with one end 
mono-protected by phthalimide. Subsequently, 1,3-dipolar cycloaddition was 
performed to introduce N-functionalized pyrrolidine rings, bearing Boc-protected 
amino groups, on the external walls of the tubes (Scheme 3.1). As the two protecting 
groups are reciprocally orthogonal, it allows controlled incorporation of fluorescein 
for imaging and an anti-fungal drug amphotericin B.  
 
Scheme 3.1. Double and orthogonal functionalization of MWCNTs with FITC and 
Amphotericin B. a) COCl2 ; Pht-N(CH2CH2O)2-CH2CH2-NH2, dry THF, reflux; b) Boc-
NH-(CH2CH2O)2-CH2CH2-NHCH2COOH/(CH2O)n, DMF, 125°C; c) Hydrated NH2-NH2, 
Ethanol, reflux; d) FITC, DMF; e) 4 M HCl/dioxane; f) Fmoc-Amphotericin B, 
HOBt/EDC.HCl/DIPEA, DMF; 25% piperidine in DMF.  
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3.2 Hypotheses and objectives 
  
In this chapter, we propose that MWCNTs’ length could be shortened by 
defect functionalization as this process will not only improve MWCNTs’ 
suspendability and toxicity, but also generate abundant carboxylic groups useful for 
further functionalization with a linker possessing terminal amines. We reasoned that 
conjugating Rho 110 to amine-functionalized MWCNTs via amide coupling might 
neutralize the negatively-charged 5-carboxylate moiety and restore the positively-
charged xanthene ring, which would lead the resulting constructs to preferentially 
accumulate at mitochondria.  
 To verify these hypotheses, the following research objectives are outlined: 
1. Pristine MWCNTs were oxidized in concentrated acid mixture consisting 
H2SO4:HNO3 (3:1, v/v) to reduce the length and generate more carboxylic 
groups, consequently more sites for functionalization. 
2. Rho 110 was bound on oxidized MWCNTs via a linker 2,2′-
(ethylenedioxy)bis(ethylamine) (NH2-TEG-NH2), yielding MWCNT-Rho. To 
validate that functionalization of Rho 110 truly conferred mitochondrial 
localizing properties to MWCNTs, neutral non-mitochondrial targeting 
fluorescein (Fluo) that is structurally similar to Rho 110 was functionalized 
on MWCNTs in parallel.  
3. To validate the reaction, the constructs were scanned by UV-VIS 
spectrometry and the loading was estimated by quantitative Kaiser test.  
4. Confocal microscopy and TEM were performed to elucidate the cellular 





3.3 Materials and methods 
 
3.3.1  Materials 
 
Pristine MWCNTs were obtained with courtesy from Professor Sundara 
Ramaprabhu from the Indian Institute of Technology, Madras. Dimethylformamide 
(DMF), dichloromethane (DCM), and methanol were of ACS reagent grade from 
Merck Millipore (Darmstadt, Germany). Deionized water (DI water) was obtained 
from Sartious-Stedim biotech atrium® 611 system. (Ethylenedioxy)bis-ethylamine 
(NH2-TEG-NH2),  N,N-diisopropylethylamine (DIPEA), rhodamine 110 (Rho 110) 
chloride,  dimethyl sulfoxide (DMSO), and N-hydroxy-succinimide (NHS) were 
procured from Sigma Aldrich (St. Louis, USA). O-(7-azabenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluoro-phosphate (HATU), and 4-
(dimethylamino)pyridine (DMAP) were purchased from Alfa Aesar (Lancaster, UK). 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) was obtained from GL 
Biochem (Shanghai, China). Omnipore hydrophilic PTFE membranes (0.2 µm) were 
purchased from Millipore (Darmstadt, Germany). Dulbecco’s modified Eagle’s 
medium (DMEM) and fetal bovine serum (FBS) were procured from Thermo 
Scientific (Waltham, USA). Fluorescein isothiocyanate (FITC), TrypLE™ Express, 
Hoechst 33342 nucleic acid stain, and MitoTracker® Deep Red FM were purchased 
from Invitrogen (Carlsbad, USA). Ultrapure 10× phosphate-buffered saline (PBS) 
was procured from Vivantis Technologies Sdn. Bhd. (Malaysia). Potassium cyanide 
(KCN) was kindly provided by teaching lab of pharmacy department, National 
University of Singapore. 2.5% glutaraldehyde in PBS, 1% aqueous OsO4, absolute 
acetone, uranyl acetate, and lead citrate were supplied by Electron Microscopy Unit, 




3.3.2  Preparation of MWCNTs for functionalization with targeting 
groups 
 
Ultrapure MWCNTs were prepared as previously reported [192]. Briefly, 
MWCNTs were synthesized by chemical vapour deposition of acetylene over rare 
earth-based AB2 alloy hydride catalysts. Crude MWCNTs were purified via air 
oxidation by heating at 400ºC for 3 h to remove amorphous carbon, followed by acid 
treatment to remove catalytic impurities by refluxing in concentrated HNO3 for 24 h. 
After repeated washings with DI water, the product was air-dried at 100ºC for 30 min. 
Imaging of the MWCNTs through TEM was carried out using JEM 2010F HR-TEM 
(JEOL, Japan) (Figure 3.2 and Table 3.1) and the outer diameter of MWCNTs was 
estimated to be 30-60 nm with length ranging from 2 to 10 µm. 
The incorporation of functional groups on MWCNTs for mitochondrial 
targeting is summarized in Scheme 3.2. Pristine MWCNTs (20 mg) were first 
oxidized to create the carboxylic groups needed for subsequent functionalization by 
sonication for 8 h in 98% H2SO4:65% HNO3  (3:1 v/v, 8 mL) [167]. The oxidized 
MWCNTs were subsequently washed thoroughly with DI water via filtration with a 
0.2 µm polytetrafluoroethylene (PTFE) membrane (Millipore, presoaked in 60% 
ethanol) till the pH of the filtrate reached 5-7. The MWCNTs were recovered from 
the membrane and lyophilized yielding MWCNT-COOH. 
In order to add amine-terminated (Ethylenedioxy)bis-ethylamine (NH2-TEG-
NH2) groups, oxidized MWCNT-COOH (20 mg, 60 µmol of COOH) was treated 
with NH2-TEG-NH2 (1 mL, 6.85 µmol) in the presence of HATU (45.6 mg, 120 µmol) 
as the coupling agent and DIPEA (24 µL, 180 µmol) at 60ºC for 24 h. On completion, 
the reaction mixture was extracted with DMF (3 mL) to remove unreacted organics. 
The residual mixture containing amine functionalized MWCNTs (MWCNT-TEG-
NH2) were then filtered through a 0.2 µm PTFE membrane, and rinsed thoroughly 
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with DMF, methanol, DCM and lastly, DI water. Finally, MWCNT-TEG-NH2 was 
recovered from the membrane and lyophilized overnight.  
  
3.3.3  Functionalization of MWCNT-TEG-NH2 with either Rho 110 or 
FITC 
 
FITC (8 mg, 21 µmol) was added to MWCNT-TEG-NH2 (20 mg, 11 µmol of 
free NH2 equivalent) mixture with DIPEA (2.6 µL, 15 µmol) in dry DMF (2 mL). The 
reaction was stirred at 60ºC for 24 h to yield MWCNT-Fluo.  
Rho 110 chloride (8 mg, 22 µmol) was added to MWCNT-TEG-NH2 (20 mg, 
11 µmol of free NH2 equivalent) with EDC (2.7 mg, 22 µmol) and NHS (8.5 mg, 44 
µmol). The reaction was carried out in the presence of catalytic amount of DMAP and 
DIPEA (2.6 µL, 15 µmol) in DMF (2 mL) for 24 h at 60ºC to yield MWCNT-Rho. 
The harvesting steps of both MWCNT-Fluo and MWCNT-Rho were similar to those 
of MWCNT-TEG-NH2.  UV-VIS spectra of both constructs were obtained through 
UV-VIS spectrophotometer (UV-1800, Schimadzu). 
 
3.3.4  Kaiser test 
 
Kaiser test, which relies on the reaction between free amines and ninhydrin to 
generate the ninhydrin chromophore, was performed to monitor the extent of free 
NH2 groups on the TEG chain on MWCNTs before and after conjugation [193]. 
Briefly, a measured amount of functionalized MWCNTs (typically 0.2 mg) was 
mixed with KCN in pyridine (0.4 mM, 100 µL), ninhydrin in ethanol (5% w/w, 75 µL) 
and phenol in ethanol (4 g/mL, 75 µL). The mixture was heated for 5 min and diluted 
20× with 60% ethanol. The absorbance of the supernatant free of MWCNTs obtained 
after centrifugation was measured with a UV-VIS spectrophotometer (UV-1800, 
Schimadzu) at 570 nm. The amount of free amine (i.e. loading) present on the CNTs 
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was calculated using the following equation: Amount of -NH2 groups present on 
CNTs (µmol/g) = (Absorbance × 5 × 106) / (13000 × weight of CNT in mg). Data 
presented in Table 3.2 are representative averaged values obtained from three 
independent functionalizations and accordingly three independent measurements. 
 
3.3.5  Cell culture 
  
Human breast cancer cells MCF-7 were selected as common cancer 
prototypes to study the intracellular distribution of MWCNT-Rho due to their larger 
size and hence convenience for imaging. MCF-7 cells were purchased from ATCC 
(VA, USA). The cells were maintained in DMEM supplemented with 10% FBS and 
incubated at 37ºC in humidified air containing 5% CO2. All cells were subcultured 
every three to four days with TrypLE™ Express. 
 
3.3.6  Confocal microscopy 
 
Colocalization study was conducted to investigate the ability of either 
MWCNT-Rho or MWCNT-Fluo to localize at mitochondria. Briefly, MCF-7 cells 
were seeded in 29 mm glass bottom dish at a density of 5 × 104 cells/mL for 24 h, 
followed by incubation with either MWCNT-Rho or MWCNT-Fluo (10 µg/mL) for 
12 h. Thereafter, the cells were incubated with Hoechst 33342 (5 µg/mL) for 10 min 
as nuclear counter-stain, followed by MitoTracker® Deep Red FM (25 nM) for 5 min 
to stain mitochondria before being viewed under a confocal microscope (Confocal 
Laser Scanning Biological Microscope FV10i, Olympus). MWCNT-Fluo or 
MWCNT-Rho, MitoTracker® Deep Red FM, and Hoechst 33342 were excited at 495 
nm, 635 nm, and 352 nm respectively. Fluorescence emission was recorded at 519 nm, 
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690 nm, and 455 nm for MWCNT-Fluo or MWCNT-Rho, MitoTracker® Deep Red 
FM, and Hoechst 33342 respectively. Coefficient of colocalization between green and 
red channel was obtained with value 1 being perfect colocalization and 0 being no 
colocalization via the Fluoview® software (Olympus) and an average coefficient with 
standard error of the mean (SEM) was calculated based on five images for a single 
sample. 
 
3.3.7  Transmission electron microscopy (TEM) imaging 
 
TEM was performed to visualize the intracellular location of MWCNT-Rho. 
Confluent layers of MCF-7 cells were incubated with MWCNT-Rho (10 µg/mL) for 6 
h. After harvesting with TrypLE™ Express and washing thoroughly with 1× PBS, 
primary fixation was performed with 2.5% glutaraldehyde in PBS for 24 h at 4ºC. 
Thereafter, the cells were rinsed with DI water and a secondary fixation was 
performed with 1% aqueous OsO4 for 1 h. The cells were then dehydrated in graded 
ethanol series (50%, 70%, 90% and 100%) and absolute acetone, and embedded in 
araldite resin. Ultra-thin sections of 90-100 nm were cut with glass knives using a 
microtome (Ultracut EM UC6, Leica). The sections were placed on 300 mesh copper 
grids and stained with uranyl acetate and lead citrate. Finally, the sections were 
imaged with an electron microscope (CM10 TEM, Philips) at 80 kV. 
 
3.3.8  Statistical analysis 
 
All experiments were repeated three times unless otherwise stated. The length 
and the outer diameter of the pristine MWCNTs and oxidized MWCNTs were 
estimated by Adobe Photoshop CS5 (Adobe Systems Inc., USA). Mean and SEM of 
the MWCNTs’ dimension, extent of functional groups present, and mitochondrial 
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colocalization coefficient were computed by Microsoft Excel (Microsoft Inc., Ca, 
USA). 
 
3.4 Results and discussion 
 
The overall synthesis route for the different MWCNT constructs is illustrated 
in Scheme 3.2. 
 
  
Scheme 3.2. Synthesis route of mitochondrial targeting MWCNT-Rho and non-
targeting MWCNT-Fluo. a) NH2(CH2CH2O)2-CH2CH2NH2, HATU, DIPEA, stir at 60ºC, 
24 h; b) FITC, dry DMF, DIPEA, stir at 60ºC, 24 h; c) Rho-110, EDC.HCl, NHS, dry 
DMF, DIPEA, stir at 60ºC, 24 h. 
 
3.4.1 Defect functionalization and oxidation of pristine MWCNTs  
 
The pristine MWCNTs prepared from chemical vapour deposition were 
ultrapure and free of metal impurities [192] but they were long, ranging from 2 to 10 
µm (Figure 3.2 & Table 3.1). Oxidation treatment for 10 h was necessary to reduce 
the length, while generating more carboxylic acid groups and consequently more sites 
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for functionalization [110]. Figure 3.2 and Table 3.1 demonstrate around 90% 
reduction in length after oxidation. In addition, it is explicit that numerous “defects” 
were introduced on MWCNTs sidewall after oxidation (Figure 3.2b), which is 










Figure 3.2. TEM characterization of 10 µg/mL MWCNTs. a) pristine MWCNTs; b) 10 
h-oxidized MWCNTs. 
 
Table 3.1. Distribution of length and diameter of MWCNTs as measured based on 





3.4.2 Functionalization of MWCNTs with linker NH2-TEG-NH2 
 
Thereafter, 2,2’-(ethylenedioxy)bis(ethylamine) (NH2-TEG-NH2) was 
conjugated onto MWCNT-COOH via HATU-mediated amide coupling reaction and 
the amount of free amine groups was estimated by Kaiser test. To verify whether 
intra- or inter-MWCNT crosslinking occurred, we carried out functionalization using 
mono-protected BocNH-TEG-NH2 as control [110]. The mono-protected BocNH-
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TEG-NH2 linker would be incapable of crosslinking since only one free amino group 
could conjugate to MWCNT-COOH. The BocNH- group could then be de-protected 
using 4 M HCl/dioxane to reveal the extent of functionalization. 
The Kaiser test revealed the mean of free -NH2 and BocNH- concentration to 
be 567.3 mmol/g and 411.0 mmol/g, respectively. The comparable values suggest that 
most of the functional groups conjugated were not cross-linked. This was confirmed 
by a separate study, where unprotected diamine-terminated oligomeric PEG (MW = 
1500) was used to functionalize and solubilize SWCNTs successfully [194]. We 
therefore carried out functionalization on MWCNT-COOH using NH2-TEG-NH2 
directly.  
 
3.4.3 Functionalization of Rho 110 and FITC on MWCNT-TEG-NH2 
 
MWCNT-TEG-NH2 was further functionalized with Rho 110, which is 
structurally analogous to rhodamine 123 but de-esterified at 5-position on the benzene 
ring to yield a carboxylic group (Figure 3.1b), for targeting to mitochondria. As a 
non-mitochondrial targeting control, fluorescein (Fluo), which comprises a similar 
structural xanthene moiety but lacks the persistent positive charge (Figure 3.3b), was 
conjugated onto MWCNT-TEG-NH2 via thiourea linkage, using fluorescein 
isothiocyanate (FITC) as precursor. After functionalization, MWCNT-Fluo and 
MWCNT-Rho exhibited characteristic UV-VIS absorbance at 498 nm and 520 nm, 
respectively, indicating successful conjugation (Figure 3.3c). To determine the 
amount of fluorescent molecules functionalized on MWCNT-Fluo and MWCNT-Rho, 
Kaiser test was performed again to ascertain the residual primary amine groups. The 
test revealed the residual amino groups to be ca. 109.2 µmol/g and 82.7 µmol/g for 
MWCNT-Fluo and MWCNT-Rho, respectively. Based on an initial value of 567.3 
µmol/g, ca. 458.1 µmol/g (80.8%) of FITC and 484.6 µmol/g (85.4%) of Rho 110 











Figure 3.3. Qualitative characterization by UV-VIS scanning of a) Rho 110; b) FITC; c) 
different functionalized MWCNTs constructs: MWCNT-TEG-NH2 (black), MWCNT-
Fluo (green), and MWCNT-Rho (red). 
 





(µmol/g of CNTs) 
Amount of molecules 
functionalized (µmol/g) 
TEG Fluo or Rho 
MWCNT-TEG-NH
2
 567.3 ± 30 567.3 (100%) - 
MWCNT-Fluo 109.2 ±15 109.2 (19%) 458.1 (81%) 
MWCNT-Rho 82.7 ± 14 82.7 (15%) 484.6 (85%) 
 
3.4.4 Rho 110 as mitochondria-targeting group for MWCNTs 
 
Both MWCNT-Fluo and MWCNT-Rho were incubated independently with 
MCF-7 cells and their intracellular distribution was examined by confocal 
microscopy (Figure 3.4). MWCNTs were tracked using their respective fluorophores 
while the nucleus and the mitochondria were stained using Hoechst 33342 and 






localized with mitochondria with an average colocalization coefficient of 0.79 (ca. 
around 80% of colocalization, Figure 3.4b). On the other hand, MWCNT-Fluo was 
poorly associated with mitochondria, with an average colocalization coefficient of 
0.21 (ca. around 20% of colocalization, Figure 3.4a). Despite being structurally 
similar, Rho 110 was able to enter cells and localize to mitochondria while FITC 
fluorescence was excluded from intracellular space (Appendix I). Collectively, these 
findings indicate that MWCNTs are able to deliver molecules intracellularly and only 
Rho 110 was able to confer mitochondrial targeting properties to functionalized 






Figure 3.4. Subcellular localization of MWCNT-Fluo and MWCNT-Rho. MCF-7 cells 
were exposed to a) control MWCNT-Fluo (10 µg/mL) and b) targeted MWCNT-Rho 
(10 µg/mL) for 24 h. Mitochondria were stained red using MitoTracker® Deep Red 
(red) while nuclei were labeled with Hoechst 33342 (cyan). 
 
TEM was performed to provide a direct high resolution visualization of 
MWCNT-Rho in cells and to validate their mitochondria-directed distribution 
patterns. Figure 3.5a shows individual MWCNT-Rho (indicated by black arrow) 
localized on top of a mitochondrion (indicated by their characteristic oval shape) and 
in vicinity of another mitochondrion. Moreover, a small aggregate of MWCNT-Rho 
was observed to be in close proximity to two mitochondria, as indicated by the 
characteristic cristae of the organelle (Figure 3.5b). Figure 3.5c demonstrates a cluster 
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of MWCNT-Rho localized in the vicinity of three mitochondria, and in a zoom-in 
view, it is revealed that one of the MWCNT-Rho was piercing into the cristae of a 
dividing mitochondrion (Figure 3.5d). Furthermore, MWCNT-Rho constructs were 
observed to be lying intimately in parallel with a mitochondrion (Figure 3.5e) and 
located closely with their end pointing another mitochondrion (Figure 3.5f).  
Under both live cell confocal imaging and TEM, MWCNT-Rho was observed 
to colocalize with the negatively charged mitochondria (Figures 3.4b & 3.5). This 
echoes with the reported phenomenon that SWCNTs mobility, in the presence of an 
electrical potential, is greatly enhanced when the tubes are charged by covalent or 
non-covalent functionalities [195-197]. Our strategy takes advantage of the lipophilic 
yet cationic nature of rhodamine based dyes for mitochondria-targeting and thus the 
effects were negated when its structural analogue Fluo (Figure 3.3b), which lacks the 
persistent positive charge on the xanthene ring, was conjugated to MWCNT-TEG-





Figure 3.5. TEM images of MCF-7 cells [a)-i)] incubated with 10 µg/mL of MWCNT-
Rho for 6 h. Images a-c are taken at lower magnification compared to images d)-f). 
Image d) is the zoom-in snap shot of the red squared-area in image c, showing that 
MWCNT-Rho are in close proximity to mitochondria and one of the MWCNT-Rho was 
even observed to be piercing through mitochondria. In all images, CNTs are 
highlighted with black arrows, whereas mitochondria can be identified by the 




Our findings differ from previous reports, which showed that SWCNTs 
functionalized with Fluo-linked PEG could accumulate in mitochondria due to the 
electric potential maintained at the inner mitochondrial membrane [103, 146, 147]. In 
addition, our findings are in disagreement with another previous report on 
carboxylated SWCNTs that, despite being negatively charged at physiological pH, 
could also localize at mitochondria, leading to a decrease in mitochondrial membrane 
potential, and impairment to the mitochondrial oxygen uptake and redox activity of 
cytochrome c [198]. Passive targeting of MWCNTs to mitochondria by conjugation 
with Fluo was not observed in this study and our data collectively suggest that active 
targeting of MWCNTs using rhodamine family of DLCs is necessary for preferential 
mitochondrial accumulation. 
Our inference that active targeting of MWCNTs to mitochondria is essential 
for mitochondrial localization are consistent with the findings by Battigelli et al. [148]. 
In that study, MWCNTs functionalized with peptide-based MTS derived from N-
terminal region of subunit VIII of human cytochrome c oxidase, were localized to 
mitochondria in murine RAW264.7 macrophages and human HeLa cells. On the other 
hand, MWCNTs functionalized with uncharged sulforhodamine B were unable to 
accumulate at mitochondria in RAW264.7 macrophages under confocal microscope.  
In fact, delivery of rhodamine 123 by oxidized SWCNTs into human 
leukemic K562 cells was previously demonstrated [199]. However, in that study 
rhodamine 123 was loaded via physical adsorption and the main focus was to 
illustrate the role of SWCNTs as an efficient drug carrier to deliver small molecules 
such as rhodamine 123 into cells, while circumventing multi-drug resistance mediated 
by the efflux activity of P-gp. To our best knowledge, our study is the first 
demonstration that covalent functionalization of small molecule targeting fluorescent 
moiety Rho 110 onto MWCNTs confers dual-functionalities for fluorescent imaging 






We have successfully functionalized MWCNTs with mitochondrial targeting 
Rho 110 and non-targeting Fluo. The loading of the functional groups Rho 110 and 
Fluo was qualitatively validated by UV-VIS scanning and quantitatively estimated by 
Kaiser test to be 458.1 µmol/g and 486.6 µmol/g, respectively. Importantly, 
MWCNTs functionalized with Rho 110 displayed unique intracellular distribution 
pattern localizing at mitochondria with colocalization coefficient of 0.79 (ca. 80% 
colocalization). Functionalization with structurally similar but non-targeting 
fluorescein failed to deliver such mitochondrial directing effect to MWCNTs 
(colocalization coefficient = 0.21). In addition, high resolution TEM revealed the 
actual location of MWCNT-Rho at close proximity to mitochondria, confirming that 
MWCNT-Rho is indeed mitochondrial targeted. Our findings emphasize the 













Chapter 4  Evaluation of mitochondrial targeting 
MWCNT-Rho as a drug delivery platform 
 
The information contained in this chapter was collated in the following article: 
 
• Yoong Sia Lee, et al. Enhanced cytotoxicity to cancer cells by mitochondria-
targeting MWCNTs containing platinum(IV) prodrug of cisplatin. Biomaterials, 




4.1.1 Platinum (Pt) based anticancer complexes 
 
Platinum(II) [Pt(II)] complexes constitute a major class of anticancer drugs 
for a wide spectrum of malignancies [200]. Cis-diamminedichloroplatinum(II) 
(Figure 4.1), generally known as cisplatin (CDDP), is the first member of Pt-
containing anticancer drug, which now also include carboplatin and oxaliplatin. 
CDDP was approved by FDA in 1978 and is widely used alone or with other drugs to 
treat a multitude of cancers, including bladder cancer, cervical cancer, germ cell 
cancer, lymphomas, malignant mesothelioma, non-small cell lung cancer, squamous 
cell carcinoma of head and neck, testicular cancer, etc. [201, 202].  
 
 
Figure 4.1. Structure of cisplatin (CDDP). 
 
Following i.v. administration in a patient, the relatively high chloride 
concentration in the blood plasma (~ 100 mM) limits replacement of CDDP’s 
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chloride ligands by water molecules, i.e., the process of CDDP aquation is hindered. 
Therefore, untimely activation of CDDP in blood stream before reaching tumour cells 
is unfavourable. Nevertheless, CDDP is highly susceptible to attack by plasma 
proteins, especially those containing thiol groups (human serum albumin, amino acid 
cysteine etc.). In fact, studies have demonstrated that 65–98% of the Pt in blood 
plasma was protein bound one day after CDDP administration [203, 204]. This non-
specific protein interaction has been shown to account for CDDP’s premature 
inactivation [205, 206] and partly result in undesirable complications [203, 205, 207]. 
These side effects include nephrotoxicity (most common adverse reaction), 
neurotoxicity, nausea and vomiting, ototoxicity, myelotoxicity, as well as a temporary 
depression of erythrocytes, leukocytes, platelet production [208-211]. Therefore, 
effective delivery of CDDP is pressingly demanded to increase the bioavailability at 
target tumours and reduce non-specific accumulation in normal tissues to alleviate 
adverse reactions. 
The CDDP that remains intact from systemic circulation can then enter 
tumour cells mainly by diffusion through the cellular membrane [212] or active 
transport via copper transporter [213]. As the intracellular chloride concentration is 
relatively low (~ 4-20 mM), one of CDDP’s chloride ligands is gradually replaced by 
water (aqua ligand). The aqua ligand in the resulting [PtCl(H2O)(NH3)2]+ is itself 
labile for further displacement. In vitro studies have reported that the mono-aquated 
Pt species is responsible for at least 98% of the Pt binding to nuclear DNA bases 
[214], usually guanine, forming a monofunctional DNA adduct [215]. Ring closure 
and formation of a bifunctional adducts, primarily guanine-guanine and adenine-
guanine [216], lead to substantial distortion of the DNA structure. Detection of such 
abnormality by DNA binding proteins will either initiate DNA damage repair or 





4.1.2 Delivery of Pt-based compounds using CNTs by encapsulation 
 
CNTs had been investigated for their potential to deliver Pt drugs to mitigate 
limitations of Pt-based chemotherapy, such as poor selectivity and bioavailability at 
target cells [109, 128, 129]. Earlier studies focused on delivery of CDDP or more 
stable Pt(IV) derivatives via covalent conjugation on CNTs’ surface (Section 1.5.3). 
However, this delivery method does not preclude non-specific interactions with other 
biomolecules or premature inactivation before reaching designated site of action. In 
this regard, the internal cavity of CNTs could serve as a protective repository against 
inactivation of the compounds due to environmental factors, while leaving CNTs’ 
surface intact for functionalization with targeting groups.  
Pioneering studies were performed to encapsulate CDDP and carboplatin in 
CNTs and release was achieved by diffusion, which is difficult to regulate [218, 219]. 
Recently, selective controlled-release of CDDP from SWCNTs encapsulation was 
attempted in two studies. Both studies employed potentially more biotolerable 
ultrashort SWCNTs (US-SWCNTs; 20-80 nm in length and 1.4 nm in diameter) as 
drug delivery platform for CDDP [220, 221]. In the first study, besides CDDP 
encapsulated US-SWCNTs, the authors also prepared another sample, Pluronic-F108 
surfactant wrapped US-SWCNTs encapsulated with CDDP, with anticipation that the 
Pluronic wrapping would act as barriers to reduce the rate of drug release. Indeed, 
with Pluronic wrapping, only 6.1% of CDDP was released into PBS at pH 7.4 after 24 
h and only 16.9% release was achieved over 1 week. Conversely, unwrapped samples 
showed significant greater leakage with almost 50% of CDDP release in the first 3 h 
and about 80% after 1 week. Despite the low release profile, in vitro cytotoxicity 
investigation revealed that CDDP-encapsulated Pluronic-wrapped US-SWCNTs 
exhibited greater cytotoxicity, possibly due to higher Pt content in treated MCF-7 and 
MDA-MB-231 cells, compared to free CDDP treatment.  
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In the follow up study, incomplete release of CDDP from Pluronic wrapped 
US-SWCNTs was addressed by using non-invasive radiofrequency (RF) field to 
produce heat that can disrupt Pluronic wrapping to trigger CDDP release [221]. The 
authors showed that the CDDP release from samples pre-treated with RF increased by 
around 2-fold (approximately 60% release) after 1 week. For cytotoxicity study, liver 
cancer cells Hep3B or HepG2 were exposed to CDDP-encapsulated Pluronic-
wrapped US-SWCNTs and Pluronic-wrapped empty US-SWCNTs at 2.5 µM 
(corresponds to a US-SWCNTs concentration of 13.7 µg/mL) in a trans-well system 
with or without RF field exposure. In both cell lines, it was observed that even the 
bare Pluronic-wrapped US-tubes were slightly cytotoxic and this slight cytotoxicity 
was independent of increasing RF exposures. However, a general trend is observed in 
both cell lines that cytotoxicity was enhanced in a statistically significant manner with 
increasing RF exposures.  
Our group had also attempted to encapsulate CDDP and control its release by 
designing CNT-based nanobottles that were capped with gold nanoparticles (GNP) at 
both ends [222]. In the study, GNP-capped MWCNTs loaded with CDDP (capped 
MWCNT-CDDP) was synthesized by two step procedures: nano-extraction [223] of 
CDDP followed by nano-extraction of GNPs for capping the opened extremities of 
MWCNTs. However, the GNPs were observed to be incompletely blocking the 
MWCNT openings under TEM. Inductively coupled plasma optical emission 
spectroscopy (ICP-OES) analysis for Pt content in CDDP loaded uncapped and GNP 
capped MWCNTs revealed that 62.1% and 44.4% w/w of CDDP were encapsulated 
respectively. Rapid and near complete release of encapsulated CDDP from uncapped 
MWCNTs was demonstrated within 1 h in PBS. The presence of GNP caps, however 
delayed CDDP release especially in the first hour. In vitro IC50 of CDDP, uncapped 
MWCNT-CDDP, and capped MWCNT-CDDP against MCF-7 cells were found to be 
11.7 µM, 12.9 µM, and 7.7 µM, respectively.  
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Because CDDP is highly hydrophilic, confining CDDP within the 
hydrophobic cavities of CNTs is inherently challenging, as it is difficult to control the 
loading and release of CDDP from CNTs. As a result, our group reported an 
alternative approach of using a chemically inert hydrophobic Pt(IV) prodrug of 
CDDP (PtBz) as drug model to be encapsulated into MWCNTs [224]. This unique 
strategy entailed the encapsulation of PtBz into the interior core of MWCNTs and the 
stable entrapment by favourable hydrophobic-hydrophobic interactions. Upon 
selective chemical reduction by endogenous intracellular reducing agents such as 
glutathione, PtBz would be reduced into its cytotoxic and hydrophilic Pt(II) form. As 
the hydrophobicity is reversed upon reduction, the hydrophilic Pt(II) would be readily 
extruded from the hydrophobic core of MWCNTs (Scheme 4.1).  
 
 
Scheme 4.1 Design concept on entrapment of platinum(IV) prodrug of CDDP (PtBz) 
within MWCNTs and the release based on hydrophobicity reversal. 
 
In this proof of concept study, PtBz was encapsulated within pristine 
MWCNTs by nano-extraction, resulting in MWCNT-PtBz with a w/w loading 
efficiency of 51.7 ± 2.0%. Release of Pt was triggered only in the presence of 3 mM 
ascorbic acid, which simulates a reductive cellular environment. Compared to control 
CDDP encapsulated MWCNTs, PtBz encapsulated MWCNTs exhibited a slower Pt 
release that reached its completion after 8 h. This signifies that controlled-release of 




4.2 Hypothesis and objectives 
 
In this chapter, we propose that mitochondria could be an alternative cellular 
target for Pt-based anticancer compounds other than nucleus. This stems from the 
rationale that mitochondria also possess DNA (mtDNA) but lack comprehensive 
DNA repair mechanisms [4, 28]. By directing PtBz to mitochondria via encapsulation 
in MWCNT-Rho, the overall anticancer efficacy would be enhanced as a result of 
extensive mtDNA damage, which disrupts mitochondrial functions and ultimately 
leads to cell death. In addition, it is hypothesized that the interior space of MWCNTs 
could be further loaded with a chemosensitizer of Pt-based drugs, which acts at 
mitochondria but possess different cytotoxic mechanisms. In light of this, 3-
bromopyruvate (BP) is selected based on the reports that it potentiated the efficacy of 
common chemotherapeutics [225] and also CDDP and oxaliplatin [226]. BP is 
reported to deplete ATP by inhibition of glycolysis and interrupt hexokinase II-
VDAC interaction on OMM [227]. Consequently, disruption in cancer cell energy 
metabolism and enhanced susceptibility to apoptosis ensue (a key event in Pt-based 
drug mediated cell death). We reason that such targeted entities containing two 
synergistic compounds would be able to evade the issues of resistance manifested in 
Pt-based therapeutics. 
Therefore, the following research objectives are accomplished: 
1. MWCNT-Rho was characterized to validate the appropriateness of MWCNT-
Rho construct as drug delivery carrier in vitro. In this regard, uptake kinetics, 
toxicity, and impact on cellular proliferation and mitochondrial health were 
profiled.  
2. After validation of MWCNT-Rho, PtBz was encapsulated in MWCNT-Rho 
via nano-extraction. The loading of PtBz in MWCNT-Rho was estimated and 
the constructs were tested for efficacy in vitro. In addition, comparison of 
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cytotoxicity with PtBz alone was carried out to demonstrate that 
mitochondrial targeting of PtBz indeed enhanced its efficacy.  
3. Co-encapsulation of a chemosensitizer BP, together with PtBz in MWCNT-
Rho was performed via nano-extraction to demonstrate that MWCNTs could 
be engineered into a versatile mitochondrial targeting nanocarrier with 
accommodating capacity for different compounds. The loading of PtBz and 
BP in MWCNT-Rho were estimated and the constructs were tested in vitro. 
In addition, comparison of cytotoxicity and effect on mitochondrial potential 
with drugs alone were performed to demonstrate that mitochondrial targeting 
of PtBz and BP indeed enhanced their efficacy.  
 




Chloroform (CHCl3), Ethyl acetate (EA), methanol, and DCM were of ACS 
reagent grade from Merck Millipore (Darmstadt, Germany). DI water was obtained 
from Sartious-Stedim biotech atrium® 611 system. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolocarbocyanine iodide (JC-1), dimethyl sulfoxide (DMSO) 
were procured from Sigma Aldrich (St. Louis, USA). BP was purchased from Alfa 
Aesar (Lancaster, UK). cis,cis,trans-Pt(NH3)2Cl2(CO2C6H5)2 (PtBz) was kindly 
provided by Assistant Professor Wee Han Ang (Department of Chemistry, National 
University of Singapore, Singapore). Omnipore hydrophilic PTFE membranes (0.2 
µm) were purchased from Millipore (Darmstadt, Germany). DMEM and FBS were 
procured from Thermo Scientific (Waltham, USA). TrypLE™ Express and PBS were 




benzene disulfonate (WST-1) was purchased from Roche Applied Science (IN, USA). 
 
4.3.2 Cell culture 
 
MCF-7 cells were employed as common mammalian cancer prototypes. 
Human ovarian cancer cells, both CDDP sensitive (A2780) and resistant strains 
(A2780 CisR), were chosen for efficacy study as they were repeatedly used in Pt-
based drug related studies [224]. Human fetal lung fibroblast IMR-90 was employed 
as a non-cancerous control cell line. MCF-7 and IMR-90 cells were purchased from 
ATCC (VA, USA) while A2780 and A2780 CisR were obtained as a gift from Prof 
Dyson (EPFL). All cells were maintained in DMEM supplemented with 10% FBS 
and incubated at 37 ºC in humidified air containing 5% CO2. All cells were sub-
cultured every 3-4 days with 0.5% TrypLE™ Express. A2780 CisR cells were 
maintained by addition of 1 µM CDDP every 3 passages. 
 
4.3.3 Flow cytometry 
 
For determination of MWCNT-Rho uptake, MCF-7 cells were incubated with 
10 µg/mL MWCNT-Rho for the following duration: 1, 2, 3, 4, 5, 6, 18, 20, 24, 48, 
and 72 h. After that, the cells were harvested and vortexed prior to filtration through a 
60 µm nylon filter and was analysed using CyAn™ ADP Analyser (Beckman 
Coulter). Excitation was carried out at 488-nm and fluorescence emission was 
obtained in FL1 channel (530 nm). 20,000 cells were collected and the data were 
recorded and analysed using Summit 4.3 software.  
For JC-1 staining, treated MCF-7 cells were harvested and stained with JC-1 
at 2 µM with an optimal density of 1 × 106 cells/mL. After incubation for 15 min at 
37ºC, cells were analysed immediately using BD LSRFortessa™ Flow Cytometry 
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Analyser (BD Biosciences, USA). Monomers of JC-1 was excited using 488 nm laser 
and J-aggregates of JC-1 was excited using 561 nm laser. Fluorescence emissions 
were recorded at 530 nm (FL1 channel) and 575 nm (FL2 channel) for Alexa Fluor® 
488 conjugated Annexin V and PI, respectively. Mitochondria containing red JC-1 
aggregates (mitochondria with a normal membrane potential; active mitochondria) 
from viable cells were detectable in FL2 channel, and green JC-1 monomers 
(mitochondria with a depolarized membrane; impaired mitochondria) were detectable 
in FL1 channel. The results were plotted as the percentage of cells with active 
mitochondria (FL2) from total number of cells analysed (15,000 cells per analysis). 
 
4.3.4 Cytotoxicity assay 
  
MTT assay was used for experiments involving pristine drugs and drug 
combinations, while WST-1 assay was employed for experiments involving 
MWCNTs since MWCNTs could bind to the insoluble MTT formazan crystals and 
artificially affect the measured absorbance values [228]. Meanwhile, WST-1 produces 
a water-soluble formazan product and is hence able to resolve any inaccuracy 
attributable to the intrinsic interference of MWCNTs. 
To perform the cytotoxicity assays, cells were first seeded into 96-well tissue 
culture plates (Costar, Corning NY) at a density of 5000 cells/well and allowed to 
grow for 24 h. The cells were exposed to varying concentrations of test compounds 
for 6 h before being replaced with fresh FBS supplemented medium. After incubating 
for another 72 h, the medium was aspirated, replaced either with MTT (0.5 mg/mL in 
PBS) or WST-1 (1:15 dilution from ready-to-use stock), and incubated either for 4 h 
(MTT) or 15 min (WST-1). For MTT assay, the medium was aspirated and DMSO 
(100 µL) was added to dissolve the insoluble purple formazan crystals before 
absorbance were measured at 595 nm using a microplate reader (Microplate Reader 
Infinite Series M200, Tecan). For WST-1 assay, 80 µL of the assay solution was 
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aspirated into a new 96-well plate without disturbing the cell layer containing 
MWCNTs and absorbance was measured directly at 440 nm. Three independent 
experiments were performed with six repeats for each treatment condition. 
Cytotoxicity was evaluated with reference to the IC50 value, which was defined as the 
concentration of the agent required to inhibit cell viability by 50%, calculated from 
the dose-response curves using GraphPad Prism (Version 5.0, GraphPad Software). 
 
4.3.5 Colony formation assay 
  
MCF-7 cells were seeded at 1 × 104 cells/well into 96-well tissue culture 
plates and allowed to grow for 24 h. The cells were then treated with either pristine 
MWCNT or MWCNT-TEG-Rho at 30 µg/mL and further allowed to grow for 24 h. 
After that, the MWCNTs treated cells were harvested by TrypLE™ Express and 
counted via hemocytometer under microscope to obtain total number of cells in the 
suspension. Either 100 or 200 of cells were then re-seeded into 6-well tissue plate 
(Corning, NY) and allowed to grow into visible clones. After 7 days, colonies were 
fixed with 6.0% glutaraldehyde and stained with 0.5% crystal violet for 30 min for 
visualization. The culture plates containing fixed colonies were then carefully rinsed 
with tap water, dried in air, and counted using a stereomicroscope.  
 
4.3.6 Drug loading 
 
Stable entrapment of platinum(IV) prodrug of CDDP, PtBz, in MWCNTs 





Figure 4.2. Schematic illustration of nano-extraction. The relative affinities among the 
guest molecules, solvents, and CNTs needed to carry out nano-extraction are shown 
on the triangles. In nano-extraction, ideally the guest molecules are to possess strong 
affinity to CNTs core but weak affinity to solvents. Such differential potential “force” 
the guest molecules to be preferentially deposited into the hydrophobic interior of 
CNTs. Adapted with permission from Yudasaka M. et al., 2003 [223]. 
 
Briefly, PtBz (2 mg/mL) and functionalized MWCNTs (2 mg/mL), namely 
MWCNT-Rho or non-mitochondrial targeting control MWCNT-Fluo, were dispersed 
in chloroform (CHCl3) independently. They were sonicated for 15 min prior to 
mixing (1:1 w/w MWCNTs:PtBz) and stirring at room temperature (RT) for 5 days. 
The mixture was filtered through a 0.2 µm PTFE membrane and rinsed thoroughly 
with excess of washing solvent comprising 2:2.4:1 v/v/v CHCl3:methanol:DI water. 
The samples were recovered from the membrane and dried in vacuo to yield 
MWCNT-Rho(PtBz) and MWCNT-Fluo(PtBz), respectively. This protocol is 
validated to eliminate non-specific PtBz adsorbed on MWCNTs surface [224]. 
For BP encapsulation, MWCNT-Rho were suspended in CHCl3 containing 
excess BP (4 × MWCNTs’ weight equivalent, 1 mg/mL), and agitated for 3 days. The 
MWCNTs were filtered through a 0.2 µm PTFE membrane, and washed thoroughly 
with DCM. The sample was subsequently recovered from the membrane and dried in 
vacuo to yield MWCNT-Rho(BP). MWCNT-Rho(BP) was suspended in CHCl3 
containing equal weight of PtBz (1 mg/mL) and agitated for 5 days. The mixture was 
filtered through a 0.2 µm PTFE membrane and rinsed thoroughly with excess of 
washing solvent comprising 2:2.4:1 v/v/v CHCl3:methanol:water. The samples were 
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recovered from the membrane and dried in vacuo to yield MWCNT-Rho(BP+PtBz). 
Thermogravimetric analysis (TGA) and Inductively Coupled Plasma Optical 
Emission Spectrometry (ICP-OES) (Dual-view Optima 5300 DV ICP-OES system, 
Perkin Elmer) were performed by the Chemical, Molecular and Materials Analysis 
Centre (NUS) to quantify the amount of compound loaded within the CNTs. 
 
4.3.7 Statistical analysis 
 
 All experiments were performed in triplicate unless otherwise stated. Non-
linear regression was used to fit cytotoxicity data into log(inhibitor)-response curve 
with GraphPad Prism 5 (GraphPad Software Inc. USA) and IC50 was obtained 
conveniently with the software. Results of experimental repeats were averaged with 
Microsoft Excel (Microsoft Inc., California, USA) and SEM were obtained based on 
the repeated values. 
 
4.4 Results and discussion 
 
4.4.1 Evaluation of the feasibility of MWCNT-Rho as drug carrier 
  
To evaluate if the MWCNT-Rho could be an alternative mitochondrial 
targeting drug delivery platform, it is imperative to prioritize the investigation of any 
intrinsic undesired toxicity to cells. WST-1 assay demonstrated that un-functionalized 
pristine MWCNTs imposed considerable toxicity to MCF-7 cells in which only ~60% 
of cells remained viable with exposure to even the least concentration of MWCNTs (5 
µg/mL) tested (Figure 4.3a). On the other hand, MWCNT-Rho treated MCF-7 cells 
displayed a marginal decrease of ca. 20% in cell viability at the highest concentration 
tested (30 µg/mL) (Figure 4.3a). This infers that surface functionalization on pristine 











Figure 4.3. Evaluation of toxicity after Rho 110 functionalization. a) Investigation of 
cell viability via WST-1 cytotoxicity assay. MCF-7 cells were treated with pristine 
MWCNTs or MWCNT-Rho at different concentrations for 72 h. WST-1 readings from 
the control lane (i.e. cells without any treatment) were used as reference values for 
100% survival; b) Colony formation assay of MCF-7 cells upon treatment with 30 
µg/mL of pristine MWCNTs or MWCNT-Rho for 24 h. Either 100 or 200 of treated 
cells were re-seeded back to culture plate and allowed to grow into visible colonies. 
 
Colony formation assay is a cell survival assay based on the ability of a single 
cell to grow into a colony, directly indicating the proliferation capacity of a cell [229].  
Unexpectedly, regardless of the number of cells being seeded initially, MCF-7 cells 
exposed to either pristine MWCNTs or MWCNT-Rho did not display compromised 
ability in proliferation compared to non-treated control (Figure 4.3b). Together with 
the data from WST-1 assay, we inferred that MWCNTs, particularly pristine 
MWCNTs, induced cellular stress or death without affecting cellular proliferation. 
It is generally recognized that pristine un-functionalized CNTs are not 
suitable as drug carrier due to their enormous size and hence problem of aggregation 
and aqueous suspendability [63]. Hence, length reduction and surface 
functionalization have been proposed to modify CNTs to be feasible for biomedical 
application. In line with this, our approach of defect-functionalizing and appending 
targeting molecule Rho 110 on MWCNTs was demonstrated to effectively reduce 




After ascertaining that functionalized MWCNT-Rho was superior to un-
functionalized pristine MWCNTs in terms of preserving MCF-7 cell viability, the 
construct was screened for its cytotoxicity against a wider panel of cell lines, 
including cancerous cells MCF-7, A2780, A2780 CisR (CDDP resistant strain), and 
non-cancerous human lung fibroblast IMR-90, via WST-1 assay. Even at the highest 
concentration tested (50 µg/mL), MWCNT-Rho only led to a marginal decrease of ca. 
15% in cell viability (Figure 4.4). Therefore, we conclude that MWCNT-Rho was not 
significantly toxic to these cells.  
 
 
Figure 4.4. WST-1 assay of A2780, A2780 CisR, MCF-7, and IMR-90 cells upon 
incubation with 5, 25, and 50 µg/mL of MWCNT-Rho for 72 h. WST-1 readings from 
the control lane (i.e. cells without any treatment) were used as reference values for 
100% survival. 
 
To demonstrate that MWCNT-Rho is not cytotoxic at mitochondrial level, 
JC-1 staining was performed on MCF-7 cells treated with 10 µg/mL of MWCNT-Rho. 
JC-1 dye is selected as it is sensitive to transmembrane potential changes, which is an 
indicator of mitochondrial health [230]. Based on the JC-1 staining assay (Figure 4.5), 
addition of MWCNT-Rho to cells did not significantly impair mitochondrial 
membrane potential, as most cells emitted fluorescence at 590 nm resulting from the 




Figure 4.5. Mitochondrial membrane potential measurement of 10 µg/mL MWCNT-
Rho treated MCF-7 cells after 12 h incubation by JC-1 staining and flow cytometry. a) 
non-treated control; b) MWCNT-Rho treated cells.  
 
Besides evaluation of impairment to cellular viability and mitochondrial 
health, it is crucial to characterize kinetics of cellular uptake of MWCNT-Rho in its 
development into a mitochondrial targeting nanocarrier. Fluorescence emission of 
single cell after MWCNT-Rho uptake was recorded in a time-dependent manner by 
flow cytometry (Figure 4.6a). The percentage of cell population that was fluorescent, 
due to uptake of MWCNT-Rho, rose after 1 h of incubation and plateaued at around 
18-24 h time period with ca. 40% of cells being fluorescent. After 24 h, a decline in % 
cells containing MWCNT-Rho was observed, presumably due to cell division and 
growth. However, when cells incubated with MWCNT-Rho for 24 h were washed to 
remove surface bound MWCNT-Rho, replaced with fresh media and allowed to grow 
for another 24 h, the % of fluorescent cells plunged by more than 80%. Compared to 
cells incubated for 48 h without medium change, cell duplication could have only 
accounted for part of the decline (ca. 50%) (Figure 4.6b). We excluded likelihood that 
the decline in % fluorescent cells was due to instability of Rho 110 over time by 
performing preliminary stability study. The UV-VIS absorbance profile of MWCNT-
Rho was observed to be consistently stable throughout 72 h when incubated at 37ºC 
(Appendix II). This leaves the intriguing possibility that the cells could have expelled 












Figure 4.6. Characterization of cellular uptake of MWCNT-Rho in MCF-7 cells. a) 10 
µg/mL of MWCNT-Rho was incubated with MCF-7 cells and flow cytometry was 
performed to determine the percentage of cells positive for fluorescence (% 
fluorescence) upon MWCNT-Rho uptake for different durations; b) MCF-7 cells were 
incubated with 10 µg/mL of MWCNT-Rho for 24 h and an additional wash step to 
wash off surface bound MWCNT-Rho was included and flow cytometry was 
performed to determine the % fluorescence. 
 
In short, in order to function as suitable mitochondrial targeting drug carrier, 
MWCNT-Rho should neither be detrimental to cell viability nor mitochondrial 
function, and not retained by cells after delivering its payload. We found that 
incubation with MWCNT-Rho did not result in significant viability reduction in four 
cell lines (A2780, A2780 CisR, MCF-7, IMR-90) even at highest test concentration of 
50 µg/mL (Figure 4.4). Moreover, when we examine the toxicity at the mitochondrial 
level, the lack of differences in JC-1 uptake profile suggests that cells treated with 
MWCNT-Rho had comparable transmembrane potential to untreated control and 
hence their mitochondrial functions were not impaired (Figure 4.5). 
On the other hand, internalization of MWCNT-Rho plateaued at around 18-
24 h time period (Figure 4.6a), with only ca. 40% of cells taking up MWCNT-Rho. 
We speculate that either the remaining 60% did not take up MWCNT-Rho or that the 
Rho 110 on MWCNTs was insufficiently fluorescent to be detected by flow 
cytometry. For this reason, it is not possible to accurately quantify the amount of 




the observation that % cells containing MWCNT-Rho declined by half infers a 
possible dilution effect due to cell duplication, i.e. doubled the number of cells at 48 h 
and at the same time less available MWCNT-Rho in medium (Figure 4.6a). 
Serendipitously, after MWCNT-Rho was removed from external environment, less 
than 10% of cells retained their fluorescence after one round of duplication (Figure 
4.6b). This suggests the intriguing possibility that loss of MWCNTs might be related 
to the equilibrium of MWCNTs across cellular membrane, i.e., MWCNTs loss is 
increased when there are less available MWCNTs in the external environment. 
Considering previous reports showing the ability of CNTs in traversing cellular 
membrane without being pumped out by P-gp and delivering rhodamine 123 in 
K562R cells overexpressing P-gp [188, 199], we rule out the possibility that the 
observed decline in fluorescence was due to efflux of P-gp. The possible MWCNTs 
excretion from cells is in agreement with other findings in vitro, which demonstrated 
that SWCNTs were expelled from NIH-3T3 cells over hours and days [156]. 
Collectively, these findings highlight that healthy cells are able to recover from CNTs 
exposure. Nevertheless, further studies both in vitro and in vivo are warranted to 
comprehensively elucidate the safety aspects of this emerging nanomaterial. 
 
4.4.2 Examining mitochondrial targeted MWCNT-Rho as a drug 
delivery platform for Pt(IV) prodrugs (PtBz) of CDDP 
 
We previously demonstrated the entrapment of chemically stable PtBz within 
the hydrophobic interior of MWCNTs and subsequent intracellular release after 
chemical reduction of PtBz to hydrophilic Pt(II) species [224]. We postulated that the 
cytotoxic activity of Pt-based drug against cancer cells could be enhanced by 
selective delivery to mitochondria to target mtDNA [231]. As a proof of concept, 
PtBz was encapsulated in mitochondrial targeted MWCNT-Rho via nano-extraction, 





Scheme 4.2. Encapsulation of PtBz and BP in mitochondrial targeting MWCNT-Rho 
and non-targeting MWCNT-Fluo. a) PtBz, CHCl3, stir at RT, 120 h; b) BP, CHCl3, stir 
at RT, 72 h; c) PtBz, CHCl3, stir at RT, 120 h. 
 
MWCNT-Rho(PtBz) was obtained with a loading efficiency of ca. 15% 
(Table 4.1). For comparison, non-mitochondrial targeted MWCNT-Fluo was also 
loaded with PtBz to obtain MWCNT-Fluo(PtBz) as a control with similar 
encapsulation efficiency (Table 4.1). 
 
Table 4.1. PtBz loading in MWCNT-Fluo(PtBz) and MWCNT-Rho(PtBz). 
Test Sample PtBz Loading (µmol/mg)a PtBz Loading (% w/w)a 
MWCNT-Fluo 0.27 (15%) 15 
MWCNT-Rho 0.29 (16%) 16 
aPtBz loading was determined by combusting the constructs followed by ICP-OES analysis for 
quantification for Pt amount in the remaining residues. 
 
Both constructs were tested for their efficacy against CDDP sensitive A2780 
ovarian carcinoma cells using WST-1 cytotoxicity assay [228]. Based on the dose-
response curves (Figure 4.7), MWCNT-Rho(PtBz) was slightly more potent than 
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PtBz free drug in the inhibition of A2780 cell viability with IC50 value of 0.34 ± 0.07 
µM versus 0.45 ± 0.09 µM (Table 4.2).  
 
 
Figure 4.7. Representative diagram depicting mitochondrial targeting MWCNT-
Rho(PtBz) superiority in cytotoxicity than non-targeted MWCNT-Fluo(PtBz) in A2780 
cells evaluated by WST-1 cytotoxicity assay. The cells were exposed to relative PtBz 
concentration ranging from 10 nM to 5 µM. 
 
 The corresponding MWCNTs concentration at IC50 of MWCNT-Rho(PtBz) is 
1.18 µg/mL (Table 4.2), which is lesser than the lowest concentration tested (5 µg/mL) 
in intrinsic cytotoxicity study of MWCNT-Rho (Figure 4.4). Since treatment of even 
50 µg/mL MWCNT-Rho in A2780 was demonstrated to be insignificantly toxic, we 
therefore eliminated the possibility that the improvement of PtBz efficacy observed in 
MWCNT-Rho(PtBz) treatment was due to intrinsic toxicity of MWCNT-Rho. 
  
Table 4.2. Cytotoxicity of PtBz, MWCNT-Fluo(PtBz), and MWCNT-Rho(PtBz) in 
A2780. 
 Test Sample IC
50
 in A2780 (µM)a  Corresponding MWCNTs 
concentration (µg/mL)b 
PtBz 0.45 ± 0.09 - 
MWCNT-Fluo(PtBz) ≥2.64 ≥9.7 
MWCNT-Rho(PtBz) 0.34 ± 0.07 1.18 
aIC50 of PtBz free drug, MWCNT-Fluo(PtBz) and MWCNT-Rho(PtBz) were obtained by 
performing cytotoxicity assay for three times to get three independent IC50 and the values in the 
table are the mean and SEM constructed based on the results from the three assays. 
bCorresponding MWCNTs concentrations were back-calculated from PtBz loading in MWCNTs. 
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MWCNT-Fluo(PtBz), on the other hand, was 7-8 times less potent than 
MWCNT-Rho(PtBz), with IC50 valued at 2.64 µM (Figure 4.7 and Table 4.2). 
Besides wide variations in intracellular distribution, MWCNT-Rho and MWCNT-
Fluo differ drastically in terms of their effectiveness as drug carrier. These findings 
emphasize the importance of functional groups on MWCNTs in dictating the overall 
efficiency as drug delivery platform. In addition, mitochondrial delivery of PtBz 
using MWCNT-Rho resulted in improved efficacy in reducing A2780 cell viability as 
reflected in the comparison of IC50 with the free drug (Table 4.2 and Figure 4.7). 
MWCNT-Fluo(PtBz), on the other hand, was 6 times less potent than free PtBz, 
which could be attributable to the non-targeting nature of MWCNT-Fluo. This 
possibly resulted in cellular uptake of MWCNT-Fluo(PtBz) conjugate to be at basal 
rate of MWCNTs internalization, and hence led to reduced bioavailability in cells 
compared to free PtBz. These results suggested that the pharmacological profile of 
PtBz may be tuned by alternating the surface chemistry of MWCNT nanocarrier. 
 
4.4.3 Synergistic action via dual delivery of co-drugs encapsulated 
within mitochondrial targeting MWCNT-Rho  
 
The flexibility to design MWCNTs for selective delivery to target site 
expands available methodologies for drug targeting. We have demonstrated in 
previous section that MWCNT-Rho, but not MWCNT-Fluo, could act as 
mitochondrial targeting nanocarrier in enhancing PtBz efficacy. However, instead of 
delivering one specific molecule, the spacious MWCNTs cavity can be engineered to 
encapsulate complementary drug molecules to exert synergistic cytotoxic action. We 
reason that a two-pronged approach would be more effective as it not only triggers 
another mechanism of action, but also overwhelms the cellular recovery system in the 
localized mitochondrial space. Hence, 3-bromopyruvate (BP), a reported 
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chemosensitizer for CDDP and oxaliplatin [225, 226] acting at mitochondria, was 
chosen to be co-encapsulated with PtBz in mitochondrial targeting MWCNT-Rho. 
We considered that BP is a hydrophilic molecule (Clog P = -0.991) that 
cannot be stably entrapped within the hydrophobic MWCNT core. Our strategy was 
to entrap BP and PtBz sequentially so that BP could remain within the nanotubes’ 
interior. The hydrophobic PtBz has previously shown to be stably encapsulated within 
MWCNTs and thus in principle it can function as blocking agent to BP leakage. 
When PtBz is chemically reduced within the intracellular environment, it would be 
converted to hydrophilic Pt(II) species and expelled from MWCNTs [224]. Hence, 
BP would be unhindered and free to exit MWCNTs.  
In this regard, we carried out sequential nano-extraction with MWCNT-Rho, 
first using BP and then PtBz, and washed extensively to yield MWCNT-
Rho(BP+PtBz) (Scheme 4.2). Elemental analyses revealed that MWCNT-
Rho(BP+PtBz) comprised a reproducible 8.3% w/w BP and 35.4% w/w PtBz, 
corresponding to a molar loading of 0.497 and 0.653 µmol/mg of MWCNT-Rho for 
BP and PtBz, respectively (Table 4.3). 
 
Table 4.3. PtBz and BP loading in MWCNT-Rho.  
aAmount of PtBz and BP loaded in MWCNT-Rho was determined by combusting the constructs 
followed by ICP-OES analysis and quantification for Pt and Br content in the remaining 
residues. 
 
Cytotoxicity assay was performed in A2780 cells using PtBz, PtBz+BP 
(physical combination), MWCNT-Rho(PtBz), and MWCNT-Rho(BP+PtBz) (Figure 
4.8). Co-treatment of PtBz with BP was shown to enhance the cytotoxic effect of 
Drug Amount of drug loaded  (µmol/mg, % w/w)a 
MWCNT-Rho(PtBz) MWCNT-Rho(BP+PtBz) 
PtBz 0.288 (15.6%) 0.653 (35.4%) 
BP - 0.497 (8.3%) 
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PtBz, since BP alone is non-cytotoxic at <10 µM [226]. When both entities were co-
entrapped into mitochondrial targeted MWCNT-Rho yielding MWCNT-
Rho(BP+PtBz), this synergistic effect was amplified. Compared to MWCNT-




Figure 4.8. Cytotoxicity assay was performed for 3 times in A2780 cells treated with 
PtBz (black), physical mixture of PtBz+BP (green), MWCNT-Rho(PtBz) (blue) or 
MWCNT-Rho(BP+PtBz) (red), with PtBz concentration ranging from 10 nM to 5 µM.  
 
When the efficacy testing was performed in other cell lines, namely MCF-7, 
A2780, and A2780 CisR cancer cells, MWCNT-Rho(BP+PtBz) compared favourably 
against PtBz (Table 4.4 and Figure 4.9 a-c). The better pharmacological profile of 
MWCNT-Rho(BP+PtBz) in CDDP resistant A2780 (Figure 4.9b) and breast cancer 
MCF-7 cells (Figure 4.9c) is particularly encouraging. This signifies that our 
approach of dual-delivery of co-drugs could potentially improve therapeutic outcome 
in drug-resistant cells and expand the spectrum of cancer cells responsive to CDDP 
treatment with the use MWCNT-Rho as delivery platform. 
Importantly, in normal IMR-90 human lung fibroblasts, PtBz did not cause a 
significant cell death across the same concentration range (Figure 4.9d). This 
selectivity was preserved in MWCNT-Rho(BP+PtBz), implying that mitochondrial 
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targeting MWCNTs did not adversely affect normal cells while enhancing efficacy of 
PtBz in diseased cells. We reasoned that Rho 110 functionalization could have 
conferred potential selectivity towards tumour cells since preferential accumulation of 
rhodamine dyes was found in cancer cells due to higher mitochondrial membrane 
potential as compared to normal cells [232, 233].  
 
Table 4.4. Mean IC50 with SEM of PtBz and MWCNT-Rho(BP+PtBz).  
Test Sample IC50 of PtBz (µM)
a 
A2780 A2780 CisR MCF-7 IMR-90 
PtBz 0.45 ± 0.09 2.21 ± 0.05 0.69 ± 0.30 >2 
MWCNT-Rho (BP+PtBz) 0.17 ± 0.04 0.71 ± 0.06 0.39 ± 0.16 >2 
a
 Three repeats of each experiment were carried out. 
 
 
Figure 4.9. Representative diagrams showing comparison of cytotoxicity imposed by  
MWCNT-Rho(BP+PtBz) or PtBz free drug treatment in a) A2780; b) A2780 CisR; c) 
MCF-7; d) IMR-90 cells. 
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4.4.4 Mitochondrial targeting of PtBz and BP incurred additional 
mitochondrial damage compared to non-targeting control 
 
To determine whether the enhanced effect of MWCNT-Rho(BP+PtBz) stem 
from mitochondrial injury, mitochondrial membrane potential was examined using 
flow cytometry (Figure 4.10). MCF-7 cells were treated with PtBz or MWCNT-
Rho(BP+PtBz) at 0.7 µM for 12 h, stained with JC-1 and harvested. Changes in 
mitochondrial transmembrane potential were indicated by percentage of cells in 
quadrant 2 (red, live mitochondria) and quadrant 4 (green, damaged mitochondria). 
Figure 4.10a-b depicts that 5.4% of MCF-7 cells suffered lower mitochondrial 
membrane potential after incubation with PtBz free drug compared to non-treated 
control. Importantly, cells possessing unhealthy mitochondrial membrane potential 
expanded 2-fold to 16.2% after MWCNT-Rho(BP+PtBz) treatment (Figure 4.10c). 
This mirrored the enhancement of efficacy observed in Figure 4.9 and Table 4.4, 
highlighting the superiority of MWCNT-Rho(BP+PtBz) over PtBz in interrupting 
cancer cell survival at mitochondrial level. Notably, at PtBz concentration of 0.7 µM, 
the corresponding concentration of MWCNTs in MWCNT-Rho(BP+PtBz) is merely 
1 µg/mL (Table 4.3). Therefore, we rule out the possibility that the observed elevated 
impairment of mitochondrial membrane potential was due to intrinsic toxicity of 
MWCNT-Rho as 10 µg/mL of the nanocarrier alone imposed negligible effect on 
mitochondrial membrane potential (Figure 4.5). However, as the toxicity elicited at 
mitochondrial level was not as profound as overall cellular cytotoxicity, the 
enhancement in efficacy with the use of MWCNT-Rho could be due to other 
mechanisms. On the other hand, when MWCNT-Fluo was employed as carrier 
instead of MWCNT-Rho, mitochondrial membrane potential depletion was 
substantially less evident and only 3% of cells were found to shift to quadrant 4 
(Appendix III), inferring that additional mitochondrial injury is rendered by 




Figure 4.10. Investigation of mitochondrial membrane potential in MCF-7 cells via JC-1 
staining followed by flow cytometry. Mitochondrial membrane potential was assessed in a) non-
treated control; b) PtBz (0.7 µM); c) MWCNT-Rho(BP+PtBz) (0.7 µM) treated cells. After 
incubation for 12 h, cells were harvested and stained with JC-1 and analyzed by flow 
cytometry. Quadrant 2 (Q2) represents live cells whereby JC-1 was attracted to and 
aggregated in actively respiring mitochondria, which possess higher membrane potential. 
Quadrant 4 (Q4) represents unhealthy cells in which JC-1 existed in monomeric form due to 
insufficient accumulation in mitochondria having lowered mitochondrial membrane potential. 
 
4.5 Conclusions  
 
We have validated that MWCNT-Rho is a suitable nanocarrier for biomedical 
applications by demonstrating the inability of empty MWCNT-Rho carriers to 
significantly reduce cell viability, impair cellular proliferation, or incur damage to 
mitochondrial membrane potential. Interestingly, partial excretion of MWCNTs is 
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suggested after 24 h, signifying the capacity of MWCNT-Rho as mitochondrial 
targeting drug carrier that can be excluded from cells after finishing delivery of its 
payload. We proceeded to encapsulation of PtBz in mitochondrial targeting 
MWCNT-Rho and non-targeting MWCNT-Fluo by nano-extraction. Drug loading (% 
w/w) of 15% and 16% were attained for the targeting MWCNT-Rho(PtBz) and non-
targeting MWCNT-Fluo(PtBz), respectively. Compared to non-targeting MWCNT-
Fluo(PtBz), the targeting MWCNT-Rho(PtBz) exhibited ca. 8 fold enhancement in 
efficacy with respect to A2780 viability impairment, emphasizing the importance of 
presence of targeting group on MWCNTs. Notably, MWCNT-Rho(PtBz) also 
compared favourably to PtBz alone in terms of cytotoxicity. Thereafter, co-
encapsulation of PtBz with a chemosensitizer BP in MWCNT-Rho was performed 
and loading efficiency (% w/w) was estimated to be 35.4% and 8.3%, respectively. It 
is demonstrated that the synergistic effect of the two compounds was enhanced by the 
use of mitochondrial targeting MWCNT-Rho in all tested cell lines, including CDDP 
resistant A2780 CisR. The enhancement in efficacy could be attributed to additional 
mitochondrial injury due to targeting effect, evidenced by a further plunge in 











Chapter 5  Higher degree functionalization to 




The findings expounded in previous chapters are implicit indicators that 
MWCNTs could serve as a versatile targeted nanocarrier for cancer therapy.  
Despite the success in augmenting loaded cargo’s efficacy, there is still room for 
improvement on the compatibility in cells, especially for the functionalized constructs 
that are supposed to be satisfactorily compatible. In this regard, several 
macromolecules have displayed remarkable capacity in conferring the functionalities 
of better suspendability and lower cytotoxicity to MWCNTs. In the following section, 
the discussion will be focused on two prominent examples that are highly reported in 
literatures, namely bovine serum albumin (BSA) and polyethylene glycol (PEG). 
 
5.1.1 Bovine serum albumin (BSA) 
 
Albumin is a common model serum protein that has been extensively 
characterized. Albumin is inexpensive and frequently used in biological assays such 
as western blot or immunosorbent assay. In the aspect of drug delivery, human serum 
albumin is developed as nanoparticle carrier and formulated together with paclitaxel 
in order to improve its solubility and ameliorate the side effect associated with 
conventional formulation [234]. The inertness of albumin to tissues and cells has been 
harnessed in functionalization of CNTs for improving compatibility in vitro and in 
vivo. In one of the studies, BSA was functionalized on both oxidized SWCNTs and 
MWCNTs via diimide-activated amidation. The CNT-BSA conjugates obtained were 
highly water-soluble as evidenced from the formation of a relatively homogenous 
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dark-coloured aqueous suspension [190], inferring the immense potential of BSA as 
biocompatible dispersant for CNTs. As enhanced aqueous suspendability is often an 
indicator of lower toxicity in cells, this study suggests further exploration of BSA to 
generate CNT constructs with better biocompatibility profile.  
Nevertheless, covalent functionalization of BSA on CNTs via diimide-
activated amidation entails structural modifications on the CNTs’ surface. Especially 
in the case of SWCNTs, wherein the integrity of the sidewall endows unique optical 
properties useful for imaging and detection, preservation of the seamless structural 
features of CNT’s sidewall appears to be prudent in the development of SWCNT-
based nanocarriers. Fortunately, besides covalent conjugation, CNTs are also found to 
be dispersed by BSA after simple physical adsorption process via sonication. 
Moreover, all studies pertaining to BSA adsorbed CNTs are unanimous in 
demonstrating a favourable compatibility in cells [153, 235, 236]. Particularly, Holt et 
al. covered the compatibility issues across various aspects encompassing uptake and 
recovery, cytotoxicity, impact on proliferation and cellular phenotype [156]. They 
demonstrated that the uptake of BSA dispersed SWCNTs occurred rapidly, reaching a 
steady state within 1 min and the internalization was saturated with a SWCNT 
concentration of 1 µg/mL. Although incubation with BSA dispersed SWCNTs 
resulted in a dose-dependent toxicity in NIH-3T3 fibroblasts seeded at low density, 
the same observation was not noticed in cells seeded at normal density. The 
proliferation potential of the fibroblasts was not compromised by the treatment of the 
BSA dispersed SWCNTs. Importantly, by quantitative determination of the amount of 
SWCNTs in cells using confocal Raman spectroscopy, the authors showed that the 
cells were able to be recovered from SWCNTs exposure, i.e., the amount of SWCNTs 
diminished with time after replacement of SWCNT-containing media to SWCNT-free 
media. These observations accentuate the potential of CNTs for biomedical 




5.1.2 Polyethylene glycol (PEG) 
  
PEG, composed of repeating ethylene glycol units −(CH2−CH2−O)n− where 
the integer n represents the degree of polymerization, is a water soluble polymer with 
widespread applications in the biomedical field. PEG is relatively inert to human 
body. In addition, functionalization of PEG on nanocarrier surface is known to 
facilitate the evasion from systemic clearance by RES and increases the duration of 
systemic circulation [237]. Hence, it is expected that PEG is used extensively as 
biocompatible dispersant in the quest for transforming CNTs into nanocarrier with 
improved suspendability and lowered toxicity to cells. 
 PEG can be grafted onto CNTs via physical adsorption or covalent 
conjugation. To be physically adsorbed on CNTs, PEG is commonly modified at one 
of the terminal ends with hydrophobic moiety or polycyclic aromatic hydrocarbon 
with a flat aromatic surface. Physical adsorption is particularly desirable for SWCNTs 
because it allows the preservation of SWCNTs surface integrity and hence intrinsic 
optical properties such as Raman absorption, photoluminescence, photoacoustic 
property, etc.  
One pioneering example is the PL-PEG (MW = 2000 or 5000) reported by 
Dai’s group [238]. The hydrophobic lipid chains of PL-PEG adhered strongly onto 
the SWCNTs sidewall, whereas the hydrophilic PEG chain extended to interact with 
external environment, endowing water solubility and biocompatibility to CNTs. PL-
PEG functionalized SWCNTs displayed remarkable stability in various aqueous 
phases including water, physiological buffer such as PBS, cell culture medium, and 
whole serum [238]. Notably, SWCNTs functionalized with PL-PEG exhibited 
relatively long blood circulation times and low sequestration by the RES in vivo [239]. 
In another report, by utilizing the intrinsic Raman spectroscopic signatures of 
SWCNTs, i.v. injected PL-PEG functionalized SWCNTs were detected in blood 
circulation and in various organs and tissues of mice ex vivo for longer term study 
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over a period of 3 months [174]. SWCNTs functionalized with PL-PEG (branched 
PEG chains) was found to exhibit the longest blood circulation profile of up to 1 day 
with relatively low uptake in the RES. Interestingly, the majority of PL-PEG 
functionalized SWCNTs was found to be cleared from the main organs in ca. 2 
months’ time. It was revealed by Raman spectroscopy that SWCNTs were present in 
the intestine, feces, kidney, and bladder of mice, inferring the biliary and renal 
pathways as the main clearance route of SWCNTs from mice. Moreover, absence of 
toxicity of PL-PEG functionalized SWCNTs in mice emphasizes the effectiveness of 
PL-PEG in conferring biocompatibility to CNTs in vivo. 
Another example used for non-covalent surface functionalization of CNTs is 
represented by poly(γ-glutamic acid) (γPGA) or poly(maleic anhydride-alt-1-
octadecene) (PMHC18) linked PEG copolymers. These copolymers were further 
derivatized with pyrene, a polycyclic aromatic hydrocarbon that adsorb onto CNTs’ 
surface via strong pi-pi interactions [240]. The copolymer-coated SWCNTs exhibited 
high stability in aqueous solutions regardless of alterations in pH or increase in 
temperatures. Moreover, the copolymer-coated SWCNTs displayed remarkably long 
blood circulation (t1/2 = 22.1 h) upon i.v. injection into mice. This implies a 
considerable delay in clearance by the RES of mice, which is desirable for in vivo 
applications including imaging and drug delivery. 
Besides physical adsorption, covalent conjugation of PEG represents another 
option for grafting the macromolecules on CNTs. It is commonly fabricated by 
esterification or amidation of the carboxylic groups on oxidized CNTs with PEG or 
amine-modified PEG [237]. In this regard, our group has previously reported 
functionalization of PEG (MW = 600) on acyl chloride activated oxidized MWCNTs 
through esterification [98]. The PEG grafted MWCNTs were reported to be uniformly 
suspended in water at a high concentration of 10 mg/mL. Besides defect 
functionalization, PEG can also be appended covalently on CNTs sidewall via 1,3 
dipolar cycloaddition of azomethine ylides. The pyrrolidine rings generated on CNT 
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sidewalls are functionally reactive and therefore they have been used to covalently 
link with PEG, resulting in highly soluble CNTs [237].  
 
5.2 Hypothesis and objectives 
 
We propound that higher degree functionalization of MWCNT-TEG-NH2 and 
MWCNT-Rho with hydrophilic macromolecules would further enhance their 
suspendability and compatibility in cells. Both functionalized MWCNT-TEG-NH2 
and MWCNT-Rho were used as model scaffold for the higher degree 
functionalization. BSA was functionalized via covalent conjugation. It is a 66.5 kDa 
protein with 61 lysine residues, 39 aspartate residues, and 59 glutamate residues, 
which offers tremendous amount of active groups (amine and carboxylic groups) for 
amidation with functionalized MWCNTs. For MWCNT-TEG-NH2, it was estimated 
that ca. 567.3 µmol/g and > 2000 µmol/g of amine and carboxylic groups [241] were 
present. As for MWCNT-Rho, ca. 82.7 µmol/g and > 2000 µmol/g of amine and 
carboxylic groups were estimated to exist on the nanotube. In fact, in a preliminary 
experiment, we found that physical adsorption of BSA on MWCNTs was 
unsatisfactory as there was lack of detectable loading of the molecule on CNT 
sidewall. PEG (MW = 5000, PEG5000) was modified single-endedly with pyrene to 
generate an amphiphilic polymer that can be physically adsorbed onto CNT sidewall 
via pi-pi interaction. As a matter of fact, in a preliminary experiment, we failed to 
covalently link PEG on oxidized MWCNTs. This is attributed possibly to the 
presence of a low amount of active groups for amidation to MWCNTs (1 every 5000 
g/mol of molecule). Hence, physical adsorption was adopted as alternative to affix 
PEG on functionalized MWCNTs. 
To validate the hypothesis, the following objectives were set-forth: 
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1. Water soluble BSA and PEG5000 were functionalized on MWCNT-TEG-NH2 
and MWCNT-Rho to demonstrate the capacity of MWCNTs for higher 
degree functionalization.   
2. The functionalized constructs were validated for their functionalities and 
characterized for their aqueous dispersion profile to verify that higher degree 
functionalization indeed leads to improved aqueous suspendability.  
3. Cytotoxicity and apoptosis/necrosis induction were accessed to ascertain that 
further functionalization of biocompatible macromolecules on MWCNTs 
indeed impart favourable attributes to nanotubes in terms of compatibility in 
cells. 
 
5.3 Materials and methods 
 
5.3.1 Materials  
 
Pristine MWCNTs were obtained with courtesy from Professor Sundara 
Ramaprabhu from the Indian Institute of Technology, Madras. DMF, EA, and ethanol 
were of ACS reagent grade from Merck Millipore (Darmstadt, Germany). DI water 
was obtained from Sartious-Stedim biotech atrium® 611 system. 1-Pyrenebutyric 
acid N-hydroxysuccinimide ester, DIPEA, BSA, 4-morpholineethanesulfonic acid 
hydrate (MES), and NHS were procured from Sigma Aldrich (St. Louis, USA). 
DMAP was purchased from Alfa Aesar (Lancaster, UK). EDC was obtained from GL 
Biochem (Shanghai, China). Omnipore hydrophilic PTFE membranes (0.2 µm) were 
purchased from Millipore (Darmstadt, Germany). DMEM and FBS were procured 
from Thermo Scientific (Waltham, USA). TrypLE™ Express and Alexa Fluor® 488 




5.3.2 Covalent functionalization of BSA on MWCNT-TEG-NH2 and 
MWCNT-Rho  
 
BSA was functionalized on MWCNT-TEG-NH2 or MWCNT-Rho by EDC-
mediated amidation (Schemes 5.1a & b). Briefly, 8 mg of MWCNTs, suspended in 
MES buffer (pH 5), were activated for amidation by 10 mg of EDC.HCl and 5 mg of 
NHS. After 2 h stirring, 30 mg of BSA dissolved in MES buffer was added into the 
CNTs reaction mixture. The mixture was stirred for 24 h at 4ºC. The MWCNTs were 
subsequently washed thoroughly with MES buffer via filtration with a 0.2 µm 
polytetrafluoroethylene (PTFE) membrane (Millipore, presoaked in 60% ethanol). 
The MWCNTs were recovered from the membrane and lyophilized yielding 11 mg of 


































5.3.3 Synthesis of amphiphilic pyrene-PEG5000 and its non-covalent 
adsorption on sidewall of MWCNT-TEG-NH2 and MWCNT-Rho.  
 
Briefly, 1-Pyrenebutyric acid N-hydroxysuccinimide ester (50 mg, 0.125 
mmol) was reacted with H2N-PEG-OH (MW = 5000, 625 mg, 0.125 mmol), via 
stirring at 60ºC in 1 mL of dry DMF together with EDC·HCl (24 mg, 0.125 mmol), 
NHS (15 mg, 0.125 mmol), DMAP (catalytic amount), and DIPEA (32 µl, 0.25 mmol) 
for 24 h (Scheme 5.2). After that, 9 mL of water was added into the reaction mixture. 
Crude purification was performed to remove the excess of reactant pyrene by 
extraction with EA, since it is the only possible interfering factor that might impede 
adsorption of pyrene-PEG5000 on MWCNTs sidewall. The resulting hydrophilic 
product pyrene-PEG5000 remained in water/DMF fraction and the water/DMF was 
removed in vacuo and 40 mg of product was obtained. Thin layer chromatography 
(TLC) (Appendix IV) was used to monitor reaction progression and removal of 























Scheme 5.2. Synthesis of pyrene-PEG5000 via EDC mediated amidation. 1-
pyrenebutyric acid N-hydroxysuccinimide ester was stirred with NH2-PEG5000 for 24 h 
at 60 ºC. 
 
As both NH2-TEG-NH2 and Rho 110 are small molecules and the 
functionalization is presumably located at CNTs’ ends instead of sidewall as a result 
of defect functionalization, we suggest that surface on MWCNTs’ sidewall would still 
be available for pi-pi adsorption. 8 mg of pyrene-PEG5000 was stirred with 8 mg of 
MWCNT-TEG-NH2 or MWCNT-Rho in ethanol for 72 h at RT (Schemes 5.3a & b). 
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The MWCNTs were subsequently washed thoroughly with ethanol via filtration to 
remove unbound Pyrene-PEG5000. The MWCNTs were recovered from the membrane 




Scheme 5.3. Physical adsorption of pyrene-PEG5000 on a) MWCNT-TEG-NH2 and b) 
MWCNT-Rho. 
 
5.3.4 Characterization of BSA and PEG-5000 functionalization via TGA 
analysis.  
 
MWCNT-TEG-NH2 (BSA), MWCNT-Rho (BSA), MWCNT-TEG-NH2 
(PEG5000), and MWCNT-Rho (PEG5000) were characterized via thermogravimetric 
(TGA) analysis. TGA data were recorded on a TA Instruments-SDT 2960 
Simultaneous DTA-TGA (differential thermal/thermogravimetric analyzer) at a 
heating rate of 10 ºC/min in air with the help of specialist from Chemical, Molecular 






5.3.5 Cell culture  
 
 Human breast cancer cells MCF-7 was selected as common cancer prototypes 
while lung fibroblast IMR-90 was chosen as non-cancerous control. MCF-7 and IMR-
90 cells were purchased from ATCC (VA, USA). The cells were maintained in 
DMEM supplemented with 10% FBS and incubated at 37ºC in humidified air 
containing 5% CO2. All cells were subcultured every three to four days with 
TrypLE™ Express.  
 
5.3.6 Cytotoxicity assay 
 
To perform the cytotoxicity assay, cells were first seeded into 96-well tissue 
culture plates at a density of 5,000 cells/well. After 24 h, the medium was removed 
and the cells were exposed to varying concentrations of test compounds. After 
another incubation of 72 h, the medium was aspirated, replaced with 100 µL of WST-
1 (1:15 dilution from ready-to-use stock in PBS) and incubated for 30 min. 80 µL of 
the WST-1 solution without cells and MWCNTs was aspirated for absorbance 
reading. The absorbance of the assayed solution was measured at 440 nm for WST-1 
using a microplate reader (BioTekTM SynergyTM H1 Hybrid Multi-Mode Microplate 
Reader). Experiments were performed in three repeats for at least three replicates.  
 
5.3.7 Flow cytometry 
 
For apoptosis/necrosis staining, MCF-7 cells were seeded in 12-well culture 
plate (SPL Life Sciences Co. Ltd., Korea) at 2×105 cells/well and allowed to grow for 
24 h. The cells were then given different treatments for 24 h. All cells were harvested 
and stained at density of 1×106 cells/mL with 2 µL of Alexa Fluor® 488 conjugated 
Annexin V and 0.1 µg of propidium iodide (PI) for 15 min at RT. All cell samples 
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were immediately analysed by flow cytometry using CyAn™ ADP Analyser 
(Beckman Coulter). Alexa Fluor® 488 conjugated Annexin V and PI were excited 
using 488 nm laser. Fluorescence emissions were recorded at 530 nm (FL1 channel) 
and 575 nm (FL2 channel) for Alexa Fluor® 488 conjugated Annexin V and PI, 
respectively. Forward scatter (FSC) and side scatter (SSC) of the cells in light-
scattering analysis was concurrently measured up to 20,000 events. The data were 
collected and analysed using Summit 4.3 software. 
 
5.3.8 Confocal microscopy 
 
Confocal microscopy was conducted to validate if PEG5000 functionalization 
affected the original targeting capacity. Briefly, MCF-7 cells were seeded in a 29 mm 
glass bottom dish (In Vitro Scientific, USA) at a density of 5×104 cells/mL for 24 h, 
followed by incubation with 10 µg/mL of MWCNT-Rho (PEG5000) for 24 h. 
Thereafter, the cells were incubated with Hoechst 33342 (5 µg/mL) for 10 min as a 
nuclear counter-stain, followed by MitoTracker® Deep Red FM (25 nM) for 5 min to 
stain mitochondria before being viewed under a confocal microscope. MWCNT-Rho 
(PEG5000), MitoTracker® Deep Red FM, and Hoechst 33342 were excited at 495 nm, 
635 nm, and 352 nm, respectively. Fluorescence emission was recorded at 519 nm, 
690 nm, and 455 nm for MWCNT-Rho (PEG5000), MitoTracker® Deep Red FM, and 
Hoechst 33342, respectively.  
 
5.3.9 Statistical analysis 
 
 The data of cytotoxicity assay were analysed using GraphPad Prism (Version 
5.0, GraphPad Software). The assay was performed with six replicates for each 
treatment condition. Mean and SEM of % cell viability were obtained conveniently 
by the software.  
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5.4 Results and discussion  
 
5.4.1 BSA and PEG5000 functionalization improved MWCNTs 
suspendability 
 
 To further improve the aqueous suspendability and biocompatibility of 
functionalized MWCNTs, we performed further attachment of biocompatible 
macromolecules that have favourable in vivo profile, an attribute that might confer 
favourable functionalities and properties to MWCNTs’ future biomedical applications 
in vivo. The chosen macromolecules are PEGs with molecular weight of 5000 g/mol 
(PEG5000) and BSA and their in vivo behaviors have been established after extensive 
experimental characterization. BSA was functionalized covalently on MWCNTs’ 
sidewalls via EDC-mediated amidation as physical adsorption was found to be 
unsatisfactory in dispersing functionalized MWCNTs. On the contrary, for 
functionalization of PEG5000, covalent amidation did not result in detectable loading 
on MWCNTs. Therefore, PEG5000 was derivatized with pyrene to facilitate non-
covalent physical adsorption via pi-pi stacking on MWCNTs’ sidewalls. 
Thermogravimetric analysis (TGA), which detects changes in weight in 
relation to temperature program in a controlled atmosphere, showed that both 
MWCNT-TEG-NH2 (BSA) and MWCNT-Rho (BSA) contained ca. 20% w/w of 
BSA (Figures 5.1a & b). This is illustrated by the changes in weight due to 
degradation of BSA at around 380°C. Meanwhile, complete degradation of the 
MWCNTs constructs occurred at around 600 to 800°C, which is in agreement with 
previous report [98]. Moreover, derivative curves illustrated a lack of difference in 
terms of loading between the two constructs as highlighted by the red boxes. This 
could be accounted by the availability of numerous active sites (either –COOH or –
NH2) on BSA that could react with either –COOH or –NH2 on functionalized 
MWCNTs.  On the other hand, ca. 10% w/w of PEG5000 was found to be 
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functionalized on both MWCNT-TEG-NH2 (PEG5000) and MWCNT-Rho (PEG5000). 
Meanwhile, bare MWCNT-TEG-NH2 and MWCNT-Rho displayed insignificant 
weight loss during combustion at around 380°C (Appendix V). As a result, we 
conclude that both BSA and PEG5000 were grafted successfully on functionalized 













Figure 5.1. TGA analysis to validate functionalization of a) MWCNT-TEG-NH2 (BSA); 
b) MWCNT-TEG-Rho (BSA); c) MWCNT-TEG-NH2 (PEG5000) ; d) MWCNT-Rho 
(PEG5000). Red boxes highlight the presence of the functional groups due to changes 
in weight as a result of functional group loss during combustion at controlled 
temperature.  
 
To ascertain that higher degree functionalization with water soluble 
macromolecules BSA and PEG5000 impart favourable aqueous suspendability and 
stability to functionalized MWCNTs, we dispersed the resulting constructs in water at 
1 mg/mL and captured the suspension status after 2 h standing at RT. Indeed, the 
aqueous suspendability and stability of MWCNT-TEG-NH2 and MWCNT-Rho were 
enhanced with functionalization of BSA and PEG5000 (Figure 5.2). Notably, it appears 
that PEG5000 functionalized constructs were more stable in water, demonstrated by the 
higher homogeneity of the suspension. This implies that PEG5000 could be a better 
 116 
 
macromolecule for our purpose possibly due to its relatively simpler structure than 
BSA and hence more defined affinity in water.  
 
 
Figure 5.2. Suspendability test of MWCNT constructs in water.  
 
5.4.2 BSA and PEG5000 functionalization alleviated toxicity of MWCNT-
TEG-NH2 and MWCNT-Rho 
 
 When MCF-7 cells were exposed to MWCNT-TEG-NH2 and MWCNT-Rho 
for 72 h, there was a reduction in cell viability of ca. 40% and 20% at the highest 
MWCNT concentration tested (50 µg/mL) (Figures 5.3a & b).  We attribute the 
elevated toxicity observed in MWCNT-TEG-NH2 treatment to the probability of the 
aggregation as a result of ionic interaction formed between primary amine groups (-
NH3+ under physiological pH) and remaining unreacted -COOH groups (-COO- under 
physiological pH). Following further functionalization with biocompatible BSA and 
PEG5000, the impact on cellular viability imposed by MWCNT-TEG-NH2 and 
MWCNT-Rho exposure was mitigated (Figures 5.3a & b). This accentuates our 
rationale that higher degree functionalization of MWCNTs’ surface indeed led to 
improved compatibility in cells and suggests that the toxic effects caused by the 
hydrophobic surface of MWCNTs could be alleviated by masking it with 
biocompatible macromolecules.  
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 The same treatment conditions were repeated in non-cancerous IMR-90 cells 
and it was demonstrated that addition of MWCNT-TEG-NH2 and MWCNT-Rho also 
hampered cell viability, albeit to a lower extent than the viability reduction observed 
in treated MCF-7 cells, i.e. ca. 80% of cells remained viable (Figures 5.3c & d). We 
postulate that as MCF-7 cells are malignant, the uptake of foreign materials including 
nutrients has to be boosted in order to commensurate the amount of building blocks 
necessary for elevated growth and division. The higher cellular uptake and 
accumulation of MWCNTs in MCF-7 cells could be responsible for the apparent 
higher susceptibility to MWCNTs toxicity compared to non-cancerous IMR-90. 
However, to ascertain this hypothesis, a quantitative measurement of MWCNTs’ 
level in more cancer cells and normal cell lines is mandatory.  
In IMR-90 cells, higher degree functionalization with BSA and PEG5000 
resulted in marginal improvement in terms of toxicity compared to un-functionalized 
constructs, demonstrated by the slight increase in cell viability after exposure to 
MWCNT-TEG-NH2 (BSA), MWCNT-TEG-NH2 (PEG5000), MWCNT-Rho (BSA), 
and MWCNT-Rho (PEG5000) (Figures 5.3c & d). Collectively, we have substantiated 
our hypothesis that higher degree functionalization of MWCNTs’ surface with 
biocompatible BSA and PEG5000 indeed imparts favourable improvement in 
compatibility profile in cells. This highlights the potential of MWCNTs as 





Figure 5.3. WST-1 assay of various functionalized MWCNTs on cancerous MCF-7 
and non-cancerous IMR-90 cells. MCF-7 cells were treated with increasing 
concentration of a) MWCNT-TEG-NH2 and its PEG5000 and BSA functionalized 
derivatives; b) MWCNT-Rho and its PEG5000 and BSA functionalized derivatives for 
72 h. Similarly, IMR-90 cells were exposed to c) MWCNT-TEG-NH2 and its PEG5000 
and BSA functionalized derivatives and d) MWCNT-Rho and its PEG5000 and BSA 
functionalized derivatives. Asterisk indicates P < 0.05 when compared to either 
MWCNT-TEG-NH2 or MWCNT-Rho treatment at different concentration. For all 
panels, data represent three observations for each experiment and are expressed as 
mean±SEM (n=6). 
 
5.4.3 Exposure of BSA and PEG5000 functionalized MWCNTs resulted in 
lower cellular granularity compared to un-functionalized MWCNTs 
 
 One possible reason accounting for the depleted cell viability after exposure 
to MWCNT-TEG-NH2 and MWCNT-Rho (Figure 5.3) is the triggering of cell death, 
either apoptosis or necrosis. Hence, MCF-7 cells that had undergone different 
treatments were subjected to annexin V/PI staining to analyse the extent of 
apoptotic/necrotic events in cells. We also examined if BSA and PEG5000 
functionalization on MWCNTs’ sidewalls could diminish cell death induction. 
Unexpectedly, compared to untreated control wherein 95.25% cells remained healthy 
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without cell death induction (Figure 5.4a), 25 µg/mL of MWCNT-TEG-NH2 and 
MWCNT-Rho did not significantly aggravate cell death with only 1-2% of cells 
displaying apoptotic/necrotic features (Figures 5.4b & e). This reveals the presence of 
other cellular mechanisms involved in the depressed cell viability observed after 
MWCNTs treatment. Addition of MWCNTs functionalized with BSA or PEG5000 to 
MCF-7 cells for 24 h also did not result in discernible effect in terms of 
apoptosis/necrosis induction (Figures 5.4c, d, f & g).  
 
 
Figure 5.4. Apoptosis/necrosis analysis by annexin V/PI staining. Assessment of 
apoptosis/necrosis in MCF-7 cells after treatment with 25 µg/mL of b) MWCNT-TEG-
NH2; c) MWCNT-TEG-NH2 (BSA); d) MWCNT-TEG-NH2 (PEG5000); e) MWCNT-Rho; 
f) MWCNT-Rho (BSA); g) MWCNT-Rho (PEG5000); while a) is the control medium 
without MWCNTs. After incubation for 24 h, the cells were harvested and stained with 
annexin V and PI. Left bottom quadrant represents live cells (annexin V/PI negative). 
Right bottom quadrant represents early apoptotic cells (annexin V positive/PI 




 However, when the cellular morphology was scrutinized by light scattering 
analysis, it appeared that MCF-7 cells treated with MWCNT-TEG-NH2 or MWCNT-
Rho displayed an increase in side scattering (SSC) of light while the forward light 
scattering (FSC) remained unchanged (Figures 5.5b & e). FSC correlates with cross-
sectional area of a cell (cell size) and SSC associates with cellular granularity or 
intracellular complexity stem from e.g. the shape of nucleus, or the amount of 
cytoplasmic granules. In contrast, the SSC of MCF-7 cells exposed to BSA or 
PEG5000 functionalized MWCNTs appeared to be lower compared to un-
functionalized MWCNTs (Figures 5.5 c, d, f & g). Particularly for cells treated with 
BSA functionalized MWCNTs, the decrease in SSC appeared more significantly than 
cells exposed to PEG5000 functionalized MWCNTs. 
 
 
Figure 5.5. Dot plot of light scattering analysis with forward light scatter (FSC) versus 
side scatter (SSC). MCF-7 cells were subjected to different treatment conditions for 
24 h and harvested for flow cytometry analysis. a) untreated control; b) MWCNT-
TEG-NH2; c) MWCNT-TEG-NH2 (BSA); d) MWCNT-TEG-NH2 (PEG5000); e) MWCNT-
Rho; f) MWCNT-Rho (BSA); g) MWCNT-Rho (PEG5000). 
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 In fact, there are reports on qualitative estimation of CNTs’ cellular uptake 
via light scattering analysis regardless of membrane bound CNTs or internalized 
CNTs [242-244]. This qualitative measurement is based on the increase in cellular 
granularity ensuing uptake of CNTs, which resulted in elevated SSC intensity [243]. 
Exposure of cells to MWCNT-TEG-NH2 or MWCNT-Rho caused a considerable 
increase in SSC, inferring that uptake of CNTs transpired. In contrast, the lower SSC 
observed in cells treated with macromolecules functionalized MWCNTs, especially in 
BSA conjugated MWCNTs, signifies a decline in cellular uptake.  
We postulate that the seemingly reduced internalization might be due to the 
disrupted interaction of CNTs’ surface with plasma membrane by the sidewall coated 
macromolecules. In essence, our reasoning is similar with the extensively studied 
corona effects of nanoparticles that arise from the exposure to serum proteins prior to 
cellular entry [245-247]. The corona is a layer of proteins and other biomolecules, 
which strongly adsorbs on the nanoparticle surface with duration longer than cellular 
uptake. This non-specific adsorption results in a new complex unit that interacts 
differently with cellular machinery and leads to compromised uptake by cells. The 
formation of a corona also affects the material properties by simply lowering the 
surface free energy of the bare material [245].  
The macromolecules used in this study, particularly BSA, for higher degree 
functionalization might similarly form a coat on MWCNTs, hindering MWCNTs 
from interacting with plasma membrane via its unique surface properties. 
Consequently, the decrease in cellular uptake might be the reason accounting for the 
lower cytotoxicity observed for macromolecules functionalized MWCNTs exposure 
(Figure 5.3). Interestingly, this might unveil the possibility of modulating MWCNTs 
cellular uptake via different surface functionalization. Nevertheless, a quantitative 
analysis such as confocal Raman spectroscopy is warranted to complement the 
findings from light scattering analysis and confirm the inference pertaining to the 
amount of cellular uptake. 
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5.4.4 PEG5000 functionalized MWCNT-Rho did not impact the 
mitochondrial targeting capability  
 
 We propose that PEG5000 is better than BSA for functionalization on 
MWCNTs’ sidewall due to its simpler structure that leads to the attainment of a more 
defined and controlled mode of attachment on MWCNTs’ surface. In addition, based 
on the abovementioned findings, PEG5000 functionalization conferred a further 
enhancement in aqueous stability to MWCNTs than BSA functionalization (Figure 
5.2). Moreover, the relative bulkiness of BSA entails undesirable flaw that is the 
resemblance of corona protein coats on MWCNTs’ surface, which might hinder the 
interaction of nanotube with plasma membrane leading to compromised cellular 
uptake (Figures 5.5c & f).  
 However, it is imperative to validate that PEG5000 functionalization does not 
hamper the targeting capacity of MWCNT-Rho before concluding the potential of this 
macromolecule in imparting favourable attributes without confounding the original 
desired properties of the nanotubes. We performed confocal microscopy on MCF-7 
cells exposed to MWCNT-Rho (PEG5000) for 24 h to investigate the intracellular 
distribution of the nanotube constructs. Indeed, further attachment of PEG5000 on 
MWCNTs’ sidewall did not compromise the mitochondrial targeting capability of 
MWCNT-Rho, evidenced by overlapped green fluorescence with Mitotracker® red 
fluorescence (Figure 5.6b &c). Moreover, we obtained a mitochondrial colocalization 
coefficient of 0.81 and this is similar to the colocalization coefficient of MWCNT-
Rho (Section 3.4.4).  Thus, we conclude that PEG5000 adsorption on MWCNTs’ 
sidewall did not impact the mitochondrial targeting capability of MWCNT-Rho. This 






Figure 5.6. Subcellular localization of MWCNT-Rho (PEG5000). MCF-cells were 
exposed to 10 µg/mL of MWCNT-Rho (PEG5000) (green) for 24 h. The cells were then 
stained with the mitochondrial marker MitoTracker® Deep Red (red) and nuclear 
marker Hoechst 33342 (blue) and observed under confocal microscope.  
 
5.5 Conclusions  
 
We have successfully appended biocompatible macromolecules BSA and 
PEG5000 on functionalized MWCNTs by covalent amidation and pi-pi stacking, 
respectively. TGA analysis showed that there were ca. 20% or 10% of BSA or 
PEG5000 being attached on MWCNTs, respectively. Higher degree functionalization 
of BSA or PEG5000 improved the aqueous suspendability of MWCNTs and their 
toxicity profile in MCF-7 and IMR-90 cells. As the impairment of cell viability after 
exposure to either MWCNT-TEG-NH2 or MWCNT-Rho was found to be 
independent of apoptotis/necrosis induction, functionalization with BSA or PEG5000 
did not improve the compatibility profile in this aspect. From light scattering analysis, 
it appears that cells exposed to macromolecules functionalized MWCNTs, especially 
BSA conjugated MWCNTs, displayed lower SSC (indicator of granularity) compared 
to cells exposed to un-functionalized counterparts. This infers a possible decrease in 
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cellular association/uptake of BSA functionalized MWCNTs, which might be the 
reason accounting for the improved toxicity profile. Nevertheless, it will be necessary 
to perform a quantitative evaluation of cellular uptake of different functionalized 
MWCNTs in order to validate such inference. Due to more defined mode of 
functionalization, better aqueous stability, and less compromised cellular uptake, 
PEG5000 is proposed to be a superior choice to BSA for functionalization on 
MWCNTs’ sidewall. In addition, PEG5000 adsorption did not affect mitochondrial 
targeting capability of MWCNT-Rho, highlighting its immense potential for 
application in modifying targeted CNT-based nanocarrier without altering the original 



















Chapter 6  Delivery of Hexokinase II peptide using 




6.1.1 Hexokinase II and cancer 
 
 Hexokinase is an enzyme that phosphorylates glucose in an ATP-dependent 
manner, which is the first committed step in glucose metabolism [248]. Among the 
four isozymes, the Types I-III are 100 kDa proteins thought to have evolved by 
duplication and fusion of a gene encoding an ancestral 50 kDa hexokinase similar to 
the one that encodes Type IV isozyme. Among the four isozymes, only Type II 
hexokinase (hexokinase II) possesses catalytically active N- and C-terminal halves. 
Besides Type I hexokinase (hexokinase I), hexokinase II associates with mitochondria 
after its expression in cytosol by binding on the OMM via its hydrophobic N-terminal 
region [249]. VDAC (also called porin), which forms the major channel for the 
exchange of metabolites and ions between mitochondria and other cellular 
compartments, is identified to be the protein that interacts with hexokinase I and II on 
the OMM [250].  
The catabolic hexokinase I is ubiquitously expressed in all mammalian tissue 
while the anabolic hexokinase II is exceptionally limited in its expression. 
Hexokinase II is abundantly found in embryonic tissues and to a lesser extent in 
certain adult tissues, such as adipose, skeletal muscles, and cardiac muscles [248]. 
Intriguingly, malignant tumours exhibiting high glycolytic phenotype express higher 
level (>100-fold) of hexokinase II compared to normal cells [16, 17]. In such tumours, 
mitochondrial hexokinase II activity is also elevated [15], which promotes glycolysis. 
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As a result, these cells are able to survive and grow better in an oxygen-deprived 
environment brought about by neoplastic mass accrual  [251].  
Hexokinase II engages with four other partner proteins in promoting and 
maintaining malignancy in tumour cells. These key interacting proteins include 
plasma membrane glucose transporter (Glut) that allows the entry of glucose 
(substrate of hexokinase II) into the cancer cell, VDAC, the ATP synthase on IMM 
that generate ATP for hexokinase II, and finally the ANT that transports the ATP to 
the VDAC-hexokinase II complex on OMM (Figure 6.1). The cooperative actions 
among these four proteins result in rapid and efficient production of glucose-6-
phosphate by hexokinase II. Besides serving as the precursor for glycolysis, the 
glucose-6-phosphate also functions as intermediate for biosynthesis of key 
metabolites via the pentose-phosphate pathway and the mitochondrial tricarboxylic 
acid cycle, contributing profoundly for the growth and proliferation of cancer cells.  
 
 
Figure 6.1. Hexokinase II and its interacting proteins in mediating aberrant 
metabolism for cancer proliferation. To maintain the highly glycolytic metabolic flux in 
malignant cells, the product glucose-6-phosphate (which is inhibitory to hexokinase II 
activity) is rapidly distributed into key metabolic routes. The primary routes are direct 
entry into the pentose-phosphate shunt for biosynthesis of DNA precursors. (Adapted 
with permission from Mathupala et al., 2006 [15]) 
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In addition, hexokinase II association with VDAC has also been shown to 
ingeniously desensitize tumour cells from activation of cell death by preventing 
proapoptotic Bcl-2 family members such as Bax and Bad from binding to 
mitochondria, thus maintaining mitochondrial integrity [19]. Targeted disruption of 
this association strongly induces cytochrome c release from mitochondria and 
apoptosis even in the absence of Bax and Bak [18].  
Collectively, hexokinase II represents a valuable therapeutic target for cancer 
therapy given its high expression level in cancer cells compared to normal adult 
tissues [248]. Compounds such as 3-bromopyruvate, clotrimazole and methyl 
jasmonate have been investigated in vitro and in vivo for their anticancer properties 
via inhibition of hexokinase II binding to mitochondria [9]. Since these small 
molecule compounds can also trigger other cytotoxic mechanisms, the contribution of 
hexokinase II inhibition in their cytotoxicity remains debatable [227, 252, 253].  
 
6.1.2 Peptides corresponding to the N-terminal fifteen amino acids of 
hexokinase II  
 
Peptides derived from the N-terminal fifteen amino acids of hexokinase II, 
denoted as HKII (Figure 6.2), have been studied as selective mitochondrial 
hexokinase II dissociating agent to elicit apoptosis.  
 
 




As HKII peptides are impermeable to cells, they are generally conjugated to 
an internalization peptide sequence, often known as cell penetrating peptide (CPP), 
such as HIV-1 TAT or Drosophila Antennapedia at N-terminal end. CPPs generally 
consist of 10 to 30 amino acid residues that are either arginine-rich, amphipathic and 
lysine-rich, or hydrophobic [254]. They permeate plasma membrane and allow their 
therapeutic cargo to be delivered to cells and tissues. CPPs use multiple pathways to 
traverse the plasma membrane and the internalization is independent of cell types 
[255]. Since their discovery, CPPs have been demonstrated for in vitro and in vivo 
delivery of a diversified assortment of cargo, including peptides, siRNA, proteins etc. 
[256, 257].  
In one study using CPPs based on the internalization sequence of 
Antennapedia for delivery of HKII, the fusion peptide induced detachment of 
endogenous mitochondrial bound hexokinase II into cytosol in HeLa cells at a 
concentration of 100 µM [19]. However, treatment with 100 µM of the fusion peptide 
alone neither induced Bax translocation nor cytochrome c release but markedly 
sensitized apoptosis induction in Indomethacin (Bax-dependent apoptosis inducer) 
treated HeLa cells. In contrast, Nataly Shulga et al. reported that 1 µM of the same 
peptide could trigger re-localization of hexokinase II from mitochondria to cytosolic 
fraction and potentiate CDDP cytotoxicity in HCT116 cells [258].  
In another study, a 23 amino acid residues peptide corresponding to 
mitochondrial binding motif of hexokinase II was fused to six arginines at the C-
terminal [18]. The fluorescently labelled fusion peptide was internalized 
intracellularly within minutes and scattered uniquely resembling mitochondrial 
distribution pattern. In addition, 20 µM of the fusion peptide was shown to disrupt 
hexokinase II association with mitochondria. On the other hand, Federica Chiara et al. 
reported the usage of TAT sequence for delivery of 15 amino acids HKII peptide 
across plasma membrane [259]. As anticipated, 20 µM of TAT-HKII fusion peptide 
precluded hexokinase II from binding to mitochondria. Interestingly, 40 µM of the 
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peptide potently induced apoptosis, which depended on the opening of permeability 
transition pore complex of mitochondria, with more than 70% of cells displaying 
apoptotic features after 2 h treatment.  
 
6.2 Hypotheses and objectives  
 
Despite the reported success in delivering HKII peptide using CPPs in 
abovementioned studies, conjugation with CPP is unavoidably challenged by possible 
degradation (both extracellular and intracellular) [260] and endosomal entrapment 
[261]. In this regard, nanocarriers have been employed to shield cytotoxic peptide 
against rapid peptidolysis and to selectively deliver them to tumour cells via “passive” 
accumulation (through the EPR effect) or “active” targeting (by molecular 
recognition to designated sites) [262].  
CNTs have emerged as a highly attractive nanocarrier for peptide due to 
several reasons including their high ratio of length to diameter (aspect ratio) that 
facilitates cellular uptake. Hence, we hypothesize that MWCNTs, with large surface 
for peptide loading and excellent aptitude in permeating cellular membrane, could be 
utilized for peptide delivery to improve bioavailability in cells. In addition, the  
unique ability of MWCNTs in traversing cellular membrane by transmembrane 
penetration [104] was shown to have bypassed endosomal entrapment [152]. We 
suggest that this feature could be harnessed in delivering bioactive peptide to 
circumvent degradation in endo-lysosomal compartments. Importantly, numerous 
studies discussed in Section 1.6 indicate that covalent conjugation of peptides on 
CNTs will not compromise their structural integrity and hamper the display for target 
recognition. We therefore propose that HKII peptide could be alternatively delivered 
by MWCNTs via covalent conjugation without compromise in its structural display 
that is crucial for targeting endogenous hexokinase II-mitochondria interaction and 
subsequent cell death induction.  
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 In this chapter, the following research objectives are outlined to substantiate 
our hypothesis that CNTs could serve as excellent alternative vehicle for HKII 
peptide delivery into cells:  
1. HKII was covalently appended to the surface of MWCNTs with or without 
linker to generate MWCNT/HKII conjugates. The loading was characterized 
by reversed phase HPLC to validate the synthesis of MWCNT-peptide 
constructs. 
2. Cellular uptake of MWCNT-peptide conjugates was investigated in vitro and 
the uptake profile was compared with peptide alone to evaluate the 
effectiveness of our DS. 
3. The cytotoxic action of these nano-conjugates was evaluated and compared 
with commercially available cell permeable fusion peptide to demonstrate 
that MWCNTs could be developed into efficient nanocarrier for bioactive 
peptides.  
4. Mechanism of cell death was probed in vitro to validate that the toxicity 
observed with the nano-conjugates stem merely from the activity of the 
conjugated peptide. 
 




 HKII peptide (with sequence MIASHLLAYFFTELN) and its fluorescent 
derivative modified with a fluorescein moiety at the additional lysine residue (with 
sequence MIASHLLAYFFTELNK-FITC) (HKII-FITC) were purchased from 
Biomatik Corporation (De, USA).  Commercially available cell-permeable peptide 
analogue of HKII (CPP-HKII) was procured from EMD Millipore (Darmstadt, 
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Germany).  Short-length MWCNTs were purchased from Nanostructured & 
Amorphous Materials Inc. (TX, USA). NH2-TEG-NH2, DIPEA, NHS, and MTT were 
procured from Sigma Aldrich (MO, USA). HATU, DMAP, succinic anhydride, and 
2,2’-Diaminodiethyl disulfide dihydrochloride (cystamine)  were purchased from Alfa 
Aesar (Lancaster, UK). EDC was purchased from GL BioChem (Shanghai, China). 
KCN was kindly provided by teaching lab of pharmacy department, National 
University of Singapore. DMEM, FBS, and protease inhibitor cocktail were procured 
from Thermo Scientific (MA, USA). RPMI-1640 and McCoy's 5A cell culture 
medium were purchased from Life Technologies (CA, USA). WST-1 was purchased 
from Roche Applied Science (IN, USA).  CellTiter-Glo luminescent cell viability 
assay kit was purchased from Promega Corp. (WI, USA). DMF and DMSO of ACS 
reagent grade and acetonitrile (ACN) of HPLC grade were obtained from Merck 
Millipore (Darmstadt, Germany). Bradford reagent was procured from Bio-Rad 
Laboratories Inc. (CA, USA). Antibodies to VDAC-1 (20B12) and hexokinase II (C-
14) were purchased from Santa Cruz Biotechnology Inc. (TX, USA). 
  
6.3.2 Defect functionalization of CNTs for peptide delivery 
 
 The synthetic scheme starting from the functionalization of the CNT carrier 
to the final attachment of HKII peptide is summarized in Scheme 6.1. To further 
extend the possibility of developing MWCNTs into a biocompatible nanocarrier, 
short-length MWCNTs (0.5-2 µm) was employed because of the superior aqueous 
suspendability compared to normal-length MWCNTs (2-10 µm) used in 
abovementioned chapters, based on our preliminary observations. Pristine short-
length MWCNTs (20 mg) were oxidized by sonication for 10 h in 98% sulphuric acid: 
65% nitric acid (3:1 v/v, 4 mL) to create the carboxylic groups needed for subsequent 
functionalization. The oxidized MWCNTs (MWCNT-COOH) were subsequently 
washed thoroughly with DI water via filtration through a 0.2 µm PTFE membrane 
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(Millipore, presoaked in 60% ethanol) until the pH of the filtrate reached 5-7. The 
MWCNTs were recovered from the membrane and lyophilized yielding MWCNT-
COOH (19 mg). 
 
6.3.3  Modification of terminal NH2 on functionalized MWCNTs into 
COOH  
 
To append linker NH2-TEG-NH2 on oxidized short-length MWCNTs, 
HATU-mediated amidation was performed according to the procedures discussed in 
Section 3.3.2. The conversion of free terminal amino group present on the linker into 
COOH group was necessary for the HKII to be linked to the MWCNT-TEG-NH2 via 
its N-terminal amine. In light of this, 8 mg of MWCNT-TEG-NH2 were reacted with 
30 equivalents of succinic anhydride and 2 equivalents of DIPEA in 1 mL of dry 
DMF. The reaction mixtures were then stirred at 40°C for 12 h. The eventual 
MWCNT-TEG-COOH was then harvested via filtering through a 0.2 µm PTFE 
membrane, and rinsed thoroughly with DMF, followed by methanol and DI water. 
The MWCNTs were subsequently recovered from the membrane with additional DI 
water and lyophilized. The extent of NH2-TEG-NH2 functionalization and the amount 
of terminal amino groups converted into carboxylic groups were estimated by Kaiser 
test, which is detailed in Section 3.3.4.     
 
6.3.4  Conjugation of HKII/HKII-FITC peptide on MWCNTs  
 
MWCNT-COOH and MWCNT-TEG-COOH were further functionalized 
with HKII, yielding MWCNT-HKII and MWCNT-TEG-HKII. Briefly, 5 equivalent 
of EDC⋅HCl, 5 equivalents of NHS and 2 µL of DIPEA were added into 0.5 mL of 
dry DMF in the presence of a catalytic amount of DMAP before addition of the 
CNTs. The reaction mixture was then stirred at 60°C for 2 h. The resulting carboxylic 
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activated MWCNTs were then immediately filtered through a 0.2 µm PTFE 
membrane and washed 4 times with 100 µL of dry DMF. The MWCNTs were 
recovered from the membrane with 500 µL of dry DMF. Two equivalents of HKII 
were reconstituted in 500 µL of dry DMF with 4% DMSO. 10 µL of the reconstituted 
peptide solution was kept for HPLC analysis and the remaining solution was then 
added to the carboxylic activated MWCNTs in DMF and allowed to react at 40°C for 
72 h.  
On completion, the reaction mixture was then spiked with 0.5 mg HKII-
FITC. HKII-FITC shares the same solubility profile as HKII as both of them are only 
fully soluble in DMSO while poorly soluble in other solvents such as DMF, 
methanol, or EA. Hence, we assume that HKII-FITC as a fluorescent derivative of 
HKII could be used as an internal standard to account for loss during the subsequent 
filtration process as well as inconsistency during reversed phase HPLC analysis. The 
reaction mixture spiked with the internal standard was then filtered through a 0.2 µm 
PTFE membrane, and rinsed thoroughly with DMF, followed by methanol and DI 
water. The filtrate and DMF washes were collected for subsequent HPLC analysis for 
estimation of peptide loading. The MWCNTs were recovered from the membrane 
with additional DI water and lyophilized.   
HKII-FITC functionalization on MWCNT-COOH or MWCNT-TEG-COOH 
for confocal microscopy was performed similarly to the abovementioned HKII 
conjugation.  
 
6.3.5  Estimation of peptide loading via HPLC  
 
As MWCNTs could not be injected directly into a reversed phase HPLC C-18 
column, estimation of peptide loading was carried out indirectly by subtracting the 
amount of unreacted peptide after reaction from the total peptide before reaction. A 
calibration curve was constructed by injecting a series of calibration (standard) 
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solutions of known HKII concentration and a standard graph with response (area 
under curve) versus concentration was obtained. HKII solutions of differing 
concentrations were prepared (3.5 mg/mL, 1.75 mg/mL, 0.88 mg/mL, 0.44 mg/mL, 
and 0.22 mg/mL). The standards were spiked with 0.25 mg/mL HKII-FITC as 
internal standard. All the samples were analyzed using Agilent 1200 Series HPLC 
System fitted with Waters XTerra RP18 Column, 5 µm, 4.6 x 150 mm column. The 
analysis was conducted at a gradient of 35% acetonitrile (ACN)/65% H2O to 65% 
ACN/ 35% H2O in 10 min with flow rate of 0.8 mL/min. 
 
6.3.6  Cell culture  
 
Human breast cancer cells MCF-7 and human colon carcinoma HCT116 cells 
were selected as cancer prototypes to evaluate suitability of CNTs as drug DS for 
bioactive HKII due to their reported usage in hexokinase II related study [258, 263]. 
Human fetal lung fibroblasts IMR90 were employed as non-cancerous control. MCF-
7, HCT116, and IMR-90 cells were purchased from ATCC (VA, USA) and 
maintained in RPMI 1640, McCoy's 5A, and DMEM, respectively. All media were 
supplemented with 10% FBS and the cells were incubated at 37°C in humidified air 
containing 5% CO2. All cells were sub-cultured every 3 to 4 days with 0.5% 
TrypLE™ Express.  
 
6.3.7  Confocal microscopy  
 
Confocal microscopy was conducted to investigate cellular uptake and 
intracellular distribution of HKII-FITC delivered by MWCNT-COOH and MWCNT-
TEG-COOH. Briefly, MCF-7 cells were seeded in a 29 mm glass bottom dish (In 
Vitro Scientific, USA) at a density of 5×104 cells/mL for 24 h, followed by incubation 
with 25 µM of HKII-FITC peptide, 50 µg/mL of MWCNT-HKII-FITC or MWCNT-
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TEG-HKII-FITC for 6 h. Thereafter, the cells were incubated with Hoechst 33342 (5 
µg/mL) for 10 min as a nuclear counter-stain, followed by MitoTracker® Deep Red 
FM (25 nM) for 5 min to stain mitochondria before being viewed under a confocal 
microscope (Confocal Laser Scanning Biological Microscope FV10i, Olympus). 
HKII-FITC conjugated MWCNTs, MitoTracker® Deep Red FM, and Hoechst 33342 
were excited at 495 nm, 635 nm, and 352 nm, respectively. Fluorescence emission 
was recorded at 519 nm, 690 nm, and 455 nm for HKII-FITC functionalized 
MWCNTs, MitoTracker® Deep Red FM, and Hoechst 33342, respectively.  
 
6.3.8  Cytotoxicity Assay   
 
MTT assay was used for experiments involving HKII and its cell-permeable 
analogue CPP-HKII, while WST-1 assay was employed for experiments involving 
CNTs. To perform the cytotoxicity assay, cells were first seeded into 96-well tissue 
culture plates (Costar, Corning NY) at a density of 1×104 cells/well for IMR-90 and 
HCT116 cells, and 8,000 cell/well for MCF-7 cells. After 24 h, the medium was 
removed and the cells were exposed to varying concentrations of test compounds. 
HKII peptide loading on MWCNTs (Table 6.2) was used to calculate the amount of 
MWCNTs needed to prepare corresponding test concentration of peptide. After 
another incubation of 48 h, the medium was aspirated, replaced with 100 µL of either 
MTT (0.5 mg/mL in PBS) or WST-1 (1:15 dilution from ready-to-use stock in PBS), 
and incubated for 4 h or 30 min, respectively. For MTT assay, the MTT solution was 
removed and DMSO was added to dissolve the insoluble purple formazan crystals. 
For WST-1 assay, 80 µL of the WST-1 solution without cells or MWCNTs was 
aspirated for subsequent absorbance reading. The absorbance of the assayed solution 
was measured at 595nm for MTT and 440nm for WST-1 using a microplate reader 
(BioTekTM SynergyTM H1 Hybrid Multi-Mode Microplate Reader). Experiments were 
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performed in three repeats for at least three replicates. The data were analyzed using 
GraphPad Prism (Version 6.0, GraphPad Software).  
6.3.9  Apoptosis/necrosis staining and cell cycle analysis 
 
For apoptosis/necrosis staining, HCT116 cells were seeded in 12-well culture 
plate (SPL Life Sciences Co. Ltd., Korea) at 1×105 cells/well and allowed to grow for 
72 h. The cells were then given different treatments for 2 h. All cells were harvested 
and stained at density of 1×106 cells/mL with 2 µL of Alexa Fluor® 488 conjugated 
Annexin V and 0.1 µg of PI for 15 min at RT. All cell samples were immediately 
analyzed by flow cytometry using BD LSRFortessa™ Flow Cytometry Analyser (BD 
Biosciences, USA). Alexa Fluor® 488 conjugated Annexin V was excited using 488 
nm laser and PI was excited using 561 nm laser. Fluorescence emissions were 
recorded at 530 nm and 575 nm for Alexa Fluor® 488 conjugated Annexin V and PI, 
respectively. A total of 15,000 cells were collected and analyzed. 
For cell cycle analysis, HCT116 cells were seeded in 12-well culture plate 
(SPL Life Sciences Co. Ltd., Korea) at 1×105 cells/well and allowed to grow for 48 h. 
The cells were then given different treatments for 24 h. After treatment, the cells were 
harvested and fixed in ice cold 70% ethanol overnight at -20°C. Ethanol fixed cells 
were treated with 200 µg/mL RNase and 20 µg/mL PI for 15 min at 37°C and 
analysed using BD LSRFortessa™ Flow Cytometry Analyser. A total of 15,000 cells 
were collected and analyzed. 
 
6.3.10  Intracellular ATP level determination 
 
HCT-116 cells were seeded at 2×104 cells/well in 96-well culture plate and 
allowed to grow for 48 h. The cells were then treated with different conditions for 1 h, 
2 h, 4 h, and 8 h. ATP level in cells was quantified using CellTiter-Glo Luminescent 
Cell Viability Assay kit according to manufacturer’s protocol. Luminescence was 
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measured by BioTekTM SynergyTM H1 Hybrid Multi-Mode Microplate Reader from 
BioTek Instruments Inc. (VT, USA). 
6.3.11  Isolation of mitochondria and immunoblotting of hexokinase II  
 
Mitochondria isolation was performed as previously described [264]. Briefly, 
a total of 1×107 cells were resuspended in mitochondria isolation buffer [250 mM 
Sucrose, 20 mM HEPES-NaOH (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 
1 mM EGTA] supplemented with protease inhibitor cocktail and disrupted by 20 
strokes through a 25 gauge needle followed by centrifugation at 800 g for 10 min at 
4°C. Supernatants were centrifuged twice at 12,000 g for 20 min each at 4°C to pellet 
the heavy membrane fraction enriched with mitochondria for the analysis of 
hexokinase II. Immunoblotting was carried out as described [265]. Protein 
concentration of each sample was determined by Bradford assay. An equal amount of 
proteins for each sample was subjected to fractionation on SDS-PAGE followed by 
western blotting analysis for hexokinase II and VDAC-1. Densitometry of each lane 
was quantitated using ImageJ (NIH, USA). 
 
6.3.12  Statistical analysis  
 
All experiments were performed in triplicate unless otherwise stated. Results 
of experimental repeats for cytotoxicity assay, intracellular ATP quantification, and 
western blot densitometry were input into Graphpad Prism 5 (Ca, USA) and 
corresponding plot with mean and SEM were obtained. Two-tailed, unpaired 
student’s t test was employed to compare efficacy between treatment groups for 
cytotoxicity assay and the p-value was obtained by Microsoft Excel (Microsoft Inc., 




6.4  Results and discussion  
 
The overall synthesis route for the different MWCNT constructs is illustrated 
in Scheme 6.1. 
 
 
Scheme 6.1. Synthetic scheme for HKII functionalization on MWCNTs. a)  98% 
H2SO4: 65% HNO3 = 3:1 v/v, 10 h; b) NH2-TEG-NH2, HATU, DIPEA, DMF, stir at 
40°C, 12 h; c) succinic anhydride, stir at 40°C, 12 h; d) NHS, EDC, DMAP, DIPEA, 
DMF, stir at 40 °C, 2 h; e) HKII/HKII-FITC, stir at 72 h, 40°C; f) NHS, EDC, DMAP, 
DIPEA, DMF, stir at 60°C, 2 h; g) cystamine, HATU, DIPEA, DMSO, stir at RT, 12 h; 
e) succinic anhydride, stir at RT, 12 h; f) NHS, EDC, DMAP, DIPEA, DMF, stir at RT, 
2 h; c) HKII/HKII-FITC, stir at RT, 72 h. 
 
6.4.1 Functionalization of MWCNTs for peptide loading 
 
Short-length MWCNTs (0.5-2 µm in length) were chosen as the peptide 
carrier due to their superior suspendability in aqueous solution and lower intrinsic 
cytotoxicity [266, 267]. Oxidation treatment for 10 h was necessary to eliminate 
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contaminants, further reduce the length to facilitate homogenous aqueous suspension, 
and generate more carboxylic acid groups for functionalization [110].  Figures 6.3a & 
b demonstrate significant reduction in length and improvement in CNTs 






















Figure 6.3. TEM characterization of 10 µg/mL short-length MWCNTs. a) pristine 
MWCNTs; b) 10 h-oxidized MWCNTs. 
 
Thereafter, for the construct HKII conjugated MWCNTs via linker, NH2-
TEG-NH2 was conjugated onto MWCNT-COOH via HATU-mediated amide 
coupling reaction and the amount of free amine groups was estimated by the Kaiser 
test. It was estimated that 446.9 µmol/g of –NH2 groups were present on TEG- 
functionalized MWCNTs (Table 6.1). As HKII peptide is conjugated via its N-
terminal –NH2 group, conversion of MWCNT-TEG into MWCNT-TEG–COOH was 
necessary (Scheme 6.1). Indeed, this reaction was proven to be successful, as denoted 
by the decrease in Kaiser test value to 163.7 µmol/g for MWCNT-TEG-COOH 
(Table 6.1). Taking the difference of the Kaiser test values before and after reacting 
with succinic anhydride, the amount of –COOH converted was estimated to be 283.3 





Table 6.1. Determination of functional groups on different MWCNTs constructs by 
Kaiser test. 
 
6.4.2 HKII conjugation and approximation of peptide loading by HPLC 
 
 HKII was functionalized on MWCNT-COOH (without linker) and MWCNT-
TEG-COOH (with linker) via amide coupling through its N-terminal –NH2 to give 
rise to MWCNT-HKII and MWCNT-TEG-HKII, respectively. After HKII 
conjugation, the peptide loading on MWCNTs was determined indirectly by 
measuring the residual unconjugated peptide amount before and after reaction using 
reversed phase HPLC. The detection wavelengths were set at 230 nm and 280 nm 





















Figure 6.4. UV-VIS scanning of HKII dissolved in MeOH with 1% DMSO from 220 nm 
to 400 nm. Two significant peaks are identified at 280 nm and 230 nm. Different 
concentrations of HKII solution were prepared (0.6 mM, 0.3 mM, and 0.15 mM) and 
their UV/vis spectrums were obtained accordingly (black, red, and blue).  
Sample NH2 loading  (µmol/g of CNT) 
Amount of NH2 converted 
to COOH  
(µmol/g of CNT) 
MWCNT-TEG-NH2 446.9 - 
MWCNT-TEG-COOH 163.7 283.2 
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Based on calibration curve constructed over a series of standards (Appendix 
VI), amount of HKII peptide before and after reaction was quantified. MWCNT-HKII 
and MWCNT-TEG-HKII were determined to be carrying ca. 208 µmol/g HKII 
corresponding to 37% w/w loading on MWCNTs (Table 6.2).  
 





(µmol/g of MWCNTs)a 
Loading efficiency w/w 
(%) 
MWCNT-HKII  208.3 36.9 
MWCNT-TEG-HKII  208.4 36.9 
a Peptide loading was determined by quantifying peptide amount before and after reaction 
using HPLC analysis. 
 
As a matter of fact, we attempted the synthesis of another MWCNT-HKII 
peptide conjugate containing a cleavable disulfide linker 2,2′-diaminodiethyl disulfide 
(MWCNT-SS-HKII) to ascertain if this could improve efficiency of peptide delivery. 
However, the approach was abandoned due to poor peptide loading, presumably as a 
consequence of premature cleavage of the disulfide linker (Appendix VII). 
 
6.4.3 Cellular uptake and intracellular distribution of HKII-FITC 
functionalized MWCNTs 
 
Confocal fluorescence microscopy was employed to investigate cellular 
uptake and intracellular distribution of HKII conjugated MWCNTs. To visualize the 
location of the MWCNTs conjugate, the HKII peptide used was labelled with FITC 
via an additional lysine residue at the C-terminus (HKII-FITC). HKII-FITC was 
covalently conjugated on MWCNT-COOH and MWCNT-TEG-COOH in a similar 
fashion to HKII conjugation. Thereafter, the FITC labelled MWCNTs were added to 
MCF-7 cells for 6 h. The MWCNTs were tracked at 519 nm via FITC fluorescence. 
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The nucleus and the mitochondria were co-stained using Hoechst 33342 and 
MitoTracker® dyes, respectively.  
Cells treated with HKII-FITC alone did not possess obvious green 
fluorescence signal in their intracellular space (Figure 6.5a). Weak green fluorescence 
could be observed scattering across the observational plane, even in the extracellular 
space.  On the other hand, MCF-7 cells incubated with MWCNT-HKII-FITC or 
MWCNT-TEG-HKII-FITC displayed evident intensification of green fluorescence in 
cytoplasm, indicating enhanced cellular uptake compared to HKII-FITC without 
carrier (Figures 6.5b & c). Notably, the presence of linkers between MWCNTs and 
HKII did not significantly alter cellular uptake and more importantly intracellular 
distribution of the whole conjugate. 
 
 
Figure 6.5. Confocal images of MCF-7 cells incubated with a) 25 µM HKII-FITC; b) 
50 µg/mL MWCNT-HKII-FITC; c) 50 µg/mL MWCNT-TEG-HKII-FITC. Figure a’, b’, 
and c’ are images of mitochondria counterstained with 50 nM MitoTracker® Deep 
Red while figure a”, b”, and c” are merge images of a&a’, b&b’, and c&c’, 
respectively. Similarity in location of green (HKII-FITC conjugated MWCNTs) and red 
fluorescence (mitochondria) are highlighted by white arrows.  
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When we compared the distribution of green fluorescence (FITC-labelled 
MWCNTs) and red fluorescence (mitochondrial dye) in MWCNT-HKII-FITC and 
MWCNT-TEG-HKII-FITC treated MCF-7 cells (Figures 6.5b & c), we observed 
significant degree of colocalization with mitochondria (indicated by white arrows). 
Nevertheless, the lack of apparent yellow colour (due to overlap of green fluorescence 
and red fluorescence) in the merge images is attributable to the poor green 
fluorescence signal emitted from MWCNT-HKII-FITC and MWCNT-TEG-HKII-
FITC. Importantly, the images reveal that both MWCNT constructs escaped from 
endo-lysosome into cytoplasm, unlike HKII-FITC without carrier. This observation is 
consistent with previous study reporting endocytosis of bundled MWCNTs and the 
endosomal leakage of single MWCNTs from bundles into cytoplasm [152].  
Taken together, these findings confirmed our hypothesis that functionalized 
MWCNTs could facilitate the cellular uptake of HKII peptide. Specifically, the 
apparent evasion of HKII-FITC conjugated MWCNTs from endo-lysosome and 
localization at mitochondria is indicative of preservation of peptide’s structural 
integrity and display for target recognition. In fact, this intracellular distribution 
pattern resembling mitochondrial localization of HKII peptide was reported 
previously also with different delivery carrier (arginine based CPP) [18]. As such, we 
postulate that the “recognition” might form the potential force in driving the whole 
CNT conjugate to the mitochondria.  
In this regard, one recent study reported on the successful mitochondrial 
targeting of MWCNTs through a surface-functionalized peptide [148] of 25 amino 
acid length based on MTS derived from the N-terminal region of subunit VIII of 
human cytochrome c oxidase. Although the major focus in that study was to utilize 
the functionalized peptide for mitochondrial targeting, we reason that the loaded 
peptide on MWCNTs must be displayed properly for recognition by mitochondrial 
import receptors TOM70 and TOM20 on the OMM [268].  This further substantiates 
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our hypothesis that MWCNTs could be a versatile nanocarrier for delivering bioactive 
peptides acting on subcellular organelles such as mitochondria. 
 
6.4.4 Examination of cytoxicity of HKII delivered by MWCNTs 
  
As MWCNT-HKII-FITC and MWCNT-TEG-HKII-FITC displayed an 
intracellular distribution pattern suggesting delivery to mitochondria, it prompted us 
to investigate whether such phenomenon would be harnessed to improve efficacy in 
vitro. We found that HKII without carrier was not cytotoxic in tested cell lines MCF-
7 and HCT116, with at least 90% of cells being viable even after treatment with 50 
µM of HKII peptide for 48 h (Figure 6.6). This is consistent with our earlier 
observation by confocal microscopy (Figure 6.5a), which suggests that HKII peptides 
alone were incapable of permeating cellular membrane and inducing their cytotoxic 
effect. In contrast, commercially available cell-permeable HKII (CPP-HKII) that 
features a cellular internalization sequence of Antennapedia homeoprotein 
(RQIKIWFQNRRMKWKK) exhibited improved cytotoxicity in both cell lines. 
Strikingly, only ca. 40% and 60% of cells remained viable following CPP-HKII 48 h 
exposure (50 µM) to MCF7 and HCT116 cells, respectively (Figure 6.6).   
Growth inhibitory activity of MWCNT-peptide conjugates in HCT116 and 
MCF-7 cells were evaluated via WST-1 cytotoxicity assay [228]. Treatment with 
MWCNT-HKII and MWCNT-TEG-HKII resulted in a dose-dependent decrease in 
cell viability (Figure 6.6). Both MWCNT-HKII and MWCNT-TEG-HKII reduced 
cell viability in HCT116 and MCF-7 cells by more than 80% at 50 µM of peptide 
concentration. Notably, the presence of linkers between MWCNTs and HKII did not 
significantly affect the peptide’s bio-activity. Comparing CPP-HKII with HKII 
delivered by MWCNTs, HKII’s cell killing efficacy was improved using the 
MWCNTs DS. MCF-7 cells only retained 10% of cell viability after being treated 
with 50 µM MWCNT-HKII or MWCNT-TEG-HKII, which is significantly lower 
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than ca. 40 % survival in CPP-HKII treated cells based on t-test analysis. More 
obvious improvement in efficacy was observed in HCT116 cells, with greater cell 
viability reduction across all concentrations when MWCNTs were employed as 
carrier. Taken together with the observations from confocal microscopy (Figures 6.5b 
& c), we infer that MWCNTs as DS, potentiated the efficacy of HKII peptides 
primarily by increasing their availability inside the cells without affecting the 
peptide’s structural display for target recognition.  
 
 
Figure 6.6. Investigation of cell viability via MTT assay or WST-1 assay. HCT116 and 
MCF-7 cells were treated with 3 concentrations (12.5, 25, 50 µM) of HKII, CPP-HKII, 
MWCNT-HKII, or MWCNT-TEG-HKII for 48 h. MTT assay was used to assess 
viability of cells treated with HKII and CPP-HKII while WST-1 assay was used to 
assess viability of cells treated with MWCNT-HKII and MWCNT-TEG-HKII. 
MTT/WST-1 readings from the control lane (i.e. cells without any treatment) were 
used as reference values for 100% survival. Asterisk indicates P < 0.05 when 
compared to CPP-HKII treatment. For all panels, data represent three observations 
for each experiment and are expressed as mean±SEM (n=6). 
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In short, the results suggest that the issue of limited cellular internalization of 
HKII could be overcome by conjugating it with CPP peptide, in this case 
internalization sequence from Antennapedia homeoprotein (Figure 6.6). However, it 
should be noted that CPP does not prevent CPP-cargo conjugate from being 
endocytosed and peptidolytically processed in lysosomes [60], which could hamper 
its stability and hence bioactivity in cells. As a result, MWCNT-HKII and MWCNT-
TEG-HKII, which appeared to have escaped from endosomes or lysosomes (Figures 
6.5b & c), exhibited a further enhancement in cytotoxicity at equivalent HKII 
concentration compared to CPP-HKII. Furthermore, not only did MWCNTs serve as 
a delivery carrier that facilitate cellular uptake and endosomal escape, but they also 
allowed the attainment of high conjugated ligand (HKII) density owing to the high 
surface area-to-volume ratio [96]. Nevertheless, it would be informative to evaluate 
stability of HKII covalently appended on MWCNTs in the presence of intracellular or 
extracellular peptidase to ascertain the role of MWCNTs as protective peptide carrier. 
On the other hand, all the constructs were also tested on normal lung 
fibroblast IMR-90 (Figure 6.7). Compared to HKII treatment that exerted 
insignificant effect on cell survival reduction, slight toxicity was observed in cells 
treated with CPP-HKII, only ca. 60% of cells remained viable after treatment. 
Delivery of HKII peptide using MWCNTs was shown to similarly reduce the cell 
viability to ca. 60%, implying that MWCNTs DS did not aggravate HKII toxicity in 





Figure 6.7. Investigation of cell viability via MTT assay or WST-1 assay. IMR-90 was 
treated with 3 concentrations (12.5, 25, 50 µM) of HKII, CPP-HKII, MWCNT-HKII, or 
MWCNT-TEG-HKII for 48 h. MTT assay was used to assess viability of cells treated 
with HKII and CPP-HKII while WST-1 assay was used to assess viability of cells 
treated with MWCNT-HKII and MWCNT-TEG-HKII. MTT/WST-1 readings from the 
control lane (i.e. cells without any treatment) were used as reference values for 100% 
survival. Asterisk indicates P < 0.05 when compared to CPP-HKII treatment. For all 
panels, data represent three observations for each experiment and are expressed as 
mean±SEM (n=6). 
 
We performed a preliminary western blot to examine the expression level of 
hexokinase II in MCF-7, HCT116, and IMR-90 cells (Figure 6.8). MCF-7 cells 
exhibited highest level of mitochondrial hexokinase II expression while HCT116 cells 
possessed less hexokinase II bound to the mitochondria-enriched fraction. Notably, 
mitochondria extracted from IMR-90 cells contained similar amount of bound 
hexokinase II compared to HCT116 cells. However, as the physiology and 
metabolism of non-malignant IMR-90 cells and cancerous HCT116 cells is vastly 
different, the dissociation of mitochondrial bound hexokinase II by HKII delivered 
via CPP or MWCNTs could be less detrimental in IMR-90 fibroblasts compared to 
HCT116 cells (Figure 6.6 and 6.7). Nevertheless, studies in other non-cancerous cell 
lines are highly demanded to confirm the selectivity towards cancer cells. If deemed 
necessary, active targeting by folic acid or RGD peptide could be devised on the 





Figure 6.8. Preliminary western blotting assay characterizing the expression of 
mitochondrial hexokinase II in IMR-90, HCT116, and MCF-7 cells. The cells were 
harvested and crude extraction was performed to obtain mitochondria-enriched 
fraction. Western blot of hexokinase II was performed in the mitochondria-enriched 
and cytoplasmic fraction. 
  
In order to ascertain that the cytotoxicity observed with HKII conjugated 
MWCNTs construct was due to the activity of HKII rather than the intrinsic toxicity 
of short-length MWCNTs, WST-1 assay was performed on MWCNT-COOH and 
MWCNT-TEG-COOH treated cells (Figure 6.9). As peptide loading on MWCNT-
COOH and MWCNT-TEG-COOH was similar, it was back-calculated that there was 
ca. 240 µg/mL of MWCNTs at a corresponding HKII concentration of 50 µM. At the 
highest tested MWCNTs concentration of 250 µg/mL, MWCNT-COOH did not elicit 
significant cytotoxicity in HCT116 and MCF-7 cells with at least 80% of cells 
remained viable (Figure 6.9a). On the other hand, treatment of 250 µg/mL of 
MWCNT-TEG-COOH in HCT116 and MCF-7 cells resulted in ca. 40% drop in cell 
viability, signifying that toxicity of MWCNT-TEG-COOH was higher than 
MWCNT-COOH. In fact, to our surprise, MWCNT-TEG-COOH was less 
suspendable in aqueous solution compared to MWCNT-COOH, despite the additional 
hydrophilic TEG chain. This might be due to presence of unreacted amine on 
MWCNT-TEG-COOH (Table 6.1), which was able to ionically interact with 
carboxylic groups of neighbouring tubes, causing aggregations and thus resulting in 
elevated cytotoxicity. However, comparing the extent of cancer cell growth inhibition 
of HKII conjugated MWCNTs and bare MWCNTs, we conclude that majority of the 






Figure 6.9.  Investigation of cell viability via WST-1 assay. HCT116 and MCF-7 cells 
were treated with 3 concentrations (62.5, 125, 250 µg/mL) of a) MWCNT-COOH and 
b) MWCNT-TEG-COOH for 48 h. WST-1 readings from the control lane (i.e. cells 
without any treatment) were used as reference values for 100% survival. For all 
panels, data represent three observations for each experiment and are expressed as 
mean±SEM (n=6). 
 
6.4.5 MWCNT-HKII and MWCNT-TEG-HKII induced apoptosis 
without interfering cell cycle 
 
HKII interrupts hexokinase II association with mitochondria and induces 
apoptosis [18, 19]. Apoptosis is distinguished from necrosis by characteristic 
morphological and biochemical changes, including compaction and fragmentation of 
the nuclear chromatin, shrinkage of the cytoplasm, and loss of membrane asymmetry 
[270]. In apoptotic cells, phosphatidylserine is translocated from the cytoplasmic 
surface to the outer leaflet of plasma membrane. The exposed phosphatidylserine is 
then recognized by the human anticoagulant annexin V with high affinity [271].  
To investigate if the activity of HKII in apoptosis induction was retained after 
its conjugation on MWCNTs, HCT116 cells treated with 25 µM MWCNT-HKII or 
MWCNT-TEG-HKII for 2 h were subjected to apoptosis/necrosis staining.  16.8% 
and 14.4% of MWCNT-HKII and MWCNT-TEG-HKII treated cells were stained 
positively via Alexa Fluo® 488 conjugated Annexin V (Figure 6.10c & d). In contrast, 
incubation with 125 µg/mL of MWCNT-COOH or MWCNT-TEG-COOH in 
HCT116 cells did not initiate apparent apoptotic events (Figures 6.10e & f). 
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Treatment with HKII without carrier did not induce apoptosis effectively as only 4.3% 
of cells were Annexin V positive (Figure 6.10b). Consistent with previous findings, 
both oxidized or TEG linker-functionalized MWCNTs were effective in cellular 
delivery of HKII without compromising its activity.  
 
 
Figure 6.10. Investigation of apoptosis/necrosis by annexin V/PI staining followed by 
flow cytometry. a) untreated control; b) HKII (25 µM); c) MWCNT-HKII (25 µM); (d) 
MWCNT-TEG-HKII (25 µM); (e) MWCNT-COOH (125 µg/mL); (f) MWCNT-TEG-
COOH (125 µg/mL). After incubation for 2 h, HCT116 cells were stained with annexin 
V and PI. Left bottom quadrant represents live cells (annexin V/PI negative). Right 
bottom quadrant represents early apoptotic cells (annexin V positive/PI negative). 
Right upper quadrant represents necrotic/late apoptotic cells (annexin V/PI positive). 
 
Similar observations in apoptosis induction of MWCNT-HKII and MWCNT-
TEG-HKII were obtained in cell cycle analysis. Treatment with 12.5 µM MWCNT-
HKII or MWCNT-TEG-HKII for 24 h triggered apoptosis demonstrated by the 
appearance of apoptotic cells (11.4% and 14.2%, respectively) to the left of normal 
G1 peaks (Figures 6.11c & d). This is reflected by the increased number of cells with 
DNA content less than 2n (sub-G0/G1 cells), due to degradation via endonucleases 
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during apoptosis. These low molecular weight DNAs in apoptotic cells were picked 
up by PI stain, albeit weaker in fluorescence intensity. As for HKII-treated cells 
(Figure 6.11b), the extent of apoptotic events (0.9%) was comparable to control 
without treatment (1%) (Figure 6.11a), highlighting, once again, that HKII by itself is 
unable to induce apoptosis. When the population of cells in G0/G1, S, or G2/M phase 
were scrutinized, it was deduced that cell cycle profiles in MWCNT-HKII- or 
MWCNT-TEG-HKII-treated cells remained unchanged compared to non-treated 
control, i.e., cell cycle status was not affected. This is in accord with reported findings 
that hexokinase II displacement from mitochondria alone can directly induce 
apoptosis [259], bypassing all upstream cellular stress signals that could affect cell 
cycle status. To summarize, these results indicate that HKII capacity in eliciting 




Figure 6.11. Cell cycle analysis by PI staining followed by flow cytometry. a) 
untreated control; b) HKII (12.5 µM); c) MWCNT-HKII (12.5 µM); d) MWCNT-TEG-
HKII (12.5 µM); e) MWCNT-COOH (62.5 µg/mL); f) MWCNT-TEG-COOH (62.5 
µg/mL). After incubation for 24 h, HCT116 cells were harvested and stained with PI. 




6.4.6 MWCNT-HKII and MWCNT-TEG-HKII induced cellular ATP 
depletion 
 
  Intracellular ATP level was measured to examine if energy production in 
HCT116 cells was interrupted. After treatment with 25 µM of MWCNT-HKII or 
MWCNT-TEG-HKII, intracellular ATP level started to decline gradually after 2 h of 
incubation and further plunged with prolonged treatment (Figure 6.12). After 8 h of 
treatment with MWCNT-HKII or MWCNT-TEG-HKII, cellular ATP level displayed 
a considerable drop to around 50%. On the other hand, incubation with 25 µM HKII 
was ineffective in impacting ATP metabolism in cells demonstrated by the lack of 
reduction in ATP content (Figure 6.12). Similarly, addition of control MWCNT-
COOH and MWCNT-TEG-COOH did not significantly reduce ATP content in cells. 




Figure 6.12. Quantification of ATP level in HCT116 cells after different treatment. 
HCT116 cells were treated with 25 µM HKII (black line); 25 µM MWCNT-HKII (red 
line); 25 µM MWCNT-TEG-HKII (pink line); 125 µg/mL  MWCNT-COOH (blue line); 
125 µg/mL MWCNT-TEG-COOH (green line) for the indicated duration. The 
intracellular ATP level was measured using CellTiter-Glo Luminescent Cell Viability 
Assay kit. The points represent the mean±SEM (n=3). 
 
In malignant cancer manifesting highly glycolytic phenotype, hexokinase II is 
the main facilitator maintaining active glycolysis after the rapid entry of glucose 
mediated by glucose transporter [16]. As discussed in Section 6.1.1, hexokinase II 
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interaction with VDAC coupled with ANT and ATP synthase offers preferential 
access to newly synthesized ATP from mitochondria. This positional advantage 
enables the enzyme to produce glucose-6-phosphate conveniently and accelerates the 
glycolytic activity for production of building blocks and ATP to support tumour 
growth. Indeed, breaking the association of hexokinase II from mitochondria by 
MWCNT-HKII or MWCNT-TEG-HKII interrupted ATP production in HCT116 
cells, reflected by the gradual decrease in cellular ATP content (Figure 6.12). 
Nevertheless, it should be noted that the diminished intracellular ATP level could also 
be related to the cytotoxicity induced by MWCNT-HKII or MWCNT-TEG-HKII 
treatment, i.e. dead cells are unable to generate ATP. 
 
6.4.7 HKII conjugated on MWCNTs triggered hexokinase II release 
from mitochondria 
 
It is imperative to validate if all abovementioned activity of MWCNT-HKII 
or MWCNT-TEG-HKII on HCT116 cells truly arise from the action of HKII, which 
is the ability to compete and disrupt endogenous hexokinase II association with 
mitochondria. In accord, we carried out immunoblotting of hexokinase II in 
mitochondria enriched-fraction.  Figure 6.13 illustrates that in both untreated and 25 
µM HKII-treated HCT116 cells, the majority of the hexokinase II was found in the 
mitochondrial fraction (lanes 1 and 2, respectively). The densitometry plot indicates 
that hexokinase II amount in HKII treated HCT116 cells was similar to untreated 
control. On the contrary, when HCT116 cells were treated with 25 µM of MWCNT-
HKII or MWCNT-TEG-HKII for 4 h, hexokinase II level diminished by around 40-
50% in the mitochondria-enriched fraction, signifying that HKII delivered by 
MWCNTs were capable of triggering hexokinase II detachment from mitochondria 





Figure 6.13. Mitochondria extraction and immunoblotting of hexokinase II. HCT116 
cells were treated with HKII (25 µM); MWCNT-HKII (25 µM); MWCNT-TEG-HKII (25 
µM); MWCNT-COOH (125 µg/mL); MWCNT-TEG-COOH (125 µg/mL) for 4 h. The 
cells were harvested and crude extraction was performed to obtain mitochondria-
enriched fraction. Western blot of hexokinase II was performed in the mitochondria-
enriched fraction with VDAC serving as loading control. Densitometry of each lane 
was estimated using ImageJ (NIH, USA). 
 
On the other hand, it is observed from the whole cell lysate that total 
hexokinase II level was constant among different treatment conditions (Figure 6.14), 
indicating that the decrease of hexokinase II in the mitochondria-enriched fraction of 
MWCNT-HKII or MWCNT-TEG-HKII treated cells was indeed due to dissociation 
but not degradation. Hence, the results collectively highlight the advantage of 
delivering HKII peptide using MWCNTs for efficient cellular uptake bypassing 
endosomal entrapment that results in enhanced efficacy. Moreover, conjugation of 
HKII on MWCNTs did not impede the peptide display for target recognition, which 












Figure 6.14. Immunoblotting of hexokinase II in whole cell lysate. HCT116 cells were 
treated with HKII (25 µM); MWCNT-HKII (25 µM); MWCNT-TEG-HKII (25 µM); 
MWCNT-COOH (125 µg/mL); MWCNT-TEG-COOH (125 µg/mL) for 4 h. A total of 3.2 
× 106 cells were harvested and resuspended in 150 ml Total Lysis Buffer (10 mM 
HEPES [pH 7.9], 150 mM NaCl, 1 mM EGTA, 1% Triton X-100) supplemented with 
protease inhibitors and disrupted by 10 strokes through pipetting at 4˚C. After 
centrifugation at 800g for 5 min. Western blot of hexokinase II was performed and 




 MWCNT-HKII and MWCNT-TEG-HKII, were successfully synthesized via 
covalent amidation based on short-length MWCNTs that are more suspendable in 
water and assumingly less toxic to cells. Peptide loading (% w/w) was estimated to be 
ca. 37% for both MWCNT-HKII and MWCNT-TEG-HKII. HKII delivered by both 
MWCNT-COOH and MWCNT-TEG-COOH were internalized by MCF-7 cells with 
considerable enhancement in cellular uptake compared to peptide without carrier.  
Endosomal evasion and a tendency of both nanoconjugates to adopt an intracellular 
dissemination pattern resembling mitochondria distribution were observed. 
Cytotoxicity assays suggested that conjugation of HKII on MWCNTs did not hinder 
the peptide from exerting its bioactivity and MWCNTs was superior to commercially 
available CPPs in terms of efficacy of peptide delivery. The MWCNT-peptide 
conjugates were able to elicit apoptosis and deplete ATP level in cells. Importantly, 
HKII covalently conjugated on MWCNTs was able to compete with endogenous 
hexokinase II for binding on mitochondria, accentuating the fact that HKII structural 
features and bioactivity was preserved during delivery with MWCNTs. This 
highlights the immense potential of MWCNTs for peptide delivery. 
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We have successfully functionalized MWCNTs with mitochondrial targeting 
Rho 110 and non-targeting fluorescein covalent conjugation via HATU mediated 
amidation. The loading of the functional groups Rho 110 and Fluo was qualitatively 
validated by UV-VIS scanning and quantitatively estimated by Kaiser test to be 458.1 
µmol/g and 486.6 µmol/g, respectively. Importantly, we demonstrated by confocal 
microscopy that functionalization of Rho 110 conferred a unique mitochondrial 
distribution feature to MWCNTs with colocalization coefficient of 0.79 (ca. 80% 
colocalization). On the contrary, functionalization with structurally similar but non-
targeting fluorescein failed to deliver such mitochondrial directing effect to 
MWCNTs (colocalization coefficient = 0.21, ca. 20% colocalization). The 
mitochondrial targeting effect of MWCNT-Rho was confirmed under high resolution 
TEM that clearly showed the presence of MWCNTs at close proximity to 
mitochondria. Our findings emphasize the importance of surface functionalization as 
determinant for effective targeting. 
We then validated that MWCNT-Rho is a suitable nanocarrier for biomedical 
applications by investigating if empty MWCNT-Rho carrier impacted cell viability, 
proliferation, and mitochondrial membrane potential. Interestingly, partial excretion 
of MWCNTs was suggested, signifying the capacity of MWCNT-Rho as 
mitochondrial targeting drug carrier that could be excluded from cells after finishing 
delivery of its payload. We then carried out encapsulation of PtBz in mitochondrial 
targeted MWCNT-Rho and non-targeted MWCNT-Fluo by nano-extraction. Drug 
loading of 15% and 16% (% w/w) were achieved for the targeted MWCNT-Rho(PtBz) 
and non-targeted MWCNT-Fluo(PtBz), respectively. Compared to non-targeted 
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MWCNT-Fluo(PtBz), the targeted MWCNT-Rho(PtBz) exhibited around 8 fold 
enhancement in cancer cell growth inhibition, emphasizing the importance of nature 
of targeting group on MWCNTs. Notably, MWCNT-Rho(PtBz) also compared 
favourably to PtBz without carrier in terms of cytotoxicity. Thereafter, co-
encapsulation of PtBz with a chemosensitizer BP in MWCNT-Rho was performed 
and loading efficiency (% w/w) was estimated to be 35.4% and 8.3%, respectively. It 
is demonstrated that the synergistic effect of the two compounds was enhanced by the 
use of mitochondrial targeting carrier MWCNT-Rho in all tested cell lines, including 
CDDP resistant A2780 CisR. This observation could be attributed to additional 
mitochondrial injury due to targeting effect demonstrated by a plunge in 
mitochondrial membrane potential. Therefore, we conclude that targeting 
mitochondria with the use of versatile CNT-based nanocarrier MWCNT-Rho could 
be an alternative approach for effective management of multi-factorial diseases such 
as cancer.  
However, to drive MWCNTs for future potential in vivo testing, it is 
imperative to further enhance the aqueous suspendability and compatibility to cells. 
In this regard, we have successfully appended water soluble, biocompatible 
macromolecules BSA and PEG5000 on functionalized MWCNTs by covalent 
amidation and pi-pi stacking, respectively. TGA analysis showed that there were ca. 20% 
and 10% of BSA and PEG5000 being attached on MWCNTs, respectively. Higher 
degree functionalization of BSA or PEG5000 improved the aqueous suspendability of 
MWCNTs and their toxicity profile in MCF-7 and IMR-90 cells. As the impairment 
of cell viability after exposure to either MWCNT-TEG-NH2 or MWCNT-Rho was 
found to be independent of apoptotis/necrosis induction, functionalization with BSA 
or PEG5000 did not improve the compatibility profile in this aspect. From light 
scattering analysis, it appears that cells exposed to macromolecules functionalized 
MWCNTs, especially BSA conjugated MWCNTs, displayed lower SSC compared to 
cells exposed to unfunctionalized counterparts. This infers a possible decrease in 
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cellular association/uptake of BSA functionalized MWCNTs, which might be the 
reason attributing to the improved toxicity profile. Due to more defined mode of 
functionalization, better aqueous stability, and less compromised cellular uptake, 
PEG5000 is proposed to be a superior choice to BSA for functionalization on 
MWCNTs sidewall. Importantly, PEG5000 adsorption did not affect mitochondrial 
directing properties of MWCNT-Rho, highlighting its immense potential in 
improving compatibility profile of nanotube in cells without altering the original 
designed and desired attributes of CNTs. 
To explore other applications besides delivering small molecule drugs, we 
proposed that MWCNTs could be a versatile carrier in delivering anticancer peptide 
that targets hexokinase II association with mitochondria. In light of this, two different 
conjugates, MWCNT-HKII and MWCNT-TEG-HKII, were successfully synthesized 
via covalent amidation based on short-length MWCNTs that are more suspendable in 
water and assumingly less toxic to cells. Peptide loading (% w/w) was estimated to be 
around 37% for both MWCNT-HKII and MWCNT-TEG-HKII. HKII peptide carried 
by both MWCNT-COOH and MWCNT-TEG-COOH were internalized by MCF-7 
cells with considerable enhancement in cellular uptake compared to peptide without 
carrier.  Endosomal evasion and a tendency of both nano-conjugates to adopt an 
intracellular dissemination pattern resembling mitochondria distribution were 
observed. Cytotoxicity assays suggested that conjugation of HKII on MWCNTs did 
not hinder the peptide from exerting its bioactivity and MWCNTs was superior to 
commercially available CPPs in terms of efficacy in HKII delivery. The MWCNT-
peptide conjugates were able to elicit apoptosis and deplete ATP level in cells. 
Importantly, HKII covalently conjugated on MWCNTs was shown to compete with 
endogenous hexokinase II for binding on mitochondria, accentuating the fact that 
HKII structural features and bioactivity was preserved during delivery with 
MWCNTs. This highlights the immense potential of MWCNTs as effective 
nanocarriers for peptide delivery. 
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Overall, this thesis articulates that MWCNTs could be actively targeted to 
mitochondria by surface functionalization with DLCs and such targeting property was 
proven to be essential for effective delivery of anticancer compounds against cancer 
cells in vitro. The possibility of propelling this emerging nanomaterial for biomedical 
applications was strengthened by our successful attempts in improving its aqueous 
suspendability and biocompatibility to cells by higher degree surface 
functionalization. In addition, the suitability and flexibility of MWCNTs as bioactive 
peptide carrier against mitochondria in cancer cells were demonstrated by successful 
loading of cytotoxic peptides on short-length MWCNTs and the improvement in the 
cargo’s therapeutic profiles. All the findings highlighted the immense potential of 
MWCNTs as alternative DS for mitochondrial delivery in combating malignancies. 
  
7.2 Future perspectives 
 
In spite of the abovementioned achievements, there are considerable rooms 
for improvement in the design of MWCNTs to be a biocompatible and effective 
mitochondrial targeting nanocarrier. Besides, certain pressing issues also have to be 
addressed including its behaviour in the in vivo environment. As a result, the 
following future works should be considered seriously along the progress of 
developing MWCNTs as effective mitochondrial targeting nanocarrier for the 
treatment of cancer. 
 
1. Short-length (0.5-2 µm) or ultra-short MWCNTs (<0.5 µm) could be 
employed for mitochondrial targeting via functionalization with Rho 110 as 
to evaluate if reduction in length and improvement in aqueous suspendability 
enhance its compatibility profile in vitro and in vivo. 
2. The pyrene-PEG5000 could be further modified with a cancer targeting moiety 
such as folic acid or RGD peptide. The whole complex could be attached on 
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sidewall of MWCNT-Rho to achieve higher selectivity for cancer cells. In 
vivo studies could be performed to examine if the constructs accumulate 
preferably at tumour site instead of normal tissues that also exhibits higher 
mitochondrial membrane potential such as heart, muscle, and testes etc.  
3. Other compounds targeting mitochondrial OMM, such as obatoclax and 
ABT-737 (Bcl-2 inhibitor), could be tested for their efficacy after 
encapsulation in mitochondrial targeting MWCNT-Rho.  
4. It would be interesting to covalently conjugate KLA peptide, which is toxic to 
mitochondria by directly disrupting mitochondrial membrane integrity, on 
MWCNTs. Due to the intrinsic mitochondrial localizing properties of the 
peptide, other compounds acting at mitochondria such as 17-AAG (against 
Hsp90 in matrix) could be encapsulated in core of MWCNTs, achieving dual 
delivery for enhanced toxicity. 
5. It is unequivocal that extensive in vivo studies has to be performed, including 
biodistribution and efficacy testing, in order to elucidate the biotolerance and 
effectiveness of mitochondrial targeting MWCNTs-based nanocarriers. This 
pre-requisite has to be fulfilled before concluding the benefits that could be 
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Confocal microscope performed for Rho 110 (5 µM) and FITC (5 µM) treated MCF-
7 cells for 24 h. Mitochondria were stained red using MitoTracker® Deep Red (red) 













Stability study of MWCNT-Rho by evaluating the UV-VIS absorbance profile. 
MWCNT-Rho was suspended in DMSO and incubated at 37°C for 24 h (pink), 48 h 
(blue), and 72 h (green). The stability of MWCNT-Rho was examined by performing 




































Assessment of mitochondrial membrane potential in a) PtBz (0.4 µM); b) MWCNT-
Fluo(BP+PtBz) (0.4 µM); c) MWCNT-Rho(BP+PtBz) (0.4 µM) treated MCF-7 cells. 
After incubation for 12 h, cells were harvested and stained with JC-1 and analyzed by 
flow cytometry. Q2 represents live cells whereby JC-1 was attracted to and 
aggregated in actively respiring mitochondria possessing higher membrane potential. 
Q4 represents unhealthy cells in which JC-1 existed in monomeric form due to lower 





























Thin layer chromatography (TLC) performed with mobile phase of DCM:Methanol = 
1:6 to monitor progress of reaction 5.3.3 and purity of the crude pyrene-PEG5000. a) 
Monitoring progress of reaction 5.3.3. Lane 1 is starting material 1-Pyrenebutyric 
acid N-hydroxysuccinimide ester. Lane 2 is starting material H2N-PEG-OH (MW = 
5000). Lane 3 is reaction mixture after 24 h; b) the same TLC plate was subjected to 
ninhydrin staining and heating. Lane 1 is starting material 1-Pyrenebutyric acid N-
hydroxysuccinimide ester. Lane 2 is starting material H2N-PEG-OH (MW = 5000). 
Lane 3 is reaction mixture after 24 h; c) After crude purification by three rounds of 
extraction with EA, the purity of the product was monitored. Lane 1 is starting 
material H2N-PEG-OH (MW = 5000). Lane 2 is EA phase after one round of 
extraction. Lane 3 is EA phase after three rounds of extraction. Lane 4 is DMF/water 



















Estimation of peptide loading on MWCNTs via HPLC analysis performed on agilent 
1200 Series HPLC System fitted with Waters XTerra RP18 Column, 5 µm, 4.6 x 150 
mm column. The analysis was conducted at a gradient of 35% ACN & 65% water to 
65% ACN & 35% water in 10 min with flow rate of 0.8 mL/min. a) HPLC spectrum 
of HKII peptide; b) calibration curve constructed based on area under curve of 
spectrum of different standard solutions of HKII (detection wavelength = 230 nm); c) 
calibration curve constructed based on area under curve of spectrum of different 








Synthesis of cystamine functionalized MWCNTs and subsequent loading of HKII. a) 
Chemical scheme of synthesis. (i) cystamine, HATU, DIPEA, DMSO, stir at RT, 12 
h. (ii) succinic anhydride, stir at RT, 12 h. (iii) NHS, EDC, DMAP, DIPEA, DMF, 
stir at 40 °C, 2 h. (iv) HKII / HKII-FITC, stir at RT, 72 h. b) Determination of amine 
and carboxylic acid groups on cystamine functionalized MWCNTs by Kaiser test. c) 
Peptide loading for MWCNT-SS-HKII peptide conjugates. 
 
 
 
